WO2007103432A2 - Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders - Google Patents

Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders Download PDF

Info

Publication number
WO2007103432A2
WO2007103432A2 PCT/US2007/005822 US2007005822W WO2007103432A2 WO 2007103432 A2 WO2007103432 A2 WO 2007103432A2 US 2007005822 W US2007005822 W US 2007005822W WO 2007103432 A2 WO2007103432 A2 WO 2007103432A2
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
substituted
methyl
pyrazolo
unsubstituted
Prior art date
Application number
PCT/US2007/005822
Other languages
French (fr)
Other versions
WO2007103432A9 (en
WO2007103432A3 (en
Inventor
Rajeev Sivasankaran
Kaspar Zimmermann
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Priority to CA002643362A priority Critical patent/CA2643362A1/en
Priority to MX2008011430A priority patent/MX2008011430A/en
Priority to JP2008558374A priority patent/JP2009529054A/en
Priority to BRPI0708693-8A priority patent/BRPI0708693A2/en
Priority to US12/282,110 priority patent/US20090069315A1/en
Priority to AU2007223865A priority patent/AU2007223865A1/en
Priority to EP07752514A priority patent/EP1993552A2/en
Publication of WO2007103432A2 publication Critical patent/WO2007103432A2/en
Publication of WO2007103432A3 publication Critical patent/WO2007103432A3/en
Publication of WO2007103432A9 publication Critical patent/WO2007103432A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • Axonal regeneration (e.g., post-injury) is prevented by a host of inhibitory influences in the adult CNS, among them inhibitory myelin proteins and the formation of a glial scar.
  • inhibitory myelin proteins e.g., Nogo, myelin-associated glycoprotein (MAG), and oligodendrocyte-myelin glycoprotein (OMgp)
  • MAG myelin-associated glycoprotein
  • OMgp oligodendrocyte-myelin glycoprotein
  • Glial scarring is characterized by astrocytic gliosis, in which normally quiescent astrocytes proliferate and grow hypertrophic in response to injury, and otherwise form a physical and chemical barrier to axon regeneration.
  • astrocytic gliosis normally quiescent astrocytes proliferate and grow hypertrophic in response to injury, and otherwise form a physical and chemical barrier to axon regeneration.
  • Eph receptor tyrosine kinase subfamily is thought to be the largest subfamily of transmembrane receptor tyrosine kinases, and with its ligands, the ephrins, is responsible for governing proper cell migration and positioning during neural development, presumably through modulating intercellular repulsion. (Pasquale, E. (1997) Curr. Opin. Cell Biol. 9:608-615)(Orioli and Klein (1997) Trends in Genetics 13:354-359). Eph receptors are closely related, and actively signal when bound to their ephrin ligands (their effects are mediated by cell-to-cell contacts), with which they are capable of both forward and bi-directional signaling.
  • Eph receptors are known regulators of neural development, with roles in the regulation of migrating cells or axons, the establishment of tissue patterns and topographic maps in distinct regions of the developing brain, and the regulation of synapse formation and plasticity. Eph receptors, including EphA4 and EphA7, are upregulated after spinal cord damage or deafferentation. (Miranda, et al. (1999) Exp Neurol 156:218; Willson, et al. (2002) Cell Transplantation 11 :229); therefore, their inhibition is viewed as a potential therapeutic strategy for the treatment of neurological disorders.
  • the invention relates to methods of using of the compounds of the invention for the treatment of Eph receptor-related (e.g., neurological) injuries and disorders, and methods of using pharmaceutical preparations comprising the compounds of the invention in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders.
  • Eph receptor-related e.g., neurological
  • pharmaceutical preparations comprising the compounds of the invention in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders.
  • the invention also relates to methods of modulating the activity of an Eph receptor in a cell by contacting the cell with an effective amount of the compounds of the invention.
  • Eph receptors can be modulated either in vitro or in vivo.
  • the invention also relates to methods of stimulating and promoting neural regeneration (such as axon regeneration following spinal cord injury), and reversing neuronal degeneration due to traumatic injury, hypoxic conditions, or infarct (e.g., as in stroke or nerve degeneration that is an underlying cause in multiple sclerosis and other neurodegenerative diseases).
  • neural regeneration such as axon regeneration following spinal cord injury
  • infarct e.g., as in stroke or nerve degeneration that is an underlying cause in multiple sclerosis and other neurodegenerative diseases.
  • One way in which this can be achieved is through the administration to a mammal of a compound of the invention in an amount that is sufficient to stimulate and promote neural regeneration (such as axon regeneration) or reverse neuronal degeneration.
  • the compounds of the invention can be delivered to both normal and injured cells.
  • the compounds of the invention inhibit the phosphorylation of an Eph receptor.
  • the compounds of the invention inhibit the binding of ephrin ligands to Eph receptors.
  • the invention also relates to methods for delivering a therapeutic agent to a cell, such as via a conjugate which comprises a therapeutic agent (e.g., a linking reagent) linked to compound of the invention.
  • a therapeutic agent e.g., a linking reagent
  • the compounds of the invention are, among other things, useful as protein kinase inhibitors and thus in the treatment of protein kinase-related disorders.
  • the compounds of the invention are useful as receptor tyrosine kinase inhibitors, such as Ephrin receptor kinase inhibitors, and can therefore be used to treat, e.g., neurological injuries and disorders.
  • Figures IA and IB show inhibition of EphA4 auto-phosphorylation and ligand-dependent phosphorylation, respectively (from samples subjected to EphA4 immunoprecipitation followed by a phospho-tyrosine Western blot).
  • Figure IA lanes 1 and 2 represent samples from cells treated with either control IgG-Fc or with the ligand ephrinB3-Fc.
  • Lanes 2-6 represent samples from cells that have been pre- treated with Compound 1 (10OnM) and are then stimulated with IgG-Fc or ephrinB3- Fc in the combined presence of the inhibitor (Compound I)(lanes 3,4) or in its absence (lanes 5,6).
  • Figure IB lanes 1 and 2 show EphA4 phosphorylation in control (untreated) and ephrinB3-Fc stimulated cells following serum starvation. All other lanes represent samples from cells stimulated with ephiinB3-Fc in the presence of varying concentrations (as indicated) of tested Eph inhibitors.
  • Figure 2A shows immunofluroscence images demonstrating that Eph receptor inhibitors (e.g., Compound I (10OnM)) are able to overcome neurite outgrowth inhibition at nanomolar concentrations.
  • Figure 2B shows a graphical representation of experimentally-determined neurite outgrowth inhibition. The Y axis shows average neurite length in microns.
  • FIG 3 shows a graphical representation of the experimental determination that Eph receptor inhibitors block astrocyte migration induced by cytokines (TGF- ⁇ , LIF, and IFN).
  • the white bar represents the addition of Compound 6.
  • the black bar represents no compounds added.
  • Figure 4 demonstrates that Eph receptor inhibitors block EphA4 phosphorylation in vivo in mouse brain (brain homogenate lysates were subjected to EphA4 immunoprecipitation followed by a phospho-tyrosine Western blot).
  • Figures 5A and 5B shows methods of preparation of the compounds of formula (I). As described below, Figure 5B describes the preparation of compounds of formula (I) beginning with synthesizing the pyrazolo[l,5-a]pyrimidin-7-ylamine core scaffold carrying a corresponding functional group (X) where residues A, R 2 , or R 3 , respectively, can be introduced by known reactions as indicated. [0016] Figure 6 shows a method of preparation of Compounds 9 and 10.
  • the present invention relates to compounds of the invention, including pyrazolo[l,5a]pyrimidin-7-yl amine compounds, of the formula (I):
  • R 2 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
  • R3 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or an aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring,
  • R 2 or R3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
  • A is H, halogen (such as bromo), an aliphatic moiety, a functional group, substituted or unsubstituted aryl or heteroaryl; and
  • Ri is H, halogen or lower alkyl
  • a preferred embodiment is the use of a compound according to the above, wherein:
  • R 2 is H; lower alkyl; cycloalkyl; benzyl; benzo thienyl, indyl substituted by lower alkyl, pyridyl or thiazolyl optionally substituted by lower alkyl; unsubstituted phenyl or phenyl substituted by one or two substituents chosen from the group consisting of; halo, hydroxy, alkoxy, benzyloxy, cycloalkyl, amino, acetyl amino, lower alkyl sulfonamide and benzene sulfonamide substituted by one or two halo; •
  • R3 is H; lower alkyl optionally substituted by halo; phenyl, pyridyl, or oxazolyl;
  • A is: (a) H; halo; benzothienyl; pyridyl; methyl piperazinyl phenoxyl; indolyl substituted with lower alkyl;
  • phenyl which is unsubstituted or substituted with one or more of the substituents chosen from the group consisting of; mono-, di- or tri-lower alkoxy, di- lower alkylaminyl, morpholinyl which is optionally di-substituted by alkyl, piperazinyl which is substituted with one or more of the substituents chosen from the group consisting of lower alkyl, lower alkoxy, lower alkyl piperazinyl, pyrrolidinyl, dialkyl aminyl and lower alkanol; and
  • Ri is H, or pharmaceutically acceptable salts thereof for treating Eph receptor-related (e.g., neurological) injuries and disorders.
  • the compounds of the invention e.g., compounds of formula (I), e.g., pyrazolo[l,5a]pyrimidin-7-yl amine derivatives, are, among other things, useful in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders.
  • Eph receptor-related e.g., neurological
  • Pyrazolo[l,5a]pyrimidin-7-yl amine derivatives have demonstrated surprisingly pharmaceutically advantageous properties, inter alia allowing for the inhibition of specific types or classes or groups of kinases, including Eph receptor kinases.
  • the pyrazolo[l,5a]pyrimidin-7-yl amine derivatives have the advantage that their backbone in addition allows for substitution patterns that offer a broad possibility to achieve a fine tuning for specific interaction with the binding site of the targeted kinase or kinases, thus opening a new perspective and providing kinase inhibitors of various degrees of specificity.
  • the compounds of the invention can be used for the treatment of diseases related to especially aberrant or excessive activity of such types of kinases, e.g., Eph receptor-related (e.g., neurological) injuries and disorders.
  • the disease to be treated is neurological injury or disorder, as described in greater detail herein.
  • the invention relates to a compound of formula
  • R 2 is H; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; an aliphatic residue; a functional group; or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
  • F-3 can be H, substituted or unsubstituted aryl, heteroaryl, an aliphatic residue, a functional group, or an aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring,
  • R 2 or R3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a] pyrimidinyl ring, and provided that both R 2 and A cannot both be unsubstituted phenyl;
  • A is H, halogen (such as brorno), an aliphatic moiety, a functional group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; and
  • Ri is H, halogen or lower alkyl
  • a preferred embodiment is a compound according to the above, wherein;
  • R 2 is H; lower alkyl; cycloalkyl; benzyl; benzo thienyl, indyl substituted by lower alkyl, pyridyl or thiazolyl optionally substituted by lower alkyl; unsubstituted phenyl or phenyl substituted by one or two substituents chosen from the group consisting of; halo, hydroxy, alkoxy, benzyloxy, cycloalkyl, amino, acetyl amino, lower alkyl sulfonamide and benzene sulfonamide substituted by one or two halo;
  • R3 is H; lower alkyl optionally substituted by halo; phenyl, pyridyl, or oxazolyl;
  • piperazinyl which is substituted with one or more of the substituents chosen from the group consisting of lower alkyl, lower alkoxy, lower alkyl piperazinyl, pyrrolidinyl, dialkyl aminyl and lower alkanol; and
  • Ri is H; and provided that both R2 and A cannot both be unsubstituted phenyl.
  • the compound is selected from the group consisting of:
  • the compounds of the invention are used in methods of treatment of Eph receptor-related (e.g., neurological) injuries and disorders.
  • compositions prepared from the compounds of the invention are used in methods of treatment of
  • Eph receptor-related (e.g., neurological) injuries and disorders The pharmaceutical compositions preferably comprise a compound of the invention an acceptable pharmaceutical carrier. Carriers are described in greater details herein.
  • the compounds of the invention are used to contact a cell, in order to modulate the activity of an Eph receptor therein.
  • the cell can be contacted in vitro or in vivo, in an effective amount of the compounds of the invention to modulate Eph receptors therein.
  • the compounds of the invention are used in methods of stimulating and promoting neural regeneration (such as axon regeneration), and reversing neuronal degeneration due to traumatic injury, stroke, multiple sclerosis and neurodegenerative diseases.
  • neural regeneration such as axon regeneration
  • One way in which this can be achieved is through the administration to a mammal of a compound of the invention in an amount that is sufficient to stimulate and promote neural regeneration
  • the compounds of the invention can be delivered to both normal and injured cells.
  • the compounds of the invention inhibit the phosphorylation of an Eph receptor.
  • the compounds of the invention inhibit the binding of ephrin
  • the compounds of the invention are used in methods for delivering a therapeutic agent to a cell, such as via a conjugate comprising said therapeutic agent linked to compound of the invention.
  • the therapeutic agent can be a linking reagent.
  • a further embodiment is a process to prepare a compound according to the above comprising:
  • the invention in particular relates to The present invention relates to compounds of the invention, including pyrazolo[l,5a]pyrimidin-7-yl amine compounds, of the formula (I):
  • Ra is H; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted aliphatic residue; a functional group; or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
  • R. 3 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or an aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a] pyrimidinyl ring, at least one of R 2 or R 3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
  • A is H. halogen (such as bromo), an aliphatic moiety, a functional group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
  • R 1 is H, halogen or lower alkyl
  • the present invention is especially related to a compound of formula (I) wherein R 2 is H; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted aliphatic residue; a functional group; or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
  • R3 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or an aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a] pyrimidinyl ring,
  • At least one OfR 2 or R 3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a] pyrimidinyl ring, and provided that R 2 and A cannot both be unsubstituted phenyl;
  • A is H, halogen (such as bromo), an aliphatic moiety, a functional group, substituted or unsubstituted aryl or heteroaryl; and
  • Ri is H, halogen or lower alkyl,or pharmaceutically acceptable salts thereof,
  • the present invention also relates to a method of treating kinase dependent diseases comprising administering pyrazolo[l,5a] pyrimidin-7-yl amine compounds of the formula (I) to a warm-blooded animal, especially a human.
  • the present invention also relates to pharmaceutical preparations comprising an pyrazolo[l-5a]pyrimidin-7-yl amine compound of the formula (I), especially for the treatment of a kinase dependent disease, novel pyrazolo[l,5a]pyrimidin-7-yl amine compounds of the formula (I), a process for the manufacture of the pyrazolo[l,5a]pyrimidin-7-yl amine compounds of the formula (I), and novel starting materials and intermediates for their manufacture.
  • the present invention also relates to use of a compound of formula 1 in the manufacture of a pharmaceutical preparation for the treatment of an Eph receptor-related (e.g., neurological) injury or disorder.
  • Eph receptor means a receptor tyrosine kinase that belongs to the Eph family, including EphA2, E ⁇ hA4, EphA5, EphA7, EphB2 and EphB4. This family is reviewed, for instance, in Pasquale, E. (1997) Curr. Opin. Cell Biol. 9:608-615; and Orioli and Klein (1997) Trends in Genetics 13:354-359.
  • treatment includes both prophylactic or preventive treatment as well as curative or disease suppressive treatment, including treatment of patients at risk of neurological disorders, as well as ill and injured patients. This term further includes the treatment for the delay of progression of the disease.
  • Eph receptor-related injuries and disorders include neurological injuries and disorders, including but not limited to spinal cord injury (SCI); quadriplegia, hemiplegia, and paraplegia, including injury-caused and hereditary forms; neuropathies; CNS related disorders (e.g., bacterial and viral meningitis); and neurodegenerative disorders (e.g., Alzheimers Disease, cerebral toxoplasmosis, Parkinson's disease, amytropic lateral sclerosis (ALS), and multiple sclerosis).
  • SCI spinal cord injury
  • CNS related disorders e.g., bacterial and viral meningitis
  • neurodegenerative disorders e.g., Alzheimers Disease, cerebral toxoplasmosis, Parkinson's disease, amytropic lateral sclerosis (ALS), and multiple sclerosis.
  • Eph-receptor-related injuries and disorders also includes neuronal degeneration resulting from hypoxic conditions, or from an infarct as in stroke.
  • compounds of the invention include, compounds of formula (I), including pyrazolo[l,5a]pyrimidin-7-yl amine derivatives. Compounds of the invention also refers to those compounds referred to herein as "Compound [number]."
  • Aryl is an aromatic radical having 6 to 14 carbon atoms, especially phenyl, naphthyl, indenyl, azulenyl, or anthryl, and is unsubstituted or substituted by one or more, preferably one or two substituents, wherein the substituents are selected from any of the functional groups defined below, and including: lower halo, alkyl, substituted alkyl, halo lower alkyl e.g.
  • R 4 and R5 together with the N atom form a 3- to 8-membered heterocyclic ring containing 1 -4 nitrogen, oxygen or sulfur atoms (e.g. piperazinyl, lower alkyl- piperazinyl, azetidinyl, pyrrolidinyl, piperidino, morpholinyl, imidazolinyl).
  • piperazinyl lower alkyl- piperazinyl, azetidinyl, pyrrolidinyl, piperidino, morpholinyl, imidazolinyl.
  • Aryl is more preferably phenyl which is either unsubstituted or independently substituted by one or two substituents selected from a solubilizing group selected from the group consisting of: halo (such as Cl or Br); hydroxy; lower alkyl (such as C 1 -C3 lower alkyl); aryl (such as phenyl or benzyl); amino; amino lower alkyl (such as dimethylamino); acetyl amino; amino lower alkoxy (such as ethoxyamine); lower alkyl (such as methyl); alkoxy (such as methoxy or benzyloxy where the benzyl ring may be substituted or unsubstituted, such as 3, 4 - dichlorobenzyloxy); sulfoamino; substituted or unsubstituted sulfonamide (such as benzo sulfonamide, chlorobenzene sulfonamide or 2,3-dichloro benzene
  • a heteroaryl group is preferably monocyclic, but may be bi- or tri-cyclic, and comprises 3-24, preferably 4-16 ring atoms, wherein at least one or more, preferably one to four ring carbons are replaced by a heteroatom selected from O, N or S.
  • the heteroaryl group is selected from pyridyl, indolyl, pyrimidyl, pyrazolyl, oxazolyl, thiophenyl, benzothiophenyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, benzimidazolyl, pyrazolyl, indazolyl, purinyl, pyrazinyl, pyridazinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalyl, quinazolinyl, quinnolinyl, indolizinyl, 3H-indolyl, isoindolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, furazanyl and benzo[d]pyrazol.
  • heteroaryl group is selected from the group consisting of pyridyl, indolyl, pyrimidyl, pyrazolyl, oxazolyl, thiophenyl or benzothiophenyl.
  • the heteroaryl group may be unsubstituted or substituted by one or more substituents selected from the group defined above as substituents for aryl, most preferably by hydroxy, halogen, lower alkyl, such as methyl or lower alkoxy, such as methoxy or ethoxy.
  • Aliphatic refers to any non-aromatic carbon based residue.
  • aliphatic residues include substituted or unsubstituted alkyl, cycloalkyl, alkenyl and alkynyl.
  • Alkyl includes lower alkyl preferably alkyl with up to 7 carbon atoms, preferably from 1 to and including 5, and is linear or branched; preferably, lower alkyl is pentyl, such as n-pentyl, butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or methyl.
  • Preferably lower alkyl is methyl, propyl or tert-butyl.
  • a cycloalkyl group is preferably cyclopentyl, cyclohexyl or cycloheptyl, and may be unsubstituted or substituted by one or more, especially one or two, substituents selected from the group defined above as substituents for aryl, most preferably by lower alkyl, such as methyl, lower alkoxy, such as methoxy or ethoxy, or hydroxy.
  • Alkenyl and alkynyl preferably have up to 7 carbon atoms, preferably from
  • Alkyl, cycloalkyl, alkenyl and alkynyl can be substituted or unsubstituted, and when substituted may be with up to 3 substituents including other alkyl, cycloalkyl, alkenyl, alkynyl, any of the substituents defined above for aryl or any of the functional groups defined below.
  • "Halo" or "halogen” is preferably fluoro, chloro, bromo or iodo, most preferably fluoro, chloro or bromo.
  • connecting atom or group includes alkyl, (such as -CH 2 -); oxy -O-; keto -CO-; thio -S-; sulfonyl -SO 2 -; sulfoxides -SO-; amines -NH- or -NR-; carboxylic acid; alcohol; esters (-COO-); amides (- -CONR-, -CONHR'-); sulfonamides (, -SO 2 NH-, -SO 2 NR'-); sulfones (-SO 2 -); sulfoxides (-SO-); amino- group; ureas ( -NH-CO-NH-, -NR-CO-NH-, -NH-CO-NR-, -NR-CO-NR-); ethers (-
  • the term "functional group" as used herein includes: carboxylic acid; hydroxyl; halogen; cyano (-CN); ethers (-OR); ketones (-CO-R); esters (-COOR); amides (-CONH2, -CONHR, -CONRR'); thioethers (-SR); sulfonamides (-SO 2 NH 2 , -
  • R and R' are the same are different and may be H or are any aliphatic, aryl or heteroaryl moiety as defined above.
  • Salts are especially the pharmaceutically acceptable salts of compounds of formula (I).
  • Such salts are formed, for example, as acid addition salts, preferably with organic or inorganic acids, from compounds of formula (I) with a basic nitrogen atom, especially the pharmaceutically acceptable salts.
  • Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
  • Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane-sulfonic acid, 2-hydroxyethanesulfonic acid, ethane- 1,2-dis
  • salts may also be formed with bases, e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example N-ethyl-piperidine or N,N'-dimethylpiperazine.
  • bases e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example N-ethyl-piperidine or N,N'-dimethylpiperazine.
  • any reference to the compounds hereinbefore and hereinafter especially the compounds of the formula (I), is to be understood as referring also to the corresponding tautomers of these compounds, especially of compounds of the formula (I), tautomeric mixtures of these compounds, especially of compounds of the formula (I), or salts of any of these, as appropriate and expedient and if not mentioned otherwise.
  • the compounds may thus be present as mixtures of isomers or preferably as pure isomers, preferably as enantiomer-pure diastereomers or pure enantiomers.
  • the compounds of formula (I) have valuable pharmacological properties and are useful in the treatment of kinase dependent diseases, e.g., as drugs to treat neurological diseases.
  • the compounds of formula (I) have valuable pharmacological properties and are useful in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders, e.g., as drugs to treat neurological diseases.
  • Eph receptor-related e.g., neurological
  • disorders e.g., as drugs to treat neurological diseases.
  • CNS neurons appear to lose the intrinsic ability to regenerate neurites postnatally, many others, such as corticospinal tract (CST) neurons, appear able to regenerate, but are inhibited from doing so by the environment of the injury site. (Goldberg et al., (2002) Science 296: 1860). Major impediments to CNS regeneration are the presence of myelin inhibitors and astrocytic gliosis.
  • Axonal regeneration is prevented by a host of inhibitory influences in the adult CNS, among them inhibitory myelin proteins and the formation of a glial scar.
  • inhibitory myelin proteins e.g., Nogo, myelin-associated glycoprotein (MAG), and oligodendrocyte-myelin glycoprotein (OMgp)
  • targeting those proteins for the treatment or amelioration of neurological disorders is an incomplete solution.
  • Blocking individual myelin proteins or their common receptor in vivo after spinal cord injury can result in partial axon regeneration, and a concomitant improvement of functional recovery; however, only a small percentage of axons regrow, highlighting the need for the removal of other impediments to regeneration for a more complete therapeutic solution (Simonen M., et al. (2003) Neuron 38: 201 ; Zheng B., et al. (2003) Neuron 38: 213).
  • glial scarring The main component of glial scarring is astrocytic gliosis, whereby normally quiescent astrocytes show a vigorous response to injury.
  • Stichel CC et al. (1998) Cell Tissue Res 294: 1). They become hypertrophic, proliferative, upregulate expression of glial fibrillary acidic protein (GFAP), and form a dense network of glial processes both at and extending from the lesion site.
  • GFAP glial fibrillary acidic protein
  • the astrocytes secrete a variety of cytokines and produce cell adhesion and extracellular matrix molecules, some of which are inhibitory to regeneration (e.g., chondroitin sulfate proteoglycan (CSPG) and collagen IV).
  • CSPG chondroitin sulfate proteoglycan
  • Eph receptor tyrosine kinase subfamily appears to be the largest subfamily of transmembrane receptor tyrosine kinases, and with its ligands, the ephrins, is responsible for governing proper cell migration and positioning during neural development, presumably through modulating intercellular repulsion (Pasquale, E. (1997) Curr. Opin. Cell Biol. 9:608-615)(Orioli and Klein (1997) Trends in Genetics 13:354-359).
  • the Eph family is responsible for the formation of the corticospinal tract and anterior commissure. (Kullander K., et al. (2001a) Neuron 29: 73; Henkemeyer M, et al. (1996) Cell 86: 35).
  • Eph receptors are closely related, and actively signal when bound to their ephrin ligands (their effects are mediated by cell-to-cell contacts), with which they are capable of both forward and bi-directional signaling. (Murai, K.K., et al. (2003) J Cell Sci. 116(14): 2823).
  • These receptors are characterized by 3 functional domains: an intracellular tyrosine kinase catalytic domain, a single membrane spanning domain, and an extracellular ligand binding domain.
  • Binding of a ligand ephrin by a Eph receptor induces phosphorylation on tyrosine residues, which establishes binding sites for signaling proteins containing SH2 domains and activates an array of signaling pathways.
  • the ephrins are thought to activate Eph receptors by clustering them and inducing autophosphorylation, while soluble monomelic ephrins are thought to inhibit Eph receptor activation. (Davis et al. (1994) Science 266: 816).
  • EphA and EphB The sixteen known Eph receptors are divided into two subgroups (EphA and EphB) based on sequence homology. EphA receptors preferentially bind the glycosylphosphatidylinositol (GPI)-linked ephrin-A ligands, while EphB W
  • EphA4 can bind (and is therefore activated by) ligand ephrins B2 and B3, in addition to members of the ephrin A ligand family.
  • Eph receptor family members and their ephrin ligands are of interest as targets for therapy for the treatment of neurological disorders and injuries, including as targets for the promotion of axon regeneration, based on findings in the literature.
  • Eph-ephrin signaling appears to regulate axon guidance through contact repulsion, inducing the collapse of neuronal growth cones (Wahl S., et al. (2000) J Cell Biol 149: 263; Kullander et al.), and members of this family are upregulated in the adult after neural injury (Moreno-Flores MT, et al. (1999) Neuroscience 91: 193; Willson CA, et al. (2002) Cell Transplant 11: 229), the aberrant expression or absence of Eph receptors could prove pivotal in determining the outcome of injury in the adult CNS.
  • EphA4 is a receptor tyrosine kinase from the EphA family which has important functions in the developing and adult nervous system. Along with its known expression pattern during neural development (Mori, T., et al. (1995) Brain Res MoI Brain Res 29:325; Ohta, K., et al. (1996) Mechanisms of Development 54:59; Soans, C, et al. (1994) Oncogene 9:3353), EphA4 is expressed in brain regions that show extensive synaptic remodeling (Murai, K., et al. (2003) Nature Neurosci 6:153). In the adult, EphA4 is enriched in the hippocampus and cortex, two brain structures critical for learning and memory. The receptor is also enriched in migrating neural crest cells, growing axonal projections, and mature brain structures that show extensive plasticity. (Murai, et al.).
  • EphA4 is yet another directly inhibitory molecule produced during astrocytic gliosis, in addition to other inhibitory components, such as extracellular matrix and myelin-derived molecules.
  • the second, and lesser-observed, mechanism may be by activation of EphA4 on the regenerating axons, similar to on E16 cortical neurons. However, EphA4 was found to be highly expressed only on astrocytes and motor neurons, and present at low levels on descending axons in lesioned adult spinal cord. [00286]
  • the third mechanism by which EphA4 exerts an inhibitory effect involves its vital role in activating astrocytes, leading to gliosis and the formation of a glial scar. Such activation appears to be dependent on responsiveness to cytokine stimulation and may be dependent on Rho activation.
  • This cytokine-induced response may be attributable to the upregulation of EphA4 receptor expression on the astrocytes, allowing enhanced ligand binding and receptor activation. It is also possible that the cytokine-induced astrocyte proliferation and hypertrophy may be caused by transactivation of EphA4, as has been shown for FGF2- and PDGF-induced phosphorylation of EphrinB molecules (Chong et al., (2000) MoI Cell Biol 20: 724), leading to Rho activation and cytoskeletal rearrangement. The difference in glial activation seems to be astrocyte specific as there was no apparent difference in macrophage-microglial activation.
  • Ephs and Ephrins have been reported to play a role in interactions between astrocytes and meningeal fibroblasts, excluding fibroblasts from the glial scar. (Bundesen LQ, et al. (2003) J Neurosci 23: 7789).
  • ⁇ compounds of formula (I) are prepared by condensing 3-oxo- propionitriles (II) and the corresponding 2H-pyrazol-3-ylamines (III) in the presence of ethanolic HCl.
  • the 2H-pyrazol-3-ylamines (III) are prepared by condensing hydrazine monohydrate with the corresponding 3-oxo-propionitriles dissolved in an organic solvent, such as EtOH, dioxane or AcOH and heated at elevated temperatures (preferably at 100 0 C) for several hours.
  • the preferred procedure for preparing the pyrazolo moiety of the title compounds was stirring the hydrazine monohydrate with the corresponding 3-oxo-propionitriles in acetic acid at 100 0 C for 2-3 h followed by addition of aqueous HCl and further refluxing the reaction mixture for further 20 min.
  • Rl is not H
  • the corresponding substituted hydrazines are used.
  • the 3- oxo-propionitriles (I) and (II) are synthesized from the corresponding nitriles by classical formylation reaction using freshly prepared sodium ethanolate and formic acid ethyl ester (refluxing for 1 h in EtOH).
  • the corresponding 3,3-dialkoxy- propionitiles in analogy to the procedure described by Seneci, P., Nicola, M., Inglesi, M., Vanotti, E., Resnati, G. Synth. Commun. 29 (2), 311-341 (1999)
  • 3- dimethylamino-acrylonitriles can be used.
  • compounds of formula (I) can be prepared by first synthesizing the pyrazolo[l,5-a]pyrimidin-7-ylamine core scaffold carrying a corresponding functional group X, where residues A, R2, or R3, respectively, can be introduced by known reactions.
  • Salts of compounds of formula (I) having at least one salt-forming group may be prepared in a manner known per se.
  • salts of compounds of formula (I) having acid groups may be formed, for example, by treating the compounds with metal compounds, such as alkali metal salts of suitable organic carboxylic acids, e.g. the sodium salt of 2-ethylhexanoic acid, with organic alkali metal or alkaline earth metal compounds, such as the corresponding hydroxides, carbonates or hydrogen carbonates, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with corresponding calcium compounds or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt- forming agent preferably being used.
  • metal compounds such as alkali metal salts of suitable organic carboxylic acids, e.g. the sodium salt of 2-ethylhexanoic acid
  • organic alkali metal or alkaline earth metal compounds such as the corresponding hydroxides, carbonates or hydrogen carbonates,
  • Acid addition salts of compounds of formula (I) are obtained in customary manner, e.g. by treating the compounds with an acid or a suitable anion exchange reagent.
  • Internal salts of compounds of formula (I) containing acid and basic salt-forming groups, e.g. a free carboxy group and a free amino group, may be formed, e.g. by the neutralisation of salts, such as acid addition salts, to the isoelectric point, e.g. with weak bases, or by treatment with ion exchangers.
  • Salts can be converted in customary manner into the free compounds; metal and ammonium salts can be converted, for example, by treatment with suitable acids, and acid addition salts, for example, by treatment with a suitable basic agent.
  • mixtures of isomers obtainable according to the invention can be separated in a manner known per se into the individual isomers; diastereoisomers can be separated, for example, by partitioning between polyphasic solvent mixtures, recrystallisation and/or chromatographic separation, for example over silica gel or by e.g. medium pressure liquid chromatography over a reversed phase column, and racemates can be separated, for example, by the formation of salts with optically pure salt-forming reagents and separation of the mixture of diastereoisomers so obtainable, for example by means of fractional crystallisation, or by chromatography over optically active column materials.
  • the above-mentioned process steps can be carried out under reaction conditions that are known per se, preferably those mentioned specifically, in the absence or, customarily, in the presence of solvents or diluents, preferably solvents or diluents that are inert towards the reagents used and dissolve them, in the absence or presence of catalysts, condensation or neutralizing agents, for example ion exchangers, such as cation exchangers, e.g.
  • mixtures of isomers that are formed can be separated into the individual isomers, for example diastereoisomers or enantiomers, or into any desired mixtures of isomers, for example racemates or mixtures of diastereoisomers, for example analogously to the methods described under "Additional process steps.”
  • the solvents from which those solvents that are suitable for any particular reaction may be selected include those mentioned specifically or, for example, water, esters, such as lower alkyl-lower alkanoates, for example ethyl acetate, ethers, such as aliphatic ethers, for example diethyl ether, or cyclic ethers, for example tetrahydro- furane or dioxane, liquid aromatic hydrocarbons, such as benzene or toluene, alcohols, such as methanol, ethanol or 1- or 2-propanol, nitriles, such as acetonitrile, halogenated hydrocarbons, such as methylene chloride or chloroform, acid amides, such as dimethylformamide or dimethyl acetamide, bases, such as heterocyclic nitrogen bases, for example pyridine or N-methylpyrrolidin-2-one, carboxylic acid anhydrides, such as lower alkanoic acid anhydrides, for example
  • the compounds, including their salts, may also be obtained in the form of hydrates, or their crystals may, for example, include the solvent used for crystallization. Different crystalline forms may be present.
  • the invention relates also to those forms of the process in which a compound obtainable as intermediate at any stage of the process is used as starting material and the remaining process steps are carried out, or in which a starting material is formed under the reaction conditions or is used in the form of a derivative, for example in protected form or in the form of a salt, or a compound obtainable by the process according to the invention is produced under the process conditions and processed further in situ.
  • those starting materials are preferably used which result in new compounds of formula (I) described at the beginning as being especially valuable.
  • Eph receptor-related e.g., neurological
  • disorder to be treated is a neurological disorder or injury depending on Ephrin receptor kinases (e.g., EphA4 kinase).
  • the invention relates especially to use of a compound of the formula (I),
  • R 2 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
  • R 3 can be H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or an aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring,
  • R2 or R3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
  • A is H, halogen (such as bromo), an aliphatic moiety, a functional group, substituted or unsubstituted aryl or heteroaryl; and
  • R 1 is H, halogen or lower alkyl
  • the invention further relates to use of a compound of the formula (I),
  • R2 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
  • R3 can be H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a] ⁇ yrimidinyl ring, [00325] at least one of R2 or R3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring; '
  • A is H, halogen (such as bromo), an aliphatic moiety, a functional group, substituted or unsubstituted aryl or heteroaryl; and
  • Ri is H, halogen or lower alkyl
  • the connecting atom or group is selected from the group consisting of: alkyl, (such as -CH 2 -); oxy -O-; keto -CO-; thio -S-; sulfonyl -SO2-; sulfoxides -SO-; amines -NH- or -NR-; carboxylic acid; alcohol; esters (-COO-); amides (- -CONR-, -
  • the functional group is selected from the group consisting of: carboxylic acid; hydroxyl; halogens; cyano (-CN); ethers (-OR); ketones (-CO-R); esters (-COOR); amides (-CONH 2 , -CONHR, -CONRR'); thioethers (-SR); sulfonamides (-SO 2 NH 2 , -SO 2 NHR, -SO 2 NRR 1 ); sulfones (-SO 2 -R); sulfoxides (-SO-
  • R amines (-NHR, NR'R); ureas (-NH-CO-NH 2 , -NH-CO-NHR); ethers (-O-R); halogens; carbamates (-NH-CO-OR); aldehyde-function (-CHO); then also inverse amides; sulfonamides and esters (-NH-CO-R, -NH-SO 2 -R, -OOC-R); with halogens; hydroxyl; ethers (-OR); amides (-CONH 2 , -CONHR, -CONRR 1 ); sulfonamides (-
  • NH-CO-NHR being especially preferred, [00334] or a pharmaceutically acceptable salt thereof, as such or especially for use in the diagnostic or therapeutic treatment of a warm-blooded animal, especially a human.
  • Rj. and R5 together with the N atom form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms (e.g. piperazinyl or lower alkyl piperazinyl) where when R4 and R5 together with the N form an heterocyclic ring, said ring may be substituted with 1, 2 or more of any of the substituents described herein, preferably piperazinyl, pyrrolidinyl, alkyl such as methyl, or hydroxy alkyl such as ethanyl.
  • heteroring formed by R4 and R5 together with the N examples include morpholinyl, which can be unsubstituted or substituted with methyl or dimethyl; piperazinyl which can be unsubstituted or substituted with 1, 2 or 3 substituents prefereably methyl, oxy or ethanol; or piperadinyl which can be unsubstituted or substituted with 1, 2 or 3 substituents prefereably pyrrolidinyl, amine, alkyl amine, methyl amine, dialkyl amine, dimethylamine or diethylamine;
  • R 2 is H, C 1 -C 3 lower alkyl (such as methyl) or aryl (such as phenyl or benzyl) or heterocyclyl (such as pyridyl, indolyl, thiophenyl.
  • thiazolyl or benzothiophenyl wherein the aryl or heterocyclyl may be substituted or unsubstituted with up to 4, preferably up to 2 substituents, wherein the substituents are the same or different and are independently selected from halo (such as Cl, F or Br); hydroxy; amino; amino lower alkyl; C 1 -C3 lower alkyl; alkoxy (such as methoxy and benzyloxy where the benzyl ring may be substituted or unsubstituted, such as 3, 4 — dichlorobenzyloxy); sulfoamino; substituted or unsubstituted benzosulfonamide (such as 2, 3-dichlorobenzene sulfonamide); substituted or unsubstituted sulfonate (such as chloro-phenyl sulfonate); substituted or unsubstituted ureas (such as 3-trifluoro- methyl-phenyl urea or
  • R 3 is H; Ci-C 3 alkyl; phenyl; pyridinyl or oxaz-5-yl; [00340] or a pharmaceutically acceptable salt thereof, as such or especially for use in the diagnostic or therapeutic treatment of a warm-blooded animal, especially a human.
  • a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical preparation for the treatment of an Eph receptor-related (e.g., neurological) injury and disorder.
  • a compound of the formula (I), or a pharmaceutically acceptable salt thereof as shown above for use in the treatment of an Eph receptor- related (e.g., neurological) injury and disorder.
  • the invention relates also to the use of pharmaceutical compositions comprising a compound of formula (I) in the therapeutic (in a broader aspect of the invention also prophylactic) treatment of an Eph receptor-related (e.g., neurological) injury and disorde.
  • an Eph receptor-related e.g., neurological
  • the pharmacologically acceptable compounds of the present invention may be used, for example, for the preparation of pharmaceutical compositions that comprise an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as active ingredient together or in admixture with a significant amount of one or more inorganic or organic, solid or liquid, pharmaceutically acceptable carriers.
  • compositions according to the invention are those for enteral, such as nasal, rectal or oral, or parenteral, such as intramuscular or intravenous, administration to warm-blooded animals (especially a human), that comprise an effective dose of the pharmacologically active ingredient, alone or together with a significant amount of a pharmaceutically acceptable carrier.
  • the dose of the active ingredient depends on the species of warm-blooded animal, the body weight, the age and the individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
  • the invention relates also to a method of treatment for a disease that responds to inhibition of a kinase; which comprises administering an (against the mentioned disease) prophylactically or especially therapeutically effective amount of a compound of formula (I)according to the invention, especially to a warm-blooded animal, for example a human, that, on account of one of the mentioned diseases, requires such treatment.
  • the dose of a compound of the formula (I) or a pharmaceutically acceptable salt thereof to be administered to warm-blooded animals is preferably from approximately 3 mg to approximately 1O g, more preferably from approximately 10 mg to approximately 1.5 g, most preferably from about 100 mg to about 1000 mg /person/day, divided preferably into 1-3 single doses which may, for example, be of the same size. Usually, children receive half of the adult dose.
  • compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient.
  • Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragees, tablets or capsules.
  • compositions of the present invention are prepared in a manner known per se, for example by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes.
  • Solutions of the active ingredient, and also suspensions, and especially isotonic aqueous solutions or suspensions are preferably used, it being possible, for example in the case of lyophilized compositions that comprise the active ingredient alone or together with a carrier, for example mannitol, for such solutions or suspensions to be produced prior to use.
  • the pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting and/or emulsifying agents, solubilizers, salts for regulating the osmotic pressure and/or buffers, and are prepared in a manner known per se, for example by means of conventional dissolving or lyophilizing processes.
  • the said solutions or suspensions may comprise viscosity-increasing substances, such as sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone or gelatin.
  • Suspensions in oil comprise as the oil component the vegetable, synthetic or semi-synthetic oils customary for injection purposes.
  • liquid fatty acid esters that contain as the acid component a long- chained fatty acid having from 8-22, especially from 12-22, carbon atoms, for example lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brasidic acid or linoleic acid, if desired with the addition of antioxidants, for example vitamin E, ⁇ -carotene or 3,5-di- tert-butyl-4-hydroxytoluene.
  • the alcohol component of those fatty acid esters has a maximum of 6 carbon atoms and is a mono- or poly-hydroxy, for example a mono-, di- or tri-hydroxy, alcohol, for example methanol, ethanol, propanol, butanol or pentanol or the isomers thereof, but especially glycol and glycerol.
  • fatty acid esters are therefore to be mentioned: ethyl oleate, isopropyl myristate, isopropyl palmitate, "Labrafil M 2375” (polyoxyethylene glycerol trioleate, Gattefosse, Paris), "Miglyol 812” (triglyceride of saturated fatty acids with a chain length of C8 to C 12, H ⁇ ls AG, Germany), but especially vegetable oils, such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.
  • vegetable oils such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.
  • injection compositions are prepared in customary manner under sterile conditions; the same applies also to introducing the compositions into ampoules or vials and sealing the containers.
  • compositions for oral administration can be obtained by combining the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture, if desired or necessary, after the addition of appropriate excipients, into tablets, dragee cores or capsules. It is also possible for them to be incorporated into plasties carriers that allow the active ingredients to diffuse or be released in measured amounts.
  • Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and binders, such as starch pastes using for example corn, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above- mentioned starches, and/or carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate.
  • fillers such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate
  • Excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol.
  • Dragee cores are provided with suitable, optionally enteric, coatings, there being used, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as ethylcellulose phthalate or hydroxypropylmethylcellulose phthalate.
  • Capsules are dry-filled capsules made of gelatin and soft sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the dry-filled capsules may comprise the active ingredient in the form of granules, for example with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and if desired with stabilizers.
  • the active ingredient is preferably dissolved or suspended in suitable oily excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilizers and/or antibacterial agents to be added.
  • suitable oily excipients such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilizers and/or antibacterial agents to be added.
  • Dyes or pigments may be added to the tablets or dragee coatings or the capsule casings, for example for identification purposes or to indicate different dose
  • the compounds of the invention may also be used to advantage in combination with other agents known to overcome process outgrowth inhibition such as Rho kinase inhibitors; inhibitors of classical PKC isoforms; blocking antibodies against NogoA or the Nogo receptor; Chondroitinase ABC or other reagents that cleave the GAG sidechains off proteoglycans; and agents that increase intrinsic growth capacity of neurons (e.g., cAMP and bcl-2).
  • agents known to overcome process outgrowth inhibition such as Rho kinase inhibitors; inhibitors of classical PKC isoforms; blocking antibodies against NogoA or the Nogo receptor; Chondroitinase ABC or other reagents that cleave the GAG sidechains off proteoglycans; and agents that increase intrinsic growth capacity of neurons (e.g., cAMP and bcl-2).
  • the compounds of the invention may be used in combinatorial therapy with an agent capable of blocking myelin inhibitors
  • MAG myelin-associated glycoprotein
  • OMgp oligodendrocyte-myelin glycoprotein
  • lenti viral expression vectors for wild type and kinase dead EphA4 are generated and overexpressed in purified astrocytes.
  • Cortical neurons are plated on the two astrocytic populations and neurite outgrowth assayed and compared.
  • Biological peptides that have been demonstrated to block the interaction of EphA4 with relevant ligands, consequently inhibiting receptor activation (Murai, K.K., et al., (2003) MoI Cell Neurosci 24(4): p.
  • astrocytes are treated with inflammatory cytokines (which have been shown to be involved in activating astrocytes) LIF or IFN in the presence or absence of EphA4 blocking peptides, and the cells are lysed and analyzed by Western Blots for the activation of major signaling pathways (MAPK, PI3K, JNK, STAT, RhoA) using appropriate phospho-antibodies.
  • the signaling involved in neurite outgrowth inhibition by EphA4 is assessed by culturing cortical neurons on astrocytes or on CNS myelin or spinal cord extracts in the presence or absence of commercially available pharmacological inhibitors of the major signaling pathways and also the E ⁇ hA4 inhibitory peptides.
  • astrocyte cultures are established from neonatal mouse cortex and purified so as to get about 95-98 pure astrocyte cultures.
  • the cells are incubated in the presence or absence of pharmacological inhibitors and then directly lysed and subjected to immunoprecipitation and Western analysis (as seen in Figure IA).
  • the cultures are then serum starved for 36 hours to reduce basal receptor phosphorylation and then stimulated for varying lengths of time with a soluble form of the cognate ligand in the presence or absence of candidate kinase inhibitors or blocking peptides, which are added at various concentrations.
  • Cells are lysed, and the lysates subjected to EphA4 immunoprecipitation and subsequently analysed on Westerns for level of receptor phosphorylation using a phospho-tyrosine antibody.
  • Example 3 In vitro Assay for Neurite Outgrowth / Axon Regeneration
  • This assay is used to assess neurite outgrowth inhibition" of embryonic cortical neurons by Eph receptors expressed on astrocytes or neurite outgrowth inhibition of post-natal cortical neurons by ephrin ligand present in myelin.
  • El 6 embryonic day 16 cortical neurons are plated onto confluent astrocyte monolayers plated in 4-well chamber slides.
  • FIG. 2 A depicts an example of neurons plated in the presence of Compound 1 and visualized with the neuronal marker, Tuj-1) and compared to average neurite length on astrocytes in the absence of any pharmacological agents.
  • Figure 2B depicts the quantitation of neurite outgrowth effects observed with Compound 6 and Compound 7 (all tested at 10OnM concentration) in cortical cultures plated on astrocytes.
  • Example 4 In vitro Assay for Astrogliosis - Astrocyte Scratch Wound
  • Assay Astrocytes are prepared from the cerebral cortex of neonatal C57BL/6 mice(Pl-P2).
  • astrocytes are maintained in Dulbecco's modified Eagle's medium with 10% FBS.4-7 weeks old astrocytes are plated to confluence in 2 well chamber slides coated with poly-D-lysine for the scratch wound assay and serum starved. 48 hrs after serum starvation, the monolayer of astrocytes is scratched with sterile 200 ⁇ l tips and washed twice with PBS to get rid of cell debris. Conditioned medium (+/- cytokines) is added to the wounded astrocytes. The microscopic images of the scratch is captured at a magnification of 10 X right after scratch and considered as time point 0. 24hrs, 48hrs or 72hrs after scratch, the same region of scratch is imaged and fixed with methanol containing l ⁇ g/ml of DAPI to monitor migration and proliferation of astrocytes.
  • High throughput screens can be developed to look for selective and specific pharmacological inhibitors of EphA4 activity.
  • Such compounds include kinase inhibitors or binding antagonists that block EphA4 interaction with its ligand and/or specifically block EphA4 kinase activation.
  • Example 7 In vivo Target Validation in a Mouse SCI Model
  • SCI spinal cord injury
  • Drug or vehicle e.g., containing one of the compounds of the invention
  • an anterograde tracer is used to track anatomical regeneration of lesioned axons.
  • Appropriate behavioral and electrophysiological assays can be performed to assess functional recovery of sensory and motor functions.
  • EphA4 inhibitory agents e.g., the compounds of the invention
  • Nogo signaling is compromised, to see if this results in a synergistic effect leading to improved functional recovery.
  • HPLC is performed on an Agilent HP 1100 using a Nucleosil 100-3 Ci 8 HD 125 x 4.0 mm column [1 mL/min.; 20-100% NeCN / 0.1% TFA in 7 minutes) (Method A); SpectraSystem SP8800/UV2000 using a Nucleosil 100-5 C 18 AB 250 x 4.6 mm column (2 mL/min.; 2-100% MeCN / 0.1% TFA in 10 minutes) (Method B); using a Chromalith Speed ROD RP18 50-4.6 mm column (Merck) (2 mL/min.; 2-100% MeCN / 0.1% TFA in 2 minutes) (Method C); or a C82.1-50 mm 3 ⁇ m column (Waters) (2 mL/min.; 5-95% MeCN / 0.1% TFA in 2 minutes) (Method D).
  • 1 H-NMR measurements are performed on a Varian Gemini 400 or a Bruker DRX 500 spectrometer using tetraethylsilane as internal standard. Chemical shifts are expressed in ppm downfield from tetraethylsilane and coupling constants (J) are expressed in Hertz (Hz). Electrospray mass spectra are obtained with a Fisons Instruments VG Platform II. Melting points are measured with a B ⁇ chi 510 melting point apparatus. Commercially-available solvents and chemicals are used for syntheses.
  • Example 8 3- ⁇ 7-Amino-3-[4-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[ 1 ,5-a]pyrimidin-6-yl ⁇ -phenol
  • Example 9 6-(3-Methoxy-phenyl)-3-[4-(4-methyl-piperazin-l-yl)- phenyl]-pyrazolo[ 1 ,5- ⁇ ]pyrimidin-7-ylamine
  • Example 10 6-(3,5-Dimethoxy-phenyl)-3-[4-(4-methyl-piperazin-l-yl)- phenyl]-pyrazolo[l,5- «]pyrimidin-7-ylamine
  • Example 11 Stage 1.1 : 6-(3-Benzyloxy-phenyl)-3-[4-(4-methyl-piperazin-
  • Example 1 The following Examples enlisted on Table 1 are synthesized analogously to the preparation of Example 8. As far as not being commercially-available, the syntheses of intermediates for the preparation of compounds of Examples 12-76 are described below Table II. In cases where the title compounds carry a free amino group (Examples 59-61), the final products are generated from their corresponding nitro-function carrying precursors by hydrogenation in the presence of Pd/C (10 %) in THF/MeOH during several hours. [00415] Table II.
  • Example 24 The compound of Example 24 is synthesized analogously to the preparation of compound of Stage 1.1 by condensing 2,3-dichloro-N-[4-(cyano-formyl-methyl)- phenyl]-benzenesulfonamide (Stage 10.1) and 4-(4-dimethylamino-phenyl)-2H- pyrazol-3-ylamine (Stage 10.3).
  • 2-(4-Dimethylamino-phenyl)-3-oxo-propionitrile is prepared from (4- dimethylamino-phenyl)-acetonitrile, ethyl formate and sodium as described in U.S.
  • Patent No. 2,989,539 (Example 25).
  • Example 18 is prepared analogously to the synthesis of the compound of Example 17 using 4-(4-dimethylamino-phenyl)-2//-pyrazol-3- ylamine (Stage 10.3) and 4-chloro-benzenesulfbnic acid 4-(cyano-formyl-methyl)- phenyl ester (Stage 11.1).
  • Stase 22.2 (2-(3-Methoxy- ⁇ henyl)-3-oxo-propionitrile) [00459] (2-(3-Methoxy-phenyl)-3-oxo-propionitrile) is prepared as described by
  • Stage 62a.1 f4-(Cvano-l -formvl-methvD-phenvlVcarbamic acid ethyl ester
  • [4-(Cyano-methyl)-phenyl]-carbamic acid benzyl ester (Stage 62a.2) (I g, 3.76 mmol) is formylated in analogy to the preparation of Stage 1.3 giving the corresponding carbamic acid ethyl ester (thereby also transforming the benzyl ester function into the ethyl ester function): colorless crystals (654 mg, 2.66 mmol, 70%).
  • ES-MS: M+H 233.0.
  • Compounds 68, 69, 71, 74, and 75 carrying sulfonamide and acetylamide functions are prepared by reacting the amino precursor with the corresponding sulfonic acid chloride or acetic acid anhydride in the presence of pyridine.
  • Example 79 6-(3-Chloro-phenyl)-5-methyl-3-[3-(4-methyl-piperazin-l- yl)-phenyl]-pyrazo- lo[l ,5-a]pyrimidin-7-ylamine
  • Stage 72.2 4-[3-(4-Methyl-piperazin-l-yl)-phenyl]-lH-pyrazol-3-ylamine [00548] The title compound is prepared as described in example 31 ; Stage 24.1 - 24.3
  • Example 80 6-(3-Chloro-phenyl)-5-methyl-3-[4-(4-methyl-piperazin-l- yl)-phenyl]-pyrazo- lo[l ,5-a]pyrimidin-7-ylamine [00550]
  • the title compound is prepared as described in example 86; using 4-[4-(4-)
  • Example 81 6-(3-Chloro-phenyl)-3-[2-methoxy-5-(4-methyl-piperazin-l- yl)-phenyl]-5-met- hyl-pyrazolo[l ,5-a]pyrimidin-7-ylamine
  • Stage 74.1 4-[2-Methoxy-5-(4-methyl-pi ⁇ erazin- 1 -yl)-phenyl]-2H- pyrazol-3 ⁇ ylamine
  • Example 82 6-(3-Chloro-phenyl)-3-[2-methoxy-4-(4-methyl-piperazin-l- yl)-phenyl]-5-met- hyl-pyrazolo[l ,5-a]pyrimidin-7-ylamine
  • Stage 75.1 4-[2-Methoxy-5-(4-methyl-piperazin-l-yl)-phenyl]-2H-pyr- azol-3 -ylamine.
  • the title compound is prepared as described in example 8,
  • Example 83 3- ⁇ 7-Amino-3-[2-methoxy-4-(4-methyl-piperazin-l-yl)- phenyl]- ⁇ yrazolo[l,5-a- ]pyrimidin-6-yl ⁇ -phenol [00559] The title compound is prepared by dissolving 6-(3-Benzyloxy-phenyl)-3-
  • Example 84 6-(2-Chloro-phenyl)-3-[4-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l,5-a]- pyrimidin-7-ylamine
  • Stage 77.1 (Z)-2-(2-Chloro-phenyl)-3-dimethylamino-acrylonitrile.
  • N,N-Dimethylformamide-dimethylacetal (9.06 mL; 64.3 mMol) and 2- chlorobenzylcyanide (1.95 g; 12.86 mMol) is heated under stirring to 100 0 C. under an atmosphere of Argon. After cooling to rt, the mixture is concentrated under reduced pressure and purified by and chromatography (silica gel, 12O g RediSep,
  • Example 85 6-(2-Chloro-phenyl)-3-[3-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l,5-a]- pyrimidin-7-ylamine
  • Example 86 6-(4-Fluoro-phenyl)-5-methyl-3 -[4-(4-methyl-piperazin- 1 - yl)-phenyl]-pyrazo- lo[l ,5-a]pyrimidin-7-ylamine [00569] The title compound is prepared as described in example 86; using 4-[4-(4-)
  • Example 87 6-(4-Fluoro-phenyl)-5-methyl-3-[3-(4-methyl-piperazin-l- yl)-phenyl]-pyrazo- lo[l ,5-a]pyrimidin-7-ylamine
  • Example 88 6-(3-Chloro-phenyl)-5-methyl-3- ⁇ 3-[4-(l-methyl-piperidin-
  • Stage 81.1 4- ⁇ 3-[4-(l-Methyl-piperidin-4-yl)-piperazin-l-yl]-phenyl ⁇ -2H- p- yrazol-3-ylamine.
  • Stage 82.1 2-(3-Chloro-4-fluoro-phenyl)-3-oxo-butyromtrile [00581] The title compound is prepared as described for example 79, Stage 72.1 using (3-Chloro-4-fluoro-phenyl)-acetonitrile instead. White crystals; mp. 133-134
  • Example 90 6-(3-Chloro-4-fluoro-phenyl)-5-methyl-3-[4-(4-methyl- piperazin-l-yl)-pheny- l]-pyrazolo[l,5-a]pyrimidin-7-ylamine
  • Example 91 6-(3-Bromo-phenyl)-5-methyl-3-[3-(4-methyl-piperazin-l- yl)-phenyl]-pyrazol- o[l ,5-a]pyrimidin-7-ylamine
  • Example 92 6-(3-Bromo-ben2yl)-3-[3-(4-methyl-pi ⁇ erazin-l-yl)- phenyl]pyrazolo[l ,5-a]py- rimidin-7-ylamine
  • Example 93 6-(3-Bromo-phenyl)-3-[3-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l,5-a]p- yrimidin-7-ylamine
  • Stage 86.1 (Z)-2-(3-Bromo-phenyl)-3-dimethylamino-acrylonitrile is prepared as described in example 77, Stage 77.1.: Gold brown crystals; mp. 102-105
  • Example 94 6-(3-Chloro-phenyl)-5-methyl-3-(3-morpholin-4-yl-phenyl)- pyrazolo[l,5-a]py- rimidin-7-ylamine
  • Stage 87.1 4-(3-M ⁇ holin-4-yl-phenyl)-2H-pyrazol-3-ylamine
  • Example 95 6-(3-Chloro-phenyl)-3-(4-methoxy-phenyl)-5-methyl- pyrazolo[l,5-a]pyrimidin- -7-ylamine [00600]
  • the title compound is prepared as described in example 86; using 4-(4-
  • Example 96 6-(3-Chloro- ⁇ henyl)-3-[3-((2R,6S)-2,6-dimethyl-morpholin-
  • Stage 89.1 4-[3-((2R,6S)-2,6-Dimethyl-mo ⁇ holin-4-yl)-phenyl]-2H- pyrazol— 3-ylamine
  • Example 97 2-(4- ⁇ 3-[7-Amino-6-(3-chloro-phenyl)-5-methyl- pyrazolo[l,5-a]pyrimidin-3-y- l]-phenyl ⁇ -piperazin-l-yl)-ethanol
  • Stage 90.1 2- ⁇ 4-[3-(5-Amino-lH-pyrazol-4-yl)-phenyl]-piperazin-l-yl)- etha- nol
  • Example 98 6-Benzyl-3-[3-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l,5-a]pyrimidin-7- -ylamine
  • Example 99 6-(3-Chloro-phenyl)-3-(3,4-dimethoxy- ⁇ henyl)-5- fluoromethyl-pyrazolo[l,5-a- ]pyrimidin-7-ylamine
  • Stage 92.1 2-(3-Chloro-phenyl)-4-fluoro-3-oxo-butyronitrile
  • Example 100 6-(3-Chloro-phenyl)-3-(3,4-dimethoxy- ⁇ henyl)-5-methyl- pyrazolo[l,5 ⁇ a]pyrim- idin-7-ylamine
  • Example 102 6-(3-Chloro-4-fluoro-phenyl)-3-(4-methoxy-phenyl)-5- methyl-pyrazolo[l ,5-a]- pyrimidin-7-ylamine [00624]
  • the title compound is prepared as described in example 86; using 4-(4-
  • Example 103 6-(4-Fluoro-phenyl)-3-(4-methoxy-phenyl)-5-methyl- pyrazolo[l,5-a]pyrimidin- -7-ylamine
  • Example 104 2-(4- ⁇ 3-[7-Amino-6-(4-fluoro-phenyl)-5-methyl- pyrazolo[ 1 ,5-a]pyrimidin-3-y- l]-phenyl ⁇ -piperazin- 1 -yl)-ethanol
  • Example 105 6-(3,4-Difluoro-phenyl)-5-methyl-3-[3-(4-methyI-piperazin- l-yl)-phenyl]-py- razolo[l,5-a]pyrimidin-7-ylamine
  • Example 106 6-(3,4-Difluoro-phenyl)-3-(3,4-dimethoxy-phenyl)-5- methyl-pyrazolo[l ,5-a]p- yrimidin-7-ylamine
  • Example 107 2-(4-(3-[7-Amino-6-(3-chloro-4-fluoro-phenyl)-5-methyl- pyrazolofl ,5-a]pyri- raidin-3-yl]-phenyl ⁇ -piperazin- 1 -yl)-ethanol
  • the title compound is prepared as described in example 86; using 2- ⁇ 4- [3- (5-Amino-lH-pyrazol-4-yl)-phenyl]-piperazin-l-yl ⁇ -ethanol (Example 90, Stage 90.1) and 2-(3-Chloro-4-fluoro-phenyl)-3-oxo-butyronit- rile (Example 82; stage 82.1) instead.
  • Example 108 2-(4- ⁇ 3-[7-Amino-6-(3,4-difluoro-phenyl)-5-methyl- pyrazolo[ 1 ,5-a]pyrimidin- -3 -yl]-phenyl ⁇ -piperazin- 1 -yl)-ethanol
  • the title compound is prepared as described in example 86; using 2- ⁇ 4-[3- (5-Amino-lH-pyrazol-4-yl)-phenyl]-piperazin-l-yl)-ethanol (Example 90, Stage 90.1) and 2-(3,4-difluoro-phenyl)-3-oxo-butyronitrile (Example 98; Stage 98.1) instead.
  • Example 109 6-(3-Chloro- ⁇ henyl)-5-methyl-3-[3-(4- ⁇ yrrolidin-l-yl- piperidin-1 -yl)-pheny- l]-pyrazolo[l ,5-a]pyrimidin-7-ylamine
  • Stage 102.1 4-[3-(4-Pyrrolidin-l-yl-piperidin-l-yl)-phenyl]-lH-pyrazol-3- - ylamine
  • Example 110 6-(4-Fluoro-phenyl)-5-methyl-3-[3-(4-pyrrolidin-l -yl- piperidin- l-yl)-pheny- l]-pyrazolo[l,5-a]pyrimidin-7-ylamine
  • Example 111 6-(3-Chloro-phenyl)-3-[3-(4-diethylamino-piperidin-l-yl)- phenyl]-5-methyl— pvrazolo[l,5-a]pyrirnidin-7-ylarnine
  • Stage 104.1 ⁇ l-[3-(3-Amino-lH-pyrazol-4-yl)-phenyl]-piperidin-4-yl ⁇ - dieth- yl-amine
  • Example 112 3-[3-(4-Diethylamino-piperidin-l-yl)-phenyl]-6-(4-fluoro- phenyl)-5-methyl ⁇ pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine
  • Example 113 6-(4-Fluoro-phenyI)-5-methyl-3-[3-(4-methyl-4-oxy- piperazin-1 -yl)-phenyl] ⁇ pyrazolo[l,5-a]pyrimidin-7-ylamine
  • Example 114 6-(4-Fluoro-phenyl)-5-methyl-3-[3-(4-methyl-l,4-dioxy- piperazin- 1 -yl)-phen- yl]-pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine
  • Example 116 6-(3,4-Difluoro-phenyl)-3-[3-(4-dimethylamino-piperidin-l- yl)-phenyl]-5-me- thyl-pyrazolo[l,5-a]pyrimidin-7-ylamine
  • Example 117 6-(3-Chloro-phenyl)-5-methyl-3-(3,4,5-trimethoxy-phenyl)- pyrazolo[l,5-a]py- r ⁇ midin-7-ylamine
  • Example 118 6-(3,4-D ⁇ fluoro-phenyl)-5-methyl-3-(3,4,5-trimethoxy- phenyl)-pyrazolo[l ,5— a]pyrimidin-7-ylamine
  • Example 119 6-(3-Chloro-phenyl)-3-(3-methoxy-phenyl)-5-methyl- pyrazolo[l,5-a]pyrimidin- -7-ylamine
  • Example 120 6-[7-Amino-3-(3,4-dimethoxy-phenyl)-py ⁇ azolo[l,5- a]pyrimidin-6-yl]-pyridin- -2-ol
  • Example 121 6-Beri2yl-3-(3,4-dimethoxy-phenyl)-pyrazolo[l,5- a]pyrimidin-7-ylamine
  • Example 122 3-(3,4-Dimethoxy-phenyl)-6-(3-fluoro-benzyl)- pyrazolo[l,5-a]pyrimidin-7-yl- amine
  • Example 123 Tablets 1 comprising compounds of the formula (I)
  • Tablets comprising, as active ingredient, 50 mg of any one of the compounds of formula (I) mentioned in the preceding Examples 8-122 of the following composition are prepared using routine methods:
  • Example 124 Tablets 2 comprising compounds of the formula (I)
  • Tablets, comprising, as active ingredient, 100 mg of any one of the compounds of formula (I) of Examples 8-122 are prepared with the following composition, following standard procedures:
  • Capsules comprising, as active ingredient, 100 mg of any one of the compounds of formula (I) given in Examples 8-122, of the following composition are prepared according to standard procedures:
  • Manufacturing is done by mixing the components and filling them into hard gelatine capsules, size 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to methods of using the compounds of the invention, including pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof, as well as pharmaceutical compositions comprising the same, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders. The invention also relates to modulating the activity of an Eph receptor in a cell, stimulating neural regeneration, and reversing neuronal degeneration, by administering a compound of the invention to a cell or subject in an effective amount.

Description

USE OF PYRAZOLO[l,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS
BACKGROUND OF THE INVENTION
[001] Injury to the adult mammalian central nervous system (CNS) is often characterized by axonal impairment, including an inability of severed axons to regrow to their targets, resulting in permanent paralysis in subjects with said injuries. There currently exists no cure for patients who have suffered such CNS-related trauma as spinal cord injury (SCI), which is very often accompanied by debilitating clinical conditions like paraplegia or quadriplegia.
[002] Axonal regeneration (e.g., post-injury) is prevented by a host of inhibitory influences in the adult CNS, among them inhibitory myelin proteins and the formation of a glial scar. Considerable progress has been made in identifying molecules associated with myelin inhibition (e.g., Nogo, myelin-associated glycoprotein (MAG), and oligodendrocyte-myelin glycoprotein (OMgp)), but relatively little is known about the glial scar which is formed as a response of glial cells to injury. (GrandPre, T., et al. (2000) Nature, 403(6768): 439; Fournier, A.E. et al. (2001) Nature 409(6818): 341; Wang, K.C., et al. (2002) Nature 417(6892): 941; and Wang, K.C., et al. (2002) Nature 420(6911): 74). Glial scarring is characterized by astrocytic gliosis, in which normally quiescent astrocytes proliferate and grow hypertrophic in response to injury, and otherwise form a physical and chemical barrier to axon regeneration. (Silver, J., et al. (2004) Nat Rev Neurosci 5(2): 146; and Morgenstern, D.A., et al. (2002) Prog Brain Res. 137: 313). Although a range of glial cells contribute to scar formation, the astrocytic response (i.e., astrocytic gliosis) is thought to be the primary mechanism for this occurrence.
[003] The Eph receptor tyrosine kinase subfamily is thought to be the largest subfamily of transmembrane receptor tyrosine kinases, and with its ligands, the ephrins, is responsible for governing proper cell migration and positioning during neural development, presumably through modulating intercellular repulsion. (Pasquale, E. (1997) Curr. Opin. Cell Biol. 9:608-615)(Orioli and Klein (1997) Trends in Genetics 13:354-359). Eph receptors are closely related, and actively signal when bound to their ephrin ligands (their effects are mediated by cell-to-cell contacts), with which they are capable of both forward and bi-directional signaling. (Murai, K.K., et al. (2003) J Cell Sci. 116: 2823). [004] The Eph receptors are known regulators of neural development, with roles in the regulation of migrating cells or axons, the establishment of tissue patterns and topographic maps in distinct regions of the developing brain, and the regulation of synapse formation and plasticity. Eph receptors, including EphA4 and EphA7, are upregulated after spinal cord damage or deafferentation. (Miranda, et al. (1999) Exp Neurol 156:218; Willson, et al. (2002) Cell Transplantation 11 :229); therefore, their inhibition is viewed as a potential therapeutic strategy for the treatment of neurological disorders.
[005] A significant step toward curing or ameliorating complications resulting from spinal cord injury has been wanting, owing to the complex and multi-factorial nature of SCIs. In vivo studies have been performed to assess recovery following SCI by blocking either myelin inhibitors (GrandPre, T., et al. (2002) Nature 417(6888): 547; Kim, J.E., et al. (2003) Neuron 38(2): 187), chondroitin sulfate proteoglycans (Bradbury, E. J., et al. (2002) Nature 416 (6881): 636) or signaling molecules downstream of both of these (Fournier, A.E., et al. (2003) J Neurosci. 23(4): 1416; and Sivasankaran, R., et al. (2004) Nat Neurosci. 7(3): 261), with only marginal success. Experimental inhibition of Eph receptors, however, has revealed considerable axon regeneration following injury and suppressed astrocytic gliosis, leading to a dramatic reduction in glial scarring, and making these receptors an ideal therapeutic target for spinal cord injury and stroke, which also results in axonal damage and gliosis. Strategies and therapeutics designed to block Eph receptor function therefore herald a significant advance in the treatment of CNS-related disorders, and could presumably lead to vastly improved recovery following neural injury such as SCI, stroke and other neurodegenerative disorders.
SUMMARY OF THE INVENTION
[006] The invention relates to methods of using of the compounds of the invention for the treatment of Eph receptor-related (e.g., neurological) injuries and disorders, and methods of using pharmaceutical preparations comprising the compounds of the invention in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders.
[007] The invention also relates to methods of modulating the activity of an Eph receptor in a cell by contacting the cell with an effective amount of the compounds of the invention. In certain embodiments, Eph receptors can be modulated either in vitro or in vivo.
[008] The invention also relates to methods of stimulating and promoting neural regeneration (such as axon regeneration following spinal cord injury), and reversing neuronal degeneration due to traumatic injury, hypoxic conditions, or infarct (e.g., as in stroke or nerve degeneration that is an underlying cause in multiple sclerosis and other neurodegenerative diseases). One way in which this can be achieved is through the administration to a mammal of a compound of the invention in an amount that is sufficient to stimulate and promote neural regeneration (such as axon regeneration) or reverse neuronal degeneration. The compounds of the invention can be delivered to both normal and injured cells. In some embodiments, the compounds of the invention inhibit the phosphorylation of an Eph receptor. In other embodiments, the compounds of the invention inhibit the binding of ephrin ligands to Eph receptors. [009] The invention also relates to methods for delivering a therapeutic agent to a cell, such as via a conjugate which comprises a therapeutic agent (e.g., a linking reagent) linked to compound of the invention.
[0010] As described herein and in PCT publication WO05/070431 (the contents of which are hereby incorporated by reference), the compounds of the invention, e.g., pyrazolo[l,5a]pyrimidin-7-yl amine derivatives, are, among other things, useful as protein kinase inhibitors and thus in the treatment of protein kinase-related disorders. By way of example, the compounds of the invention are useful as receptor tyrosine kinase inhibitors, such as Ephrin receptor kinase inhibitors, and can therefore be used to treat, e.g., neurological injuries and disorders.
BRIEF DESCRIPTION OF THE FIGURE(S)
[0011] Figures IA and IB show inhibition of EphA4 auto-phosphorylation and ligand-dependent phosphorylation, respectively (from samples subjected to EphA4 immunoprecipitation followed by a phospho-tyrosine Western blot). Figure IA, lanes 1 and 2 represent samples from cells treated with either control IgG-Fc or with the ligand ephrinB3-Fc. Lanes 2-6 represent samples from cells that have been pre- treated with Compound 1 (10OnM) and are then stimulated with IgG-Fc or ephrinB3- Fc in the combined presence of the inhibitor (Compound I)(lanes 3,4) or in its absence (lanes 5,6). Figure IB, lanes 1 and 2 show EphA4 phosphorylation in control (untreated) and ephrinB3-Fc stimulated cells following serum starvation. All other lanes represent samples from cells stimulated with ephiinB3-Fc in the presence of varying concentrations (as indicated) of tested Eph inhibitors. [0012] Figure 2A shows immunofluroscence images demonstrating that Eph receptor inhibitors (e.g., Compound I (10OnM)) are able to overcome neurite outgrowth inhibition at nanomolar concentrations. Figure 2B shows a graphical representation of experimentally-determined neurite outgrowth inhibition. The Y axis shows average neurite length in microns.
[0013] Figure 3 shows a graphical representation of the experimental determination that Eph receptor inhibitors block astrocyte migration induced by cytokines (TGF-α, LIF, and IFN). The Y axis shows average relative distance of cell migration compared to control (serum free = 1). The white bar represents the addition of Compound 6. The black bar represents no compounds added. [0014] Figure 4 demonstrates that Eph receptor inhibitors block EphA4 phosphorylation in vivo in mouse brain (brain homogenate lysates were subjected to EphA4 immunoprecipitation followed by a phospho-tyrosine Western blot). Animals were given an i.v dose of relevant compound and sacrificed 25 minutes or 1 hour after dosing (0.25h or Ih), the brains removed and subjected to EphA4 immunoprecipitation followed by a phospho-tyrosine Western blot. Four animals were used as controls and three animals each were used per time point for each drug. From top to bottom, the compounds tested were Compound 1, Compound 7, and Compound 6.
[0015] Figures 5A and 5B shows methods of preparation of the compounds of formula (I). As described below, Figure 5B describes the preparation of compounds of formula (I) beginning with synthesizing the pyrazolo[l,5-a]pyrimidin-7-ylamine core scaffold carrying a corresponding functional group (X) where residues A, R2, or R3, respectively, can be introduced by known reactions as indicated. [0016] Figure 6 shows a method of preparation of Compounds 9 and 10.
DETAILED DESCRIPTION OF THE INVENTION
[0017] The present invention relates to compounds of the invention, including pyrazolo[l,5a]pyrimidin-7-yl amine compounds, of the formula (I):
Figure imgf000006_0001
[0018] wherein:
[0019] R2 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
[0020] R3 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or an aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring,
[0021] at least one of R2 or R3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
[0022] A is H, halogen (such as bromo), an aliphatic moiety, a functional group, substituted or unsubstituted aryl or heteroaryl; and
[0023] Ri is H, halogen or lower alkyl,
[0024] or pharmaceutically acceptable salts thereof, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders or for the manufacture of pharmaceutical compositions for use in the treatment of said injuries and disorders, methods of use of compounds of formula (I) in the treatment of said injuries and disorders, pharmaceutical preparations comprising compounds of formula (I) for the treatment of said injuries and disorders, compounds of formula (I) for use in the treatment of said diseases.
[0025] A preferred embodiment is the use of a compound according to the above, wherein:
[0026] R2 is H; lower alkyl; cycloalkyl; benzyl; benzo thienyl, indyl substituted by lower alkyl, pyridyl or thiazolyl optionally substituted by lower alkyl; unsubstituted phenyl or phenyl substituted by one or two substituents chosen from the group consisting of; halo, hydroxy, alkoxy, benzyloxy, cycloalkyl, amino, acetyl amino, lower alkyl sulfonamide and benzene sulfonamide substituted by one or two halo; •
[0027] R3 is H; lower alkyl optionally substituted by halo; phenyl, pyridyl, or oxazolyl;
[0028] A is: (a) H; halo; benzothienyl; pyridyl; methyl piperazinyl phenoxyl; indolyl substituted with lower alkyl;
[0029] (b) phenyl which is unsubstituted or substituted with one or more of the substituents chosen from the group consisting of; mono-, di- or tri-lower alkoxy, di- lower alkylaminyl, morpholinyl which is optionally di-substituted by alkyl, piperazinyl which is substituted with one or more of the substituents chosen from the group consisting of lower alkyl, lower alkoxy, lower alkyl piperazinyl, pyrrolidinyl, dialkyl aminyl and lower alkanol; and
[0030] Ri is H, or pharmaceutically acceptable salts thereof for treating Eph receptor-related (e.g., neurological) injuries and disorders.
[0031] As described herein, the compounds of the invention, e.g., compounds of formula (I), e.g., pyrazolo[l,5a]pyrimidin-7-yl amine derivatives, are, among other things, useful in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders.
[0032] Pyrazolo[l,5a]pyrimidin-7-yl amine derivatives have demonstrated surprisingly pharmaceutically advantageous properties, inter alia allowing for the inhibition of specific types or classes or groups of kinases, including Eph receptor kinases. In addition to this established activity, the pyrazolo[l,5a]pyrimidin-7-yl amine derivatives have the advantage that their backbone in addition allows for substitution patterns that offer a broad possibility to achieve a fine tuning for specific interaction with the binding site of the targeted kinase or kinases, thus opening a new perspective and providing kinase inhibitors of various degrees of specificity. In view of these activities, the compounds of the invention can be used for the treatment of diseases related to especially aberrant or excessive activity of such types of kinases, e.g., Eph receptor-related (e.g., neurological) injuries and disorders.
[0033] Most preferably, the disease to be treated is neurological injury or disorder, as described in greater detail herein.
[0034] In a further embodiment, the invention relates to a compound of formula
(D:
Figure imgf000008_0001
[0036] wherein:
[0037] R2 is H; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; an aliphatic residue; a functional group; or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
[0038] F-3 can be H, substituted or unsubstituted aryl, heteroaryl, an aliphatic residue, a functional group, or an aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring,
[0039] at least one of R2 or R3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a] pyrimidinyl ring, and provided that both R2 and A cannot both be unsubstituted phenyl;
[0040] A is H, halogen (such as brorno), an aliphatic moiety, a functional group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; and
[0041] Ri is H, halogen or lower alkyl,
[0042] or a pharmaceutically acceptable salt thereof.
[0043] A preferred embodiment is a compound according to the above, wherein;
[0044] R2 is H; lower alkyl; cycloalkyl; benzyl; benzo thienyl, indyl substituted by lower alkyl, pyridyl or thiazolyl optionally substituted by lower alkyl; unsubstituted phenyl or phenyl substituted by one or two substituents chosen from the group consisting of; halo, hydroxy, alkoxy, benzyloxy, cycloalkyl, amino, acetyl amino, lower alkyl sulfonamide and benzene sulfonamide substituted by one or two halo;
[0045] R3 is H; lower alkyl optionally substituted by halo; phenyl, pyridyl, or oxazolyl;
[0046] A is
[0047] H; halo; benzothienyl; pyridyl; methyl piperazinyl phenoxyl; indolyl substituted with lower alkyl; [0048] (b) phenyl which is unsubstituted or substituted with one or more of the substituents chosen from the group consisting of; mono-, di- or tri-lower alkoxy, di- lower alkylaminyl, moφholinyl which is optionally di- substituted by alkyl,
[0049] piperazinyl which is substituted with one or more of the substituents chosen from the group consisting of lower alkyl, lower alkoxy, lower alkyl piperazinyl, pyrrolidinyl, dialkyl aminyl and lower alkanol; and
[0050] Ri is H; and provided that both R2 and A cannot both be unsubstituted phenyl.
[0051] Most preferably, the compound is selected from the group consisting of:
[0052] 6-(3-Chloro-phenyl)-3-[3-(4-diethylamino-piperidin-l-yl)-phenyl]-5- methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine (also referred to herein as "Compound l");
[0053] ό-P-Chloro-phenyO-S-^-dimemoxy-pheny^-S-methyl- pyrazolo[l ,5- ajpyrirnidin-7-ylarnine (also referred to herein as "Compound 3");
[0054] 2-(4-{3-[7-Amino-6-(3-chloro-4-fluoro-phenyl)-5-methyl-pyrazolo[l,5- a]pyrimidin-3-yl]-phenyl}-piperazin-l-yl)-ethanol (also referred to herein as
"Compound 4");
[0055] 6-(3-Chloro-phenyl)-5-methyl-3-{3-[4-(l -methyl-piperidin- 4-yl)- piperazin-l-yl]-phenyl}-pyrazolo[l,5-a]pyrimidin-7-ylamine (also referred to herein as "Compound 5");
[0056] 6-(3-Chloro-phenyl)-3-(354-dimethoxy-phenyl)-5-piperazin-l-ylmethyl- pyrazolo[l,5-a]pyrimidin-7-ylamine (also referred to herein as "Compound 6");
[0057] 6-(3-Chloro-phenyl)-3-[4-(2-dimethylamino-ethoxy)-phenyl]-5-methyl- pyrazolo[l,5-a]pyrimidin-7ylamine (also referred to herein as "Compound 7");
[0058] N- { 3 - [ 1 -(4-Methoxy-phenyl)- 1 H-pyrazolo[3,4-d]pyrimidin-4-ylamino] -A- methyl-phenyl}-3-trifluoromethyl-benzamide (also referred to herein as "Compound
8");
[0059] 3-(3-Bromo-phenyl)-6-(3-chloro-phenyl)-5-fluoromethyl-pyrazolo[l,5- a]pyrimidin-7-ylamine (also referred to herein as "Compound 9");
[0060] 6-(3-Chloro-phenyl)-3-[3-(4-diethylamino-piperidin-l-yl)-phenyl]-5- fluoromethyl-pyrazolo[l,5-a]pyrimidin-7-ylamine (also referred to herein as
"Compound 10");
[0061] 3- {7-Amino-3-[4-(4-methyl-piperazin-l -yl)-phenyl]- pyrazolo[l ,5- a]pyrimidin-6-yl } -phenol ; [0062] 6-(3- benzyloxy-ρhenyl)-3-[4-(4-methyl~piperazin- 1 -yl)- phenyl]- pyrazolo[l ,5-a] pyrimidin-7-yl} -phenol;
[0063] 6-(3-Methoxy-phenyl)-3-[4-(4-methyl-piperazin-l -yl)- phenyl]- pyrazolo[l ,5-a]pyrimidin-7-ylamine;
[0064] 6-(3,5-Dimethoxy-ρhenyl)-3-[4-(4-methyl-piρerazin-l- yl)- phenyl]- pyrazolo[l,5-a]pyrimidin-7-ylamine;
[0065] 6-(3-Bemzyloxy-phenyl)-3-[4-(4-methyl-piperazin-l -yl)- phenyl]- pyrazolo[l ,5-a]pyrimidin-7-ylamine;
[0066] 6-(4-Chloro-phenyl)-3-[4-(4-methyl-piperazin-l-yl)-phenyl] -pyrazolo[l ,5- a]pyrimidin-7-ylamine;
[0067] 6-(3-Chloro-phenyl)-3-[4-(4-methyl-piperazin-l-yl)-phenyl]-pyrazolo[l,5- a]pyrimidin-7-ylamine;
[0068] 3-[4-(4-Methyl-piperazin-l-yl)-phenyl]-6-phenyl- pyrazolo[l,5- a]pyrimidin-7- ylamine;
[0069] 5-Methyl-3-[4-(4-methyl-piperazin-l-yl)-phenyl]-6-phenyl- pyrazx>lo[l,5- a]pyrimidin-7-ylamine;
[0070] 6-Methyl-3-[4-(4-methyl-pϊρerazin- 1 -yl)-phenyl]-5-phenyl- pyrazolo[l ,5- a]pyrimidin-7-ylamine;
[0071] N-{4-[7-Amino-3-(4-dimethylamino-phenyl)-pyrazolo[l ,5-a] pyrimidin-6- yl]-phenyl}-2,3-dichloro-benzenesulfonamide;
[0072] 4-Chloro-benzenesulfonic acid 4-[7-amino-3-(4- dimethylamino-phenyl)- pyrazolo[l ,5-a]pyrimidin-6-yl]~phenyl ester;
[0073] 6-(4-Methoxy-phenyl) -5-methyl-3-phenyl-pyrazolo[l,5-a] pyrimidin-7- ylamine;
[0074] 3-(4-Methoxy-phenyl)-5-methyl-6-phenyl-pyrazolo[l ,5-a] pyrimidin-7- ylamine;
[0075] 6-(4-Bromo-phenyl)-3-(4- methoxy-phenyl)-5-methyl- pyrazolo[l,5- a]pyrimidin-7-ylamine;
[0076] 6-(4-Bromo-phenyl)-5-methyl-3-phenyl-pyτazolo[l,5-a]pyriπiidin-7- ylamine;
[0077] 6-(2,6-Dichloro-phenyl)-3- phenyl-pyrazolo[l,5-a]pyrimidin- 7-ylamine;
[0078] 3-(3-Methoxy-phenyl)-6-phenyl-pyrazolo[l ,5-a]pyrimidin-7- ylamine;
[0079] 3-Bromo-5-phenyl-pyrazolo[l ,5-a]pyrimidin-7-ylamine; [0080] 6-Benzo[b]thiophen-3-yl-3-[4-(4-methyl-piperazin-l-yl)- phenyl]- pyrazolo [ 1 ,5 -a]pyrimidin-7-ylamine;
[0081] 3-(4-Bromo-phenyl)-5-phenyl-pyrazolo[ 1 ,5-a]pyrimidin-7- ylamine;
[0082] 3-[4-(4-Methyl-piperazin-l-yl)-phenyl]-6-thiophen-3-yl-pyrazolo[l,5- a]pyrimidin-7-ylamine;
[0083] 3-Benzo[b]thiophen-3-yl-6-(3-methoxy-phenyl)-pyrazolo[l ,5- a]pyrimidin-
7-ylamine;
[0084] 6-Benzo-3-[4-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l, 5- a]pyrimidin-7-ylamine;
[0085] 6-(3-Methoxy-phenyl)-3-[3-(4-methyl-piperazin-l-yl)- phenyl]- pyrazolo [ 1 ,5-a]pyrimidin-7-ylamine;
[0086] 6-(l-Methyl-lH-indol-3-yl)-3-[4-(4-methyl-piperazin-l-yl)- phenyl]- pyrazolo [1,5 -a]pyrimidin-7-ylamine;
[0087] 6-(4-Methoxy-phenyl)-3-[4-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolofl >5-a]pyrimidin-7-ylamine;
[0088] 6-(2-Methoxy-phenyl)-3-[4-(4-methyl-piperazin-l -yl)- phenyl]- pyrazolo[l,5-a] pyrimidin-7-ylamine;
[0089] 6-(3-Methoxy-phenyl)-3-pyridin-3-yl-pyrazolo[l ,5-a] pyrimidin-7-ylamine;
[0090] 3-{7- Amino-3-[3-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l,5- a]pyrimidin-6-yl } -phenol ;
[0091] 6-(3-Benzyloxy-phenyl)-3-[2-methoxy-5-(4-methyl-piperazin- 1-yl)- phenyl]-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[0092] 3-{7-Amino-3-[2-methoxy-5-(4-methyl-piperazin-l-yl)- phenyl]- pyrazolo[l,5-a]pyrimidin-6-yl}-phenol;
[0093] 6-(2-Benzyloxy-phenyl)-3-[4-(4-methyl-piperazin- 1 -yl)- phenyl]- pyrazolo [ 1 , 5 -a]pyrimidin-7-ylamine;
[0094] 2-{7-Amino-3-[4-(4-methyl-piperazin-l-yl)-phenyl]- pyτazolo[l ,5- a]pyrimidin-6-yl} -phenol;
[0095] 6-(4-Benzyloxy-phenyl)-3-[4-(4-methyl-piperazin- 1 -yl)- phenyl]- pyrazolo [ 1 ,5-a]pyrimidin-7-ylamine;
[0096] 4-{7-Amino-3-[4-(4-methyl-piperazin-l-yl)-phenyl]- pyrazoIo[l,5- a]pyrimidin-6-yl } -phenol ;
[0097] 6-(2-Benzyloxy-phenyl)-3-[3-(4-methyl- piperazin-1 -yl)- phenyl]- pyrazolo[l,5-a]pyrimidin-7-ylamine; [0098] 2-{7-Amino-3-[3-(4-methyl-piperazin-l-yl)-phenyl]- pyτazolo[l, 5- a]pyrimidin-6-yl}-phenol;
[0099] 6-(4-Benzyloxy-phenyl)-3-[3-(4-methyl-piperazin-l -yl)- phenyl]- pyrazolo[l,5-a]pyrimidin-7- ylamine;
[00100] 4-{7-Amino-3-[3-(4-methyl-piperazin-l-yl)-phenyl]- pyτazolo[l,5- a]pyrimidin-6-yl} -phenol;
[00101] 6-(2-Ben2yloxy-phenyl)-3-[2-methoxy-5-(4-methyl-piperazin- 1-yl)- phenyl]- pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine;
[00102] 2- {7-Amino-3-[2-methoxy-S-(4-methyl-piperazin- 1 -yl)- phenyl]- pyrazolo[l ,5-a]pyrimidin-6-yl} -phenol;
[00103] 6-(4-Benzyloxy-phenyl)-3-[2-methoxy-5-(4-methyl-piperazin- 1-yl)- phenyl)-pyrazololo[ 1 ,5-a]pyrimidin-7-ylamine;
[00104] 4-{7-Amino-3-[2-methoxy-5-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l ,5-a]pyrimidin-6-yl} -phenol;
[00105] 6-(3-Benzyloxy-phenyl)-3-[l-methyl-lH-indol-3-yl)- pyrazolofl ,5- a]pyrimidin-7-ylamine;
[00106] 3-[7-Amino-3-(l-methyl-lH-indol-3-yl)-pyrazolo[l ,5-a] pyrimidin-6-yl]- phenol;
[00107] 3-[7-Amino-3-pyridin-3-yl-pyrazolo[l,5-a]pyrimidin-6-yl]- phenol;
[00108] 6-(3-Benzyloxy-phenyl)-3-(2-methoxy-phenyl)-pyrazolo[l,5- a] pyrimidin-
7-ylamine;
[00109] 3-[7-Amino-3-(2-methoxy-phenyl)-pyrazolo[l ,5-a]pyrimidin- 6-yl]-phenol;
[00110] 3-[3-(4-Methyl-piperazin-l -yl)-phenyl]-6-thiophen-3-yl- pyrazolo[l,5- a]pyrimidin-7-ylaraine;
[00111] 3-(2-Methoxy-5-(4-methyl-piperazin-l-yl)-phenyl]-6- thiophen-3-yl- pyrazolofl ,5-a]pyrimidin-7-ylamine;
[00112] 3-[4-(4-Methyl-piperazin-l-yl)-phenyl]-6-pyridin-4-yl-pyrazolo[l,5- a]pyrimidin-7-ylamine;
[00113] 6-(3-Amino-phenyl)-3-[3-(4-methyl-piperazin-l-yl)-phenylJ- pyrazolo[l ,5- ajpyrimidin- 7-ylamine;
[00114] 6-(3-Amino-phenyl)-3-[4-(4-methyl- piperazin- 1 -yl)-phenyl]- pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00115] 6-(2-Amuio-phenyl)-3-[4-(4-methyl-piperazin-l-yl)-phenyl]-pyrazolo[l,5- a]pyrimidin-7-ylamine; [00116] 3-[4-(4-Methyl-piperazin-l-yl)-phenyl]-6-(4-methyl- thiazol-2-yl)- pyrazolo[l,5-a] pyrimidin-7-ylamine;
[00117] 6-Benzo[b]thiophen-3-yl-3-[2-methoxy-5-(4-methyl- piperazin-l-yl)- phenyl]-pyrazolo[l ,5-a]pyrimidin-7- ylamine;
[00118] 6-Benzo[b]thiophen-3-yl-3-[4-methoxy- phenyl)-pyrazolo[l,5- a]pyrimidin-7-ylamine;
[00119] 3-(3- Methoxy-phenyl)-6-thiophen-3-yl-pyrazolo[l ,5-a] pyrimidin-7- ylamine;
[00120] 6-(3-Benzyloxy-phenyl)-3-(3-methoxy-phenyl)-pyrazolo[l,5-a]pyrimidin-
7-ylamine;
[00121] 3-[7-Amino-3-(3-methoxy-phenyl)-pyrazolo[l ,5-a]pyrimidin- 6-yl]-phenol;
[00122] (4-{7-Amino-3-[4-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l,5- a]pyrimidin- 6-yl}-phenyl)-carbamic acid ethyl ester
[00123] 6-(3-Chloro- phenyl)-5-methyl-3-[3-(4-methyl-piperazin-l- yl)-phenyl]- pyrazolo[l,5-a] pyrimidin-7-ylamine;
[00124] 6-(3-Chloro-phenyl)-5-methyl-3-[4-(4-methyl-piperazin-l - yl)-phenyl]- pyrazolo [ 1 ,5-a]pyrimidin-7-ylamine;
[00125] 6-(3-Chloro-phenyl)-3-[2-methoxy-5-(4-methyl-piperazin- 1 - yl)-phenyl]-5- methyl-pyτazolo[ 1 ,5-a]pyrimidin-7-ylamine;
[00126] 6-(3-Chloro-phenyl)-3-[2-methoxy-4-(4-methyl-piperazin-l- yl)-phenyl]-5- methyl-pyrazolo [ 1 ,5-a]pyrimidin-7-ylamine;
[00127] 3-{7-Amino-3-[2-methoxy-4-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo [ 1 ,5 -a]pyrimidin-7-phenol;
[00128] 6-(2-Chloro-phenyl)-3-[4-(4-methyl-piperazin- 1 -yl)-phenyl] -pyrazolo[l ,5- a] pyrimidin-7-ylamine;
[00129] 6-(2-Chloro-ρhenyl)-3-[3-(4-methyl-piperazin-l-yl)-phenyl] -pyrazolo[l,5- a]pyrimidin-7-ylamine;
[00130] 6-(4-Fluoro-phenyl)-5-methyl-3-[4-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l ,5-a]pyrimidin-7-ylamine;
[00131] 6-(4-Fluoro-phenyl)-5-methyl-3-[3-(4-methyl-piperazin-l - yl)-phenyl]- pyτazolo[l ,5-a]pyrimidin-7-ylamine;
[00132] 6-(3-Chloro-4-fluoro-phenyl)-5-methyl-3-[3-(4-methyl- piperazin- 1 -yl)- phenyl] pyrazolo[l ,5-a]pyrimidin-7-ylamine; [00133] 6-(3-Chloro-4-fluoro-phenyl)-5-methyl-3-[4-(4-methyl- piperazin-1-yl)- phenyl]- pyrazolo[l ,5-a]pyrimidin-7-ylamine;
[00134] 6-(3-Bromo-phenyl)-5-methyl-3-[3-(4-methyl-piperazin-l -yl) -phenyl]- pyrazolo[l,5-a] pyrimidin-7-ylamine;
[00135] 6-(3-Bromo-benzyl)-3-[3-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l ,5- a]pyrimidin-7-ylamine;
[00136] 6-(3-Bromo-phenyl)-3-[3-(4-methyl-piperazin-l-yl)-phenyl]-pyrazolo[l,5- a]pyrimidin-7-ylamine;
[00137] β-CS-Chloro-pheny^-S-methyl-S-CS-morpholin^-yl-phenyO- pyrazoIotUS- a]pyrimidin-7- ylamine;
[00138] 6-(3-Chloro-phenyl)-3-(4-methoxy- phenyl)-5-methyl-pyrazolo[l ,5- a]pyrimidin-7-ylamine;
[00139] 6-(3-Chloro-phenyl)-3-[3-((2R,6S)-2,6-dimethyl-moφholin- 4-yl)-phenyl]-
5-methyl-pyrazolo[l ,5-a] pyrimidin-7-ylamine;
[00140] 2-(4-{3-[7-Amino-6-(3-chloro- phenyl)-5-methyl-pyrazolo[l, 5- a]pyrimidin-3-yl]-phenyl}-piperazin-l-yl)- ethanol;
[00141] 6-Benzyl-3-[3-(4-methyl-piperazin-l -yl)- phenyl]- pyrazolo[l,5- a]pyrimidin-7-ylamine;
[00142] 6-(3- Chloro-phenyl)-3-(3,4-dimethoxy-phenyl)-5- fluoromethyl- pyrazolo[l,5-a] pyrimidin-7-ylamine;
[00143] ό-CS-Chloro^-fluoro-phenyO^-CS^-dimethoxy-pheny^-S-methyl- pyrazolo [1 ,5-a]pyrimidin-7-ylamine;
[00144] 6-(3-Chloro-4-fluoro-phenyl)-3-(4-methoxy-phenyl)-5- methyl- pyrazolo[l,5-a] pyrimidin-7-ylamine;
[00145] 6-(4-Fluoro-phenyl)-3-(4-methoxy-phenyl)-5-methyl- pyrazolo[l ,5- a]pyrimidin-7 -ylamine;
[00146] 2-(4-{3-[7-Amino-6-(4-fluoro-phenyl)-5-methyl-pyrazolo[l , 5-a] pyrimidin-3-yl]-phenyl} -piperazin-1 -yl)-ethanol;
[00147] 6-(3,4-Difluoro-phenyl)-5-methyl-3-[3-(4-methyl-piperazin- l-yl)-phenyl]- pyrazolo[l ,5-a]pyrimidin-7-ylamine;
[00148] 6-(3,4-Difluoro-phenyl)-3-(3,4-dimethoxy-phenyl)-5-methyl- pyrazolo[l ,5- a]pyrimidin-7- ylamine;
[00149] 2-(4-{3-[7-Amino-6-(3-chloro-4-fluoro- ρhenyl)-5-methyl- pyrazolo[l ,5- a]pyrimidin-3-yl]-phenyl}-piperazin-l -yl)- ethanol; [00150] 2-(4-{3-[7-Amino-6-(3,4-difluoro-phenyl)-5-methyl- pyrazolo[l,5- a]pyrimidin-3-yl]-phenyl}-piperazin-l-yl)-ethanol;
[00151] 6-(3-Chloro-phenyl)-5-methyl-3-[3-(4-pyrrolidin-l-yl- piperidin-l-yl)- phenyl]-pyrazolo[l,5-a]pyrimϊdin-7-ylamine;
[00152] 6-(4-Fluoro-phenyl)-5-methyl-3-[3-(4-pyrrolidin-l-yl-piperidin-l-yl)- phenyl]-pyrazolo[ 1 ,5-a]pyrimidin-7~ylamine;
[00153] 3 -[3-(4-Diethylamino-piperidin- 1 -yl)-phenyl]-6-(4-fluoro- phenyl)-5- methyl-pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine;
[00154] 6-(4-Fluoro-phenyl)-5-methyl-3-[3-(4-methyl-4-oxy- ρiperazin-1-yl)- phenyl]- pyrazolo[l ,5-a]pyriπiidin-7-ylamine;
[00155] 6-(4-Fluoro-phenyl)-5-methyl-3-[3-(4-methyl-l,4-dioxy- piperazin-l-yl)- phenyl]- pyrazolo[l ,5-a]pyrimidin-7-ylamine;
[00156] 6-(3-Chloro-phenyl)-3-[3-(4-dimethyIamino-piperidin-l -yl)- phenyl]-5- methyl- pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine;
[00157] 6-(3,4-Difluoro-phenyl)-3-[3-(4-dimethylamino-piperidin-l- yl)-phenyl]-5~ methyl-pyrazolo[ 1 ,5-a]pyrimidm-7-ylamine;
[00158] 6-(3-Chloro-phenyl)-5-methyl-3-(3,435-trimethoxy-phenyl)- pyrazolo[l ,5- a]pyrimidin-7- ylamine; 6-(3,4-Difluoro-phenyl)-5-methyl-3-(3, 4,5-trimethoxy- phenyl)- pyrazolo[l ,5-a]pyrimidin-7-ylamine;
[00159] 6-(3-Chloro-phenyl)-3-(3-methoxy-phenyl)-5-methyl- pyrazolo[ 1 ,5- a]pyrimidin-7-ylamine;
[00160] 6-[7-Amino-3-(3,4-dimethoxy-phenyl)-pyrazolo[l,5-a] pyrimidin-6-yl]- pyτidin-2-ol;
[00161] 6-Benzyl-3-(3,4-dimethoxy-phenyl)-pyrazolo[l ,5-a] pyrimidin-7-ylamine; [00162] 3-(3,4-Dimethoxy-phenyl)-6-(3-fluoro-benzyl)-pyrazolo[l,5- a] pyrimidin- 7-ylamine; f [00163] 6-(3-Chloro-phenyl)-3-(2-methoxy-5-piperazin- 1 -yl-phenyl)-5-methyl- pyrazolo[l ,5-a]pyrimidin-7-ylamine;
[00164] 6-(3-Chloro-phenyl)-3-(2-methoxy-5-morpholiπ-4-yl-phenyl)-5-methyl- pyrazolo[l ,5-a]pyrimidin-7-ylamine;
[00165] S-Ca-Methoxy-S-morpholin^-yl-phenyO-S-methyl-β-CS-morpholin^-yl- phenyl)-pyrazolo [1,5 -a]pyrimidin-7-y lamine;
[00166] N-{3-[7-Amino-6-(3-chloro-phenyl)-5-methyl-pyrazolo[l,5-a]pyrimidin-3- yl]-4-methoxy-phenyl}-N,Nl,Nl-trimethyl-ethane-l,2-diamine; [00167] ^{S-fy-Amino-ό-CS-cMoro-phenyO-S-methyl-pyrazololljS-ajpyrimidin-S- yl]-4-methoxy-phenyl}-N,N',N'-trimethyl-propane-lJ3-diamine;
[00168] 6-(3-Chloro-phenyl)-3-[5-(4-diethylamino-piperiditt- 1 -yl)-2-methoxy- phenyl]-5-methyl-pyrazolo[l ,5-a]pyrimidin-7-ylainine;
[00169] 6-(3-Chloro-ρhenyl)-3-{2-methoxy-5-[4-(l-methyl-ρiperidin-4-yl)- piperazin- 1 -yl]-phenyl} -5-methyl-pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine;
[00170] 6-(3-Chloro-phenyl)-3-[2-methoxy-5-(4-pyrrolidin-l-yl-piperidin-l-yl)- ρhenyl]-5-methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00171] N-{3-[7-Amino-6-(3-chloro-phenyl)-5-methyl-pyrazolo[l,5-a]pyrimidin-3- ylJ^-methoxy-pheny^-N'-N'-dimethyl-ethane-l^-diamine;
[00172] ^{S-p-Amino-ό-CS-cUoro-phenyO-S-methyl-pyrazolofl-S-alpyrimidin-S- yl]-4-methoxy-phenyl}-N',N'-dimethyl-propane-l,3-diamine;
[00173] 3-[5-(4-Amino-piperidin-l-yl)-2-methoxy-phenyl]-6-(3-chloro-phenyl)-5- methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00174] 6-(3-Chloro-phenyl)-3- { 2-methoxy-5-[4-(4-methyl-piperazin- 1 -yl> piperidin-1 -yl] -phenyl} -5-methyl-pyrazolo[l ,5-a]pyrimidin-7-ylamine;
[00175] 2-(4-{3-[7-Amino-6-(3-chloro-phenyl)-5-methyl-pyrazolo[l-5-a]pyrimidin-
3 -yl]-4-methoxy-phenyl} -piperazin- 1 -yl)-ethanol;
[00176] 6-(3-Chloro-phenyl)-3-[5-(4-dimethylamino-piperidin-l-yl)-2-methoxy- phenyl]-5-methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00177] 6-(3-Chloro-phenyl)-3-[2-methoxy-5-(l-methyl-piperidin-4-ylamino)- phenyl]-5-methyl-pyrazolo[l,5-a]pyτimidin-7-ylamine;
[00178] 3-(5-[l ,4']Bipiperidinyl- 1 '-yl-2-methoxy-phenyl)-6-(3-chloro-phenyl)-5- methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00179] 6-(3-Chloro-phenyl)-3-[2-fluoro-5-(4-methyl-piperazin-l-yl)-phenyl]-5- methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00180] 6-(3-Chloro-phenyl)-3-[5-(4-dimethylamino-piperidin-l-yl)-2-fluoro- phenyl]-5-methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00181] 6-(3-Chloro-phenyl)-3-[5-(4-diethylamino-piperidin-l-yl)-2-fluoro- phenyl]-5-methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00182] β-CS-Chloro-phenyO-S^-fluoro-S-morpholin^-yl-phenyO-S-methyl- pyrazolofl ,5-a]pyrimidin-7-ylamine;
[00183] 6-(3-Chloro-phenyl)-3-[5-((2R,6S)-2,6-dimethyl-morpholin-4-yl)-2-fluoro- phenyl]-5-methyl-pyτazolo[l,5-a]pyrimidin-7-ylamine; [00184] 6-(3-Chloro-ρhenyl)-3-[2-fluoro-5-(4-pyrrolidin-l-yl-piperidin-l-yl)- phenyl]-5-methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00185] β-CS-Chloro-phenyO-S-P-fluoro-S-Cl-methyl-piperidin^-ylamino)- phenyl]-5-methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00186] 6-(3-Chloro-phenyl)-3- {2-fluoro-5-[4-(4-methyl-piperazin-l -yl)-piperidin-
1 -yl] -phenyl} -5-methyl-pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine;
[00187] 6-(3-Chloro-phenyl)-3-{2-fluoro-5-[4-(l-methyl-piperidin-4-yl)-piperazin-
1 -yl] -phenyl } -5-methyl-pyrazolo[ 1 ,5-a3pyrimidin-7-ylamine;
[00188] 2-(4-{3-[7-Amino-6-(3-cWoro-phenyl)-5-methyl-p3^azolo[l,5-a]pyrimidin-
3-yl]-4-fluoro-phenyl}-piperazin-l-yl)-ethanol;
[00189] 3-[5-(4-Amino-piperidin-l-yl)-2-fluoro-ρhenyl]-6-(3-chloro-phenyl)-5- methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00190] 6-(3-Chloro-phenyl)-3-[2-fluoro-5-(piperidin-4-ylamino)-phenyl]-5- methyl-pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine;
[00191] 6-(3-Chloro-phenyl)-3-{2-fluoro-5-[methyl-(l-methyl-piperidin-4-yl)- amino] -phenyl } -5-methyl-pyrazolo[l ,5-a]pyrimidin-7-ylamine;
[00192] N-{3-[7-Amino-6-(3-chloro-phenyl)-5-methyl-pyrazolo[l,5-a]pyrimidin-3- yl] -4-fluoro-phenyl } -N,N',N'-triniethyl -ethane- 1 ,2-diamine;
[00193] N-{3-[7-Amino-6-(3-chloro-phenyl)-5-methyl-pyrazolo[l,5-a]pyrimidin-3- yl]-4-fluoro-phenyl}-N,N',N'-trimethyl-propane-l,3-diamine;
[00194] N- {3-[7-Amino-6-(3-chloro-phenyl)-5-methyl-pyrazolo[l ,5-a]pyrimidin-3- yl]-4-fluoro-phenyl} -Nf ,N'-dimethyl-ethane- 1 ,2-diamine;
[00195] N-{3-[7-Amino-6-(3-chloro-phenyl)-5-methyl-pyrazolo[l,5-a]pyrimidin-3- yl]-4-fluoro-phenyl}-N',N'-dimethyl-propane-l,3-diamine;
[00196] 6-(3-Chloro-phenyl)-3-[5-(4-ethyl-piperazin-l-yl)-2-fluoro-phenyl]-5- methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00197] 6-(3-Chloro-phenyl)-3-[2-fluoro-5-(4-isopropyl-piperazin-l-yl)-phenyl]-5- methyl-pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine;
[00198] N-{3-[7-Amino-6-(3-cWoro-phenyl)-5-niethyl-pyrazolo[l,5-a]pyriinidin-3- yl]-4-fluoro-phenyl } -N-ethyl-N',N'-dimethy 1-ethane- 1 ,2-diamine;
[00199] N-{3-[7-Amino-6-(3-chloro-phenyl)-5-methyl-pyrazolo[l,5-a]pyrimidin-3- yl]-4-fluoro-phenyl} -N'-methyl-propane-l ,3-diamine;
[00200] 6-(3-Chloro-phenyl)-3-[2-fluoro-4-(4-methyl-piperazin-l-yl)-phenyl]-5- methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine; [00201] 6-(3-Chloro-phenyl)-3-[4-(4-diethylamino-piperidin-l-yl)-2-fluoro- phenyl]-5-methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00202] 6-(3-Chloro-phenyl)-3-(2-fluoro-4-moφholin-4-yl-phenyl)-5-methyl- pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine;
[00203] N-{4-[7-Amino-6-(3-cWoro-phenyl)-5-methyl-pyrazolo[l,5-a]pyrimidin-3- yl]-3 -fluoro-phenyl } -N,N',N'-trimethyl-ethane- 1 ,2-diamine;
[00204] 6-(3-Chloro-phenyl)-3-[4-(4-dimethylamino-piperidin-l-yl)-2-fluoro- phenyl]-5-methyl-ρyrazolo[l,5-a]ρyrimidin-7-ylamine;
[00205] 6-(3-Chloro-phenyl)-3-{2-fluoro-4-[4-(4-methyl-piperazin-l-yl)-piperidin- l-yl]-phenyl}-5-methyl-pyrazoIo[l,5-a]pyrimidin-7-ylamine;
[00206] 6-(3-Chloro-phenyl)-3-[4-((2R,6S)-2,6-dimethyl-morpholin-4-yl)-2-fluoro- phenyl]-5-methyl-pyrazolo[l,5-a]pyrimidin-7-ylamine;
[00207] N-{4-[7-Amino-6-(3-chloro-phenyl)-5-methyl-pyrazolo[l,5-a]pyrimidin-3- yl]-3-fluoro-phenyl}-N,N',N'-trimethyl-proρane-l,3-diamine;
[00208] and pharmaceutically acceptable salts thereof.
[00209] A number of preferred compounds of the invention, including some of those listed above, are additionally described in TABLE I:
Figure imgf000019_0001
Figure imgf000020_0001
6-(3-Chloro-phenyl)-3-(2-methoxy-S- pιperazin-1 -yl-phenyl)-5-methyl-
0.92 449 pyrazolo[1.5-a]pyπmιdιn-7-ylamine
6-(3-Chloro-phenyI)-3-(2-methoxy-5- morpholin-4-yl-phenyl)-5-methyl-
0.95 450 pyrazolo[1 ,5-a]pyrιmidιn-7-ylamιπe
3-(2-Methoxy-5-morpholin-4-yl-phenyl)-5- methyl-6-(3-morpholιπ-4-yl-phenyl)-
0.84 501 pyrazolo[1 ,5-a]pyrimιdιn-7-ylamιne
N-{3-[7-Amino-6-(3-chloro-phenyl)-5-methyl- pyrazolo[1 ,5-a]pyrimιdin-3-yl]-4-methoxy-
0 94 465 phβnyl}-N.N',N'-trimethyl-ethane-1,2-dιamine
N-{3-[7-Amino-6-(3-chloro-phenyl)-5-methyl-
Figure imgf000020_0002
pyrazolo[1,5-a]pyrimidin-3-yl]-4-methoxy- phenylJ-N.N'.N'-trimethyl-propane-I.S-
0.84 479 diamine
Figure imgf000021_0001
N-{3-[7-Amino-6-(3-ch!oro-ρhenyl)-5-methyl- pyrazolo{1,5-a]ρyrimidιn-3-ylJ-4-methoxy- n.d. 465 ph enyl)-N' , N'-dimethyl-propane- 1.3-dιamιnβ
3-[5-(4-Amino-piperιdιn-1-yl)-2-methoxy- phenyl]-6-(3-chloro-phenyl)-5-methyl- n.d. 463 pyrazoioH ,5-a1pyrimidin-7-ylamine
6-(3-Chlorophenyl)-3-{2-methoxy-5-[4-(4- methyl-piperazin-1 -yl)-piperidin- 1 -yl]- phenyl}-5-methyl-pyrazolo[1,5-a]pyrimidin-7-
0 86 546 ylamine
Figure imgf000022_0001
2-(4-{3-[7-Amιno-6-(3-chloro-phenyl)-5- mβthyl-pyrazolo[1 ,5-a]pyrimιdιn-3-yl]-4-
0.Θ2 493 methoxy-phenyl}-pιperazιn-1-yl)-ethanol
Figure imgf000023_0001
3-(3-Bromo-phenyl)-6-(3-chloro-phenyl)-5- fluoromethyl-pyrazolo[1,5-a]pyrιmidin-7-
3.94 431 ylamme
6-(3-Chloro-phenyl)-3-[3-(4-dιethylamino- pipendιn-1-yl)-phenyI]-5-fiuoromethyl-
2.4 508 pyrazolo[1,5-a]pyπrήιdιn-7-ylamιne
6-(3-Chloro-phenyl)-3-[2-fluoro-5-(4-methyl- pιpera2in-1-yl)-phenyl]-5-methyl-
0.78 451 pyrazolo[1,5-a]pyrimιdιn-7-ylamιne
Figure imgf000024_0001
6-(3-Chloro-phenyl)-3-[5-(4-dιmethylamιno- pιpeπdιn-1-yl)-2-fluoro-phenyl]-5-methyl-
0.78 479 Pyrazolori,5-aipyrimιdin-7-ylamιne
6-(3-Chloro-phenyl)-3-[5-(4-diethylamino- pιperidin-1-yl)-2-fluoro-phenyl]-5-mettiyl-
0.81 507 pyrazolori ,5-alpyrimidin-7-ylamine
6-(3-Chloro-phenyl)-3-(2-fluoro-5-morpholιn- 4-yl-phenyl)-5-methyl-pyra2olo[1 ,5-
091 438 aipyrimιdιn-7-ylamιne
6-(3-Chloro-phenyl)-3-[5-((2R,6S)-2,6- dimethyl-moφholin-4-yl)-2-fluoro-phenyl]-5-
1.03 466 methyl-pyrazolo[1,5-a1pyπmidin-7-ylamine
Figure imgf000025_0001
6-(3-Chloro-phenyl)-3-[2-fluoro-5-(4- pyrrolidin-1-yl-piperidιn-1-yl)-phenyl]-5-
0.8 505 methyl-pyrazolo[1,5-aipyrimιdin-7-ylamine
Figure imgf000026_0001
3-f5-(4-Amino-piperidin-1-yl)-2-f!uoro- pheπyl]-6-(3-chloro-phenyl)-5-methyl-
0.75 451 pyrazolσ[1,5-a]pyrimidiπ-7-ylamine
β-CS-Chloro-phenylJ-S-p-fluoro-δ-Cpiperidin- 4-ylamino)-phenyl]-5-mettiyl-pyrazolo[1,5- π.d. 451 aipyπmιdιn-7-ylamιne
6-(3-Chloro-phenyl)-3-{2-fluoro-5-[methyl-(1- methyl-pipeπdιn-4-yl)-amιπo]-phenyl}-5- n.d. 479 methyl-pyrazoloF1.5-alpyιimidin-7-γlamine
Figure imgf000027_0001
N-{3-I7-Amino-6-(3-chloro-ρheπyl)-5-methyl- pyrazolo[1,5-a]pyrimιdιn-3-yl]-4-fluoro-
0.81 453 phenyl}-N.N',N'-tπmethyl-ethane-1.2-dιamιne
,5-
Figure imgf000028_0001
,2-
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
6-(3-Chloro-phenyl)-3-[4-(4-dιmethylamiπo- piperidin-1-yl)-2-fluαro-phenyl]-5-methyl-
0.92 479 pyrazolo[1 ,5-alpyrimidin-7-ylamιπe
6-(3-Chloro-phenyl)-3-{2-fluoro-4-[4-(4-
Figure imgf000031_0002
methyl-piperazin-1-yl)-piperidιn-1-yl]- phenyl}-5-methyl-pyrazolo[1,5-a]pyrimιdin-7-
0.86 534 ylamine
6-(3-Chloro-phenyl)-3-[4-((2R,6S)-2,6- dιmethyl-morpholin-4-yl)-2-fluoro-phenyl]-5-
1 31 466 methyl-pyrazolo[1 , 5-aipyπmιdιn-7-ylannιne
N-{4-[7-Amιno-6-(3-chloro-phenyl)-5-methyl-
Figure imgf000031_0003
pyrazoloELS-aJpyrimidin-S-ylJ-S-fluoro- phenyl}-N,N>,N'-tπmethyl-propane-1,3-
0.97 467 diamine [00210] In an embodiment of the invention, the compounds of the invention are used in methods of treatment of Eph receptor-related (e.g., neurological) injuries and disorders.
[00211] In another embodiment of the invention, pharmaceutical compositions prepared from the compounds of the invention are used in methods of treatment of
Eph receptor-related (e.g., neurological) injuries and disorders. The pharmaceutical compositions preferably comprise a compound of the invention an acceptable pharmaceutical carrier. Carriers are described in greater details herein.
[00212] In another embodiment of the invention, the compounds of the invention are used to contact a cell, in order to modulate the activity of an Eph receptor therein.
The cell can be contacted in vitro or in vivo, in an effective amount of the compounds of the invention to modulate Eph receptors therein.
[00213] In yet another embodiment of the invention, the compounds of the invention are used in methods of stimulating and promoting neural regeneration (such as axon regeneration), and reversing neuronal degeneration due to traumatic injury, stroke, multiple sclerosis and neurodegenerative diseases. One way in which this can be achieved is through the administration to a mammal of a compound of the invention in an amount that is sufficient to stimulate and promote neural regeneration
(such as axon regeneration) or reverse neuronal degeneration. The compounds of the invention can be delivered to both normal and injured cells. In some embodiments, the compounds of the invention inhibit the phosphorylation of an Eph receptor. In other embodiments, the compounds of the invention inhibit the binding of ephrin
Iigands to Eph receptors.
[00214] In still yet another embodiment of the invention, the compounds of the invention are used in methods for delivering a therapeutic agent to a cell, such as via a conjugate comprising said therapeutic agent linked to compound of the invention. As described in greater detail herein, the therapeutic agent can be a linking reagent.
[00215] A further embodiment is a process to prepare a compound according to the above comprising:
[00216] reacting a nitrile, A-CH2-C≡N, with ethyl formate in the presence of an organic solvent to form a substituted 3-oxo-propionitrile, [00217J condensing the substituted 3-oxo-propionitriles of step (a) with hydrazine monohydrate in an organic solvent to form a 2H-pyrazol-3-ylamine of formula (III):
Figure imgf000033_0001
[00218] ■«
[00219] formylating a substituted nitrile in the presence of ethanolate and formic acid ethyl ester to prepare a 3-oxo-propionitrile of formula (II):
Figure imgf000033_0002
[00220] condensing the 3-oxo- propionitrile of formula (II) and the 2H-pyrazol-3- ylamines of formula (III) in the presence of an organic solvent to form a compound of formula (I).
[00221] The invention in particular relates to The present invention relates to compounds of the invention, including pyrazolo[l,5a]pyrimidin-7-yl amine compounds, of the formula (I):
Figure imgf000033_0003
[00222] wherein:
[00223] Ra is H; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted aliphatic residue; a functional group; or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
[00224] R.3 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or an aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a] pyrimidinyl ring, at least one of R2 or R3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
[00225] A is H. halogen (such as bromo), an aliphatic moiety, a functional group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
[00226] R1 is H, halogen or lower alkyl,
[00227] or pharmaceutically acceptable salts thereof,
[00228] in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders or for the manufacture of pharmaceutical compositions for use in the treatment of said injuries and disorders, methods of use of compounds of formula (I) in the treatment of said injuries and disorders, or pharmaceutical preparations comprising compounds of formula (I) for the treatment of said injuries and disorders.
[00229] The present invention is especially related to a compound of formula (I) wherein R2 is H; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted aliphatic residue; a functional group; or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
[00230] R3 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or an aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a] pyrimidinyl ring,
[00231] at least one OfR2 or R3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a] pyrimidinyl ring, and provided that R2 and A cannot both be unsubstituted phenyl;
[00232] A is H, halogen (such as bromo), an aliphatic moiety, a functional group, substituted or unsubstituted aryl or heteroaryl; and
[00233] Ri is H, halogen or lower alkyl,or pharmaceutically acceptable salts thereof,
[00234] in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders or for the manufacture of pharmaceutical compositions for use in the treatment of said injuries and disorders, methods of use of compounds of formula (I) in the treatment of said injuries and disorders, pharmaceutical preparations comprising compounds of formula (I) for the treatment of said injuries and disorders, compounds of formula (I) for use in the treatment of said injuries and disorders. [00235] The present invention also relates to a method of treating kinase dependent diseases comprising administering pyrazolo[l,5a] pyrimidin-7-yl amine compounds of the formula (I) to a warm-blooded animal, especially a human. The present invention also relates to pharmaceutical preparations comprising an pyrazolo[l-5a]pyrimidin-7-yl amine compound of the formula (I), especially for the treatment of a kinase dependent disease, novel pyrazolo[l,5a]pyrimidin-7-yl amine compounds of the formula (I), a process for the manufacture of the pyrazolo[l,5a]pyrimidin-7-yl amine compounds of the formula (I), and novel starting materials and intermediates for their manufacture. The present invention also relates to use of a compound of formula 1 in the manufacture of a pharmaceutical preparation for the treatment of an Eph receptor-related (e.g., neurological) injury or disorder.
[00236] Definitions
[00237] The general terms used hereinbefore and hereinafter preferably have within the context of this disclosure the following meanings, unless otherwise indicated: [00238] The following abbreviations are used herein to represent commonly used terms (in parenthesis) in the present application, including but not limited to the examples section: DMSO (dimethylsulfoxide); ES-MS (electrospray mass spectrometry); EtOAc (Ethyl Acetate); HPLC (high-pressure liquid chromatography); mL (mililiter(s)); NMR (nuclear magnetic resonance); RT (room temperature); ^RET (HPLC retention time in minutes (method A)); BtREτ (HPLC retention time in minutes (method B)); SRET (HPLC retention time in minutes (method C)); DtREτ (HPLC retention time in minutes (method D)); TFA (trifluoroacetic acid); THF (tetrahydrofuran); TMSCI (Trimethylsilyl chloride).
[00239] As used herein, "Eph receptor" means a receptor tyrosine kinase that belongs to the Eph family, including EphA2, EρhA4, EphA5, EphA7, EphB2 and EphB4. This family is reviewed, for instance, in Pasquale, E. (1997) Curr. Opin. Cell Biol. 9:608-615; and Orioli and Klein (1997) Trends in Genetics 13:354-359. [00240] As used hererin, the term "treatment" includes both prophylactic or preventive treatment as well as curative or disease suppressive treatment, including treatment of patients at risk of neurological disorders, as well as ill and injured patients. This term further includes the treatment for the delay of progression of the disease.
[00241] "Eph receptor-related injuries and disorders" include neurological injuries and disorders, including but not limited to spinal cord injury (SCI); quadriplegia, hemiplegia, and paraplegia, including injury-caused and hereditary forms; neuropathies; CNS related disorders (e.g., bacterial and viral meningitis); and neurodegenerative disorders (e.g., Alzheimers Disease, cerebral toxoplasmosis, Parkinson's disease, amytropic lateral sclerosis (ALS), and multiple sclerosis). [00242] "Eph-receptor-related injuries and disorders" also includes neuronal degeneration resulting from hypoxic conditions, or from an infarct as in stroke. This condition can result in deficits in motor, sensory and cognitive functions, in large part due to the inability of injured axons to regenerate and undergo synaptic reorganization. As with SCI, stroke is followed by the formation of a glial scar at the site of infarction, and inhibiting EphA4 (e.g., as with the compounds of the invention) can inhibit scarring and thus enable improved regeneration and reorganization of connections. An in vitro model of stroke using astrocyte— hippocampal neuron co- cultures, has been shown that the inter-astrocytic gap-junctions are very important for the survival of neurons following hypoxic stress. (Blanc, E.M., et al. (1998) J Neurochem, 70(3): 958). As Eph receptors are known to be involved in signaling at gap-junctions, this represents another potential impliocation of EphA4 in ischemic stroke (Mellitzer, G., et al. (1999) Nature, 400(6739): 77). [00243] As used herein, "compounds of the invention" include, compounds of formula (I), including pyrazolo[l,5a]pyrimidin-7-yl amine derivatives. Compounds of the invention also refers to those compounds referred to herein as "Compound [number]."
[00244] "Aryl" is an aromatic radical having 6 to 14 carbon atoms, especially phenyl, naphthyl, indenyl, azulenyl, or anthryl, and is unsubstituted or substituted by one or more, preferably one or two substituents, wherein the substituents are selected from any of the functional groups defined below, and including: lower halo, alkyl, substituted alkyl, halo lower alkyl e.g. trifluoromethyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower alkoxy, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, amino lower alkyl, amino lower alkoxy; acetyl amino; amidino, halogen, nitro, cyano, cyano lower alkyl, carboxy, esterified carboxy especially lower alkoxy carbonyl, e.g. methoxy carbonyl, n-propoxy carbonyl or iso- propoxy carbonyl, alkanoyl, benzoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, carbamates, alkyl carbamic acid esters, amidino, guanidino, urea, ureido, mercapto, sulfo, lower alkylthio, sulfoamino, sulfonamide, benzosulfonamide, sulfonate, phenyl, benzyl, phenoxy, benzyloxy, phenylthio, phenyl-lower alkylthio, alkylphenylthio, lower alkylsulfϊnyl, phenylsulfinyl, phenyl-lower alkylsulfinyl, alkylphenylsulfinyl, lower alkanesulfonyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, alkylphenylsulfonyl, halogen-lower alkylmercapto, halogen-lower alkylsulfonyl, such as especially trifluoromethane sulfonyl, dihydroxybora (-B(OHb), heterocyclyl, and lower alkylene dioxy bound at adjacent C-atoms of the ring, such as methylene dioxy, phosphono (-P(=O)(OH)2), hydroxy-lower alkoxy phosphoryl or di- lower alkoxyphosphoryl, carbamoyl, mono- or di-lower alkylcarbamoyl, mono- or di- (hydroxy-lower alkyl)-carbamoyl, or -NR4R5, wherein R4 and R5 can be the same or different and are independently H; lower alkyl (e.g. methyl, ethyl or propyl); or R4 and R5 together with the N atom form a 3- to 8-membered heterocyclic ring containing 1 -4 nitrogen, oxygen or sulfur atoms (e.g. piperazinyl, lower alkyl- piperazinyl, azetidinyl, pyrrolidinyl, piperidino, morpholinyl, imidazolinyl). [00245] Aryl is more preferably phenyl which is either unsubstituted or independently substituted by one or two substituents selected from a solubilizing group selected from the group consisting of: halo (such as Cl or Br); hydroxy; lower alkyl (such as C1-C3 lower alkyl); aryl (such as phenyl or benzyl); amino; amino lower alkyl (such as dimethylamino); acetyl amino; amino lower alkoxy (such as ethoxyamine); lower alkyl (such as methyl); alkoxy (such as methoxy or benzyloxy where the benzyl ring may be substituted or unsubstituted, such as 3, 4 - dichlorobenzyloxy); sulfoamino; substituted or unsubstituted sulfonamide (such as benzo sulfonamide, chlorobenzene sulfonamide or 2,3-dichloro benzene sulfonamide); substituted or unsubstituted sulfonate (such as chloro-phenyl sulfonate); substituted urea (such as 3-trifluoro-methyl-phenyl urea or 4-morpholin-4-yl-3- trifiurormethyl-phenyl-urea); alkyl carbamic acid ester or carbamates (such as ethyl- N-phenyl-carbamate) or -NR4R5, wherein R4 and Rs can be the same or different and are independently H; lower alkyl (e.g. methyl, ethyl or propyl); or R4 and Rs together with the N atom form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms (e.g. piperazinyl, lower alkyl-piperazinyl, pyridyl, indolyl, thiophenyl, thiazolyl, morpholinyl n-methyl piperazinyl, benzothiophenyl, azetidinyl, pyrrolidinyl, piperidino or imidazolinyl); [00246] A heteroaryl group is preferably monocyclic, but may be bi- or tri-cyclic, and comprises 3-24, preferably 4-16 ring atoms, wherein at least one or more, preferably one to four ring carbons are replaced by a heteroatom selected from O, N or S. Preferably the heteroaryl group is selected from pyridyl, indolyl, pyrimidyl, pyrazolyl, oxazolyl, thiophenyl, benzothiophenyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, benzimidazolyl, pyrazolyl, indazolyl, purinyl, pyrazinyl, pyridazinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalyl, quinazolinyl, quinnolinyl, indolizinyl, 3H-indolyl, isoindolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, furazanyl and benzo[d]pyrazol.
[00247] More preferably the heteroaryl group is selected from the group consisting of pyridyl, indolyl, pyrimidyl, pyrazolyl, oxazolyl, thiophenyl or benzothiophenyl.
[00248] The heteroaryl group may be unsubstituted or substituted by one or more substituents selected from the group defined above as substituents for aryl, most preferably by hydroxy, halogen, lower alkyl, such as methyl or lower alkoxy, such as methoxy or ethoxy.
[00249] "Aliphatic," as used herein, refers to any non-aromatic carbon based residue. Examples of aliphatic residues include substituted or unsubstituted alkyl, cycloalkyl, alkenyl and alkynyl.
[00250] "Alkyl" includes lower alkyl preferably alkyl with up to 7 carbon atoms, preferably from 1 to and including 5, and is linear or branched; preferably, lower alkyl is pentyl, such as n-pentyl, butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or methyl. Preferably lower alkyl is methyl, propyl or tert-butyl.
[00251] A cycloalkyl group is preferably cyclopentyl, cyclohexyl or cycloheptyl, and may be unsubstituted or substituted by one or more, especially one or two, substituents selected from the group defined above as substituents for aryl, most preferably by lower alkyl, such as methyl, lower alkoxy, such as methoxy or ethoxy, or hydroxy.
[00252] Alkenyl and alkynyl preferably have up to 7 carbon atoms, preferably from
1 to and including 5, and can be linear or branched.
[00253] Alkyl, cycloalkyl, alkenyl and alkynyl can be substituted or unsubstituted, and when substituted may be with up to 3 substituents including other alkyl, cycloalkyl, alkenyl, alkynyl, any of the substituents defined above for aryl or any of the functional groups defined below. [00254] "Halo" or "halogen" is preferably fluoro, chloro, bromo or iodo, most preferably fluoro, chloro or bromo.
[00255] The term "connecting atom or group" as used herein includes alkyl, (such as -CH2-); oxy -O-; keto -CO-; thio -S-; sulfonyl -SO2-; sulfoxides -SO-; amines -NH- or -NR-; carboxylic acid; alcohol; esters (-COO-); amides (- -CONR-, -CONHR'-); sulfonamides (, -SO2NH-, -SO2NR'-); sulfones (-SO2-); sulfoxides (-SO-); amino- group; ureas ( -NH-CO-NH-, -NR-CO-NH-, -NH-CO-NR-, -NR-CO-NR-); ethers (-
O-); carbamates (-NH-CO-O-, -NR-CO-O-); or inverse amides sulfonamides and esters (-NH-CO-, -NR-CO-, -NH-SO2-, -NR-SO2-, -OOC-).
[00256] The term "functional group" as used herein includes: carboxylic acid; hydroxyl; halogen; cyano (-CN); ethers (-OR); ketones (-CO-R); esters (-COOR); amides (-CONH2, -CONHR, -CONRR'); thioethers (-SR); sulfonamides (-SO2NH2, -
SO2NHR, -SO2NRR1); sulfones (-SO2-R); sulfoxides (-SO-R); amines (-NHR, NR'R); ureas (-NH-CO-NH2, -NH-CO-NHR); ethers (-O-R); halogens; carbamates (-NH-CO-
OR); aldehyde-function (-CHO); then also inverse amides; sulfonamides and esters (-
NH-CO-R, -NH-SO2-R, -OOC-R);
[00257] R and R' are the same are different and may be H or are any aliphatic, aryl or heteroaryl moiety as defined above.
[00258] Where the plural form is used for compounds, salts, pharmaceutical preparations, diseases and the like, this is intended to mean also a single compound, salt, or the like.
[00259] Salts are especially the pharmaceutically acceptable salts of compounds of formula (I).
[00260] Such salts are formed, for example, as acid addition salts, preferably with organic or inorganic acids, from compounds of formula (I) with a basic nitrogen atom, especially the pharmaceutically acceptable salts. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane-sulfonic acid, 2-hydroxyethanesulfonic acid, ethane- 1,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1,5- naphthalene-disulfonic acid, 2-, 3- or 4-methylbenzenesulfonic acid, methyl sulfuric acid, ethylsulfuric acid, dodecylsulfuric acid, N-cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid.
[00261] In the presence of negatively charged radicals, such as carboxy or sulfo, salts may also be formed with bases, e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example N-ethyl-piperidine or N,N'-dimethylpiperazine. [00262] When a basic group and an acid group are present in the same molecule, a compound of formula (I) may also form internal salts. [00263] For isolation or purification purposes it is also possible to use pharmaceutically unacceptable salts, for example picrates or perchlorates. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations), and these are therefore preferred.
[00264] In view of the close relationship between the compounds in free form and those in the form of their salts, including those salts that can be used as intermediates, for example in the purification or identification of the compounds, tautomers or tautomeric mixtures and their salts, any reference to the compounds hereinbefore and hereinafter especially the compounds of the formula (I), is to be understood as referring also to the corresponding tautomers of these compounds, especially of compounds of the formula (I), tautomeric mixtures of these compounds, especially of compounds of the formula (I), or salts of any of these, as appropriate and expedient and if not mentioned otherwise.
[00265] Where "a compound ..., a tautomer thereof; or a salt thereof or the like is mentioned, this means "a compound ..., a tautomer thereof, or a salt of the compound or the tautomer."
[00266] Any asymmetric carbon atom may be present in the (R)-, (S)- or (Reconfiguration, preferably in the (R)- or (S)-configuration. Substituents at a ring at atoms with saturated bonds may, if possible, be present in cis- (= Z-) or trans (= E-) form. The compounds may thus be present as mixtures of isomers or preferably as pure isomers, preferably as enantiomer-pure diastereomers or pure enantiomers. [00267] The compounds of formula (I) have valuable pharmacological properties and are useful in the treatment of kinase dependent diseases, e.g., as drugs to treat neurological diseases.
[00268] The compounds of formula (I) have valuable pharmacological properties and are useful in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders, e.g., as drugs to treat neurological diseases.
[00269] CNS-related injuries and disorder
[00270] Injury to the central nervous system usually results in very limited, if any, regeneration of lesioned axons, with subsequent permanent impairment of function. Although some CNS neurons appear to lose the intrinsic ability to regenerate neurites postnatally, many others, such as corticospinal tract (CST) neurons, appear able to regenerate, but are inhibited from doing so by the environment of the injury site. (Goldberg et al., (2002) Science 296: 1860). Major impediments to CNS regeneration are the presence of myelin inhibitors and astrocytic gliosis.
[00271] Axonal regeneration is prevented by a host of inhibitory influences in the adult CNS, among them inhibitory myelin proteins and the formation of a glial scar. Although considerable progress has been made in identifying molecules associated with myelin inhibition (e.g., Nogo, myelin-associated glycoprotein (MAG), and oligodendrocyte-myelin glycoprotein (OMgp)), targeting those proteins for the treatment or amelioration of neurological disorders is an incomplete solution. Blocking individual myelin proteins or their common receptor in vivo after spinal cord injury can result in partial axon regeneration, and a concomitant improvement of functional recovery; however, only a small percentage of axons regrow, highlighting the need for the removal of other impediments to regeneration for a more complete therapeutic solution (Simonen M., et al. (2003) Neuron 38: 201 ; Zheng B., et al. (2003) Neuron 38: 213).
[00272] The main component of glial scarring is astrocytic gliosis, whereby normally quiescent astrocytes show a vigorous response to injury. (Stichel CC, et al. (1998) Cell Tissue Res 294: 1). They become hypertrophic, proliferative, upregulate expression of glial fibrillary acidic protein (GFAP), and form a dense network of glial processes both at and extending from the lesion site. At the same time, the astrocytes secrete a variety of cytokines and produce cell adhesion and extracellular matrix molecules, some of which are inhibitory to regeneration (e.g., chondroitin sulfate proteoglycan (CSPG) and collagen IV). Blocking the deposition of said astrocytic products can promot axonal regeneration is promoted. (Stitchel CC, et al.). [00273] As most spinal cord injury-related attempted therapeutics to date have centered on overcoming either myelin inhibitors or components of the glial scar, agents aimed at inhibiting Eph receptors (e.g., the compounds of the invention) are representative of a new strategy to promote nerve regeneration.
[00274] Eph Receptors and Ephrins
[00275] The Eph receptor tyrosine kinase subfamily appears to be the largest subfamily of transmembrane receptor tyrosine kinases, and with its ligands, the ephrins, is responsible for governing proper cell migration and positioning during neural development, presumably through modulating intercellular repulsion (Pasquale, E. (1997) Curr. Opin. Cell Biol. 9:608-615)(Orioli and Klein (1997) Trends in Genetics 13:354-359). The Eph family is responsible for the formation of the corticospinal tract and anterior commissure. (Kullander K., et al. (2001a) Neuron 29: 73; Henkemeyer M, et al. (1996) Cell 86: 35).
[00276] Eph receptors are closely related, and actively signal when bound to their ephrin ligands (their effects are mediated by cell-to-cell contacts), with which they are capable of both forward and bi-directional signaling. (Murai, K.K., et al. (2003) J Cell Sci. 116(14): 2823).
[00277] These receptors are characterized by 3 functional domains: an intracellular tyrosine kinase catalytic domain, a single membrane spanning domain, and an extracellular ligand binding domain.
[00278] Binding of a ligand ephrin by a Eph receptor induces phosphorylation on tyrosine residues, which establishes binding sites for signaling proteins containing SH2 domains and activates an array of signaling pathways. The ephrins are thought to activate Eph receptors by clustering them and inducing autophosphorylation, while soluble monomelic ephrins are thought to inhibit Eph receptor activation. (Davis et al. (1994) Science 266: 816).
[00279] The sixteen known Eph receptors are divided into two subgroups (EphA and EphB) based on sequence homology. EphA receptors preferentially bind the glycosylphosphatidylinositol (GPI)-linked ephrin-A ligands, while EphB W
preferentially receptors bind the transmembrane ephin-B ligands. However, the ephrin ligands are rather promiscuous, and tend to lack selectivity in their activation of Eph receptors. (Murai, K. et al. (2003) Molecular and Cellular Neuroscience 24:1000). For instance, EphA4 can bind (and is therefore activated by) ligand ephrins B2 and B3, in addition to members of the ephrin A ligand family. [00280] Eph receptor family members and their ephrin ligands are of interest as targets for therapy for the treatment of neurological disorders and injuries, including as targets for the promotion of axon regeneration, based on findings in the literature. For instance, because Eph-ephrin signaling appears to regulate axon guidance through contact repulsion, inducing the collapse of neuronal growth cones (Wahl S., et al. (2000) J Cell Biol 149: 263; Kullander et al.), and members of this family are upregulated in the adult after neural injury (Moreno-Flores MT, et al. (1999) Neuroscience 91: 193; Willson CA, et al. (2002) Cell Transplant 11: 229), the aberrant expression or absence of Eph receptors could prove pivotal in determining the outcome of injury in the adult CNS.
[00281] EphA4
[00282] EphA4 is a receptor tyrosine kinase from the EphA family which has important functions in the developing and adult nervous system. Along with its known expression pattern during neural development (Mori, T., et al. (1995) Brain Res MoI Brain Res 29:325; Ohta, K., et al. (1996) Mechanisms of Development 54:59; Soans, C, et al. (1994) Oncogene 9:3353), EphA4 is expressed in brain regions that show extensive synaptic remodeling (Murai, K., et al. (2003) Nature Neurosci 6:153). In the adult, EphA4 is enriched in the hippocampus and cortex, two brain structures critical for learning and memory. The receptor is also enriched in migrating neural crest cells, growing axonal projections, and mature brain structures that show extensive plasticity. (Murai, et al.).
[00283] A recent study implicates EphA4 in two critical aspects of spinal cord injury, axonal inhibition and astrocytic gliosis. (Goldshmit, Y., et al. (2004) J Neurosci. 24(45): 10064). Goldshmit compared neural regeneration after spinal cord hemisection in wild-type and EphA4-/- mice, and discovered an overall functional improvement in the latter, characterized by a lack of astrocytic gliosis and regeneration of ipsilateral axons. Regarding the mechanisms through which improvements were seen, the experiments (as well as literature) demonstrates three roles for Eph receptors in axonal regeneration:
[00284] The first, as demonstrated by in vitro assays, is the direct inhibition of neurite outgrowth mediated by EphA4 on the astrocytes binding to a receptor-ligand on the axon. Such an action of EphA4 may provide a mechanism for the inhibition of neurite outgrowth on astrocytes observed in the presence of IFN, which Goldshmit has shown upregulates EphA4 expression. (Fok-Seang J., et al. (1998) Eur J Neurosci 10: 2400). These results suggest that EphA4 is yet another directly inhibitory molecule produced during astrocytic gliosis, in addition to other inhibitory components, such as extracellular matrix and myelin-derived molecules. [00285] The second, and lesser-observed, mechanism may be by activation of EphA4 on the regenerating axons, similar to on E16 cortical neurons. However, EphA4 was found to be highly expressed only on astrocytes and motor neurons, and present at low levels on descending axons in lesioned adult spinal cord. [00286] The third mechanism by which EphA4 exerts an inhibitory effect involves its vital role in activating astrocytes, leading to gliosis and the formation of a glial scar. Such activation appears to be dependent on responsiveness to cytokine stimulation and may be dependent on Rho activation. This cytokine-induced response may be attributable to the upregulation of EphA4 receptor expression on the astrocytes, allowing enhanced ligand binding and receptor activation. It is also possible that the cytokine-induced astrocyte proliferation and hypertrophy may be caused by transactivation of EphA4, as has been shown for FGF2- and PDGF-induced phosphorylation of EphrinB molecules (Chong et al., (2000) MoI Cell Biol 20: 724), leading to Rho activation and cytoskeletal rearrangement. The difference in glial activation seems to be astrocyte specific as there was no apparent difference in macrophage-microglial activation. Ephs and Ephrins have been reported to play a role in interactions between astrocytes and meningeal fibroblasts, excluding fibroblasts from the glial scar. (Bundesen LQ, et al. (2003) J Neurosci 23: 7789).
[00287] Synthetic Procedure
[00288] As seen in Figure 5 A, compounds of formula (I) are prepared analogously to the procedure described by Alicade, E; De Mendoza, J; Garcia-Marquina, JM; Almera, C; J. Heterocycl. Chem. 11, 423 (1974) by: [00289] (a) reacting a nitrile, A-CH2-C≡N, with ethyl formate in the presence of an organic solvent to form a substituted 3-oxo-propionitrile, [00290] (b) condensing the substituted 3-oxo-propionitriles of step (a) with hydrazine monohydrate in an organic solvent to form a 2H-pyrazol-3-ylamine of formula (III):
Figure imgf000045_0001
III
[00291] formylating a substituted nitrile in the presence of ethanolate and formic acid ethyl ester to prepare a 3-oxo-propionitrile of formula (II):
Figure imgf000045_0002
[00292] (c) condensing the 3-oxo- propionitrile of formula (II) and the 2H-pyrazol- 3-ylamines of formula (III) in the presence of an organic solvent to form a compound of formula (I).
[00293] Specifically ^compounds of formula (I) are prepared by condensing 3-oxo- propionitriles (II) and the corresponding 2H-pyrazol-3-ylamines (III) in the presence of ethanolic HCl. The 2H-pyrazol-3-ylamines (III) are prepared by condensing hydrazine monohydrate with the corresponding 3-oxo-propionitriles dissolved in an organic solvent, such as EtOH, dioxane or AcOH and heated at elevated temperatures (preferably at 100 0C) for several hours. The preferred procedure for preparing the pyrazolo moiety of the title compounds was stirring the hydrazine monohydrate with the corresponding 3-oxo-propionitriles in acetic acid at 100 0C for 2-3 h followed by addition of aqueous HCl and further refluxing the reaction mixture for further 20 min. In case where Rl is not H, the corresponding substituted hydrazines are used. The 3- oxo-propionitriles (I) and (II) are synthesized from the corresponding nitriles by classical formylation reaction using freshly prepared sodium ethanolate and formic acid ethyl ester (refluxing for 1 h in EtOH). Alternatively, instead of performing the condensation reactions with the 3-oxo-propionitiles, the corresponding 3,3-dialkoxy- propionitiles (in analogy to the procedure described by Seneci, P., Nicola, M., Inglesi, M., Vanotti, E., Resnati, G. Synth. Commun. 29 (2), 311-341 (1999)) or 3- dimethylamino-acrylonitriles can be used.
[00294] Alternatively, as seen in Figure 5B, compounds of formula (I) can be prepared by first synthesizing the pyrazolo[l,5-a]pyrimidin-7-ylamine core scaffold carrying a corresponding functional group X, where residues A, R2, or R3, respectively, can be introduced by known reactions.
[00295] Ri, R2, R3, and X of Figure 5B are as defined for compounds of the formula
(I),
[00296] and, if desired, after reaction (a), (b) or (c), transforming an obtainable compound of formula (I) into a different compound of formula (I); transforming a salt of an obtainable compound of formula (I) into the free compound or a different salt or an obtainable free compound of formula (I) into a salt; and/or separating an obtainable mixture of isomers of compounds of formula (I) into the individual isomers; [00297] where for all reactions mentioned functional groups in the starting materials that shall not take part in the reaction are, if required, present in protected form by readily removable protecting groups, and any protecting groups are subsequently removed.
[00298] The following reaction conditions are preferred, respectively: [00299] Within the scope of this text, only a readily removable group that is not a constituent of the particular desired end product of formula (I) is designated a "protecting group", unless the context indicates otherwise. The protection of functional groups by such protecting groups, the protecting groups themselves, and their cleavage reactions are described for example in standard reference works, such as J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999, in "The Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981, in "Methoden der organischen Chemie" {Methods of Organic Chemistry), Houben Weyl, 4th edition, Volume 15/1, Georg Thieme Verlag, Stuttgart 1974, in H.- D. Jakubke and H. Jeschkeit, "Aminosauren, Peptide, Proteine" (Amino acids, Peptides, Proteins), Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and in Jochen Lehmann, "Chemie der Kohlenhydrate: Monosaccharide und Derivate" (Chemistry of Carbohydrates: Monosaccharides and Derivatives), Georg Thieme Verlag, Stuttgart 1974. A characteristic of protecting groups is that they can be removed readily (i.e. without the occurrence of undesired secondary reactions) for example by solvolysis, reduction, photolysis or alternatively under physiological conditions (e.g. by enzymatic cleavage).
[00300] Salts of compounds of formula (I) having at least one salt-forming group may be prepared in a manner known per se. For example, salts of compounds of formula (I) having acid groups may be formed, for example, by treating the compounds with metal compounds, such as alkali metal salts of suitable organic carboxylic acids, e.g. the sodium salt of 2-ethylhexanoic acid, with organic alkali metal or alkaline earth metal compounds, such as the corresponding hydroxides, carbonates or hydrogen carbonates, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with corresponding calcium compounds or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt- forming agent preferably being used. Acid addition salts of compounds of formula (I) are obtained in customary manner, e.g. by treating the compounds with an acid or a suitable anion exchange reagent. Internal salts of compounds of formula (I) containing acid and basic salt-forming groups, e.g. a free carboxy group and a free amino group, may be formed, e.g. by the neutralisation of salts, such as acid addition salts, to the isoelectric point, e.g. with weak bases, or by treatment with ion exchangers. [00301] Salts can be converted in customary manner into the free compounds; metal and ammonium salts can be converted, for example, by treatment with suitable acids, and acid addition salts, for example, by treatment with a suitable basic agent. [00302] Mixtures of isomers obtainable according to the invention can be separated in a manner known per se into the individual isomers; diastereoisomers can be separated, for example, by partitioning between polyphasic solvent mixtures, recrystallisation and/or chromatographic separation, for example over silica gel or by e.g. medium pressure liquid chromatography over a reversed phase column, and racemates can be separated, for example, by the formation of salts with optically pure salt-forming reagents and separation of the mixture of diastereoisomers so obtainable, for example by means of fractional crystallisation, or by chromatography over optically active column materials.
[00303] Intermediates and final products can be worked up and/or purified according to standard methods, e.g. using chromatographic methods, distribution methods, (re-) crystallization, and the like. [00304] General process conditions
[00305] The following applies in general to all processes mentioned hereinbefore and hereinafter, while reaction conditions specifically mentioned above or below are preferred:
[00306] AU the above-mentioned process steps can be carried out under reaction conditions that are known per se, preferably those mentioned specifically, in the absence or, customarily, in the presence of solvents or diluents, preferably solvents or diluents that are inert towards the reagents used and dissolve them, in the absence or presence of catalysts, condensation or neutralizing agents, for example ion exchangers, such as cation exchangers, e.g. in the H+ form, depending on the nature of the reaction and/or of the reactants at reduced, normal or elevated temperature, for example in a temperature range of from about -1000C to about 1900C, preferably from approximately -800C to approximately 15O0C, for example at from -80 to -600C, at room temperature, at from -20 to 400C or at reflux temperature, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under an argon or nitrogen atmosphere. [00307] At all stages of the reactions, mixtures of isomers that are formed can be separated into the individual isomers, for example diastereoisomers or enantiomers, or into any desired mixtures of isomers, for example racemates or mixtures of diastereoisomers, for example analogously to the methods described under "Additional process steps."
[00308] The solvents from which those solvents that are suitable for any particular reaction may be selected include those mentioned specifically or, for example, water, esters, such as lower alkyl-lower alkanoates, for example ethyl acetate, ethers, such as aliphatic ethers, for example diethyl ether, or cyclic ethers, for example tetrahydro- furane or dioxane, liquid aromatic hydrocarbons, such as benzene or toluene, alcohols, such as methanol, ethanol or 1- or 2-propanol, nitriles, such as acetonitrile, halogenated hydrocarbons, such as methylene chloride or chloroform, acid amides, such as dimethylformamide or dimethyl acetamide, bases, such as heterocyclic nitrogen bases, for example pyridine or N-methylpyrrolidin-2-one, carboxylic acid anhydrides, such as lower alkanoic acid anhydrides, for example acetic anhydride, cyclic, linear or branched hydrocarbons, such as cyclohexane, hexane or isopentane, or mixtures of those solvents, for example aqueous solutions, unless otherwise indica- ted in the description of the processes. Such solvent mixtures may also be used in working up, for example by chromatography or partitioning.
[00309J The compounds, including their salts, may also be obtained in the form of hydrates, or their crystals may, for example, include the solvent used for crystallization. Different crystalline forms may be present. [00310] The invention relates also to those forms of the process in which a compound obtainable as intermediate at any stage of the process is used as starting material and the remaining process steps are carried out, or in which a starting material is formed under the reaction conditions or is used in the form of a derivative, for example in protected form or in the form of a salt, or a compound obtainable by the process according to the invention is produced under the process conditions and processed further in situ. In the process of the present invention those starting materials are preferably used which result in new compounds of formula (I) described at the beginning as being especially valuable.
[00311] Preferred embodiments according to the invention:
[00312] In the following preferred embodiments, general expression can be replaced by the corresponding more specific definitions provided above and below, thus yielding stronger preferred embodiments of the invention.
[00313] Preferred is the use of compounds of the formula (I), tautomers thereof or pharmaceutically acceptable salts thereof, where the Eph receptor-related (e.g., neurological) injuries and disorder to be treated is a neurological disorder or injury depending on Ephrin receptor kinases (e.g., EphA4 kinase).
[00314] The invention relates especially to use of a compound of the formula (I),
Figure imgf000049_0001
wherein:
[00315] R2 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
[00316] R3 can be H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or an aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring,
[00317] at least one of R2 or R3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
[00318] A is H, halogen (such as bromo), an aliphatic moiety, a functional group, substituted or unsubstituted aryl or heteroaryl; and
[00319] R1 is H, halogen or lower alkyl,
[00320] or pharmaceutically acceptable salts thereof,
[00321] and use of compounds of formula (I) in the treatment of kinase dependent diseases or for the manufacture of pharmaceutical preparations for the treatment of kinase dependent diseases.
[00322] The invention further relates to use of a compound of the formula (I),
Figure imgf000050_0001
wherein:
[00323] R2 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
[00324] R3 can be H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a]ρyrimidinyl ring, [00325] at least one of R2 or R3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring; '
[00326] and provided that Rz and A cannot both be unsubstituted phenyl;
[00327] A is H, halogen (such as bromo), an aliphatic moiety, a functional group, substituted or unsubstituted aryl or heteroaryl; and
[00328] Ri is H, halogen or lower alkyl,
[00329] or pharmaceutically acceptable salts thereof,
[00330] and use of compounds of formula (I) in the treatment of kinase dependent diseases or for the manufacture of pharmaceutical preparations for the treatment of kinase dependent diseases.
[00331] More preferred is a compound of the formula (I), wherein
[00332] the connecting atom or group is selected from the group consisting of: alkyl, (such as -CH2-); oxy -O-; keto -CO-; thio -S-; sulfonyl -SO2-; sulfoxides -SO-; amines -NH- or -NR-; carboxylic acid; alcohol; esters (-COO-); amides (- -CONR-, -
CONHR'-); sulfonamides ( -SO2NH-, -SO2NR1-); (-SO3-); sulfoxides (-SO-); amino- group; ureas ( -NH-CO-NH-, -NR-CO-NH-, -NH-CO-NR-, -NR-CO-NR-); ethers (-
O-); carbamates (-NH-CO-O-, -NR-CO-O-); or inverse amides sulfonamides and esters (-NH-CO-, -NR-CO-, -NH-SO2-, -NR-SO2-, -OOC-); with alkyl, (such as -CH2-
); oxy -O-; keto -CO-; sulfonyl -SO2-; sulfonamides (-SO2NH-, -SO2NR'-); (-SO3-); and ureas ( -NH-CO-NH-, -NR-CO-NH-, -NH-CO-NR-, -NR-CO-NR-) being especially preferred,
[00333] and the functional group is selected from the group consisting of: carboxylic acid; hydroxyl; halogens; cyano (-CN); ethers (-OR); ketones (-CO-R); esters (-COOR); amides (-CONH2, -CONHR, -CONRR'); thioethers (-SR); sulfonamides (-SO2NH2, -SO2NHR, -SO2NRR1); sulfones (-SO2-R); sulfoxides (-SO-
R); amines (-NHR, NR'R); ureas (-NH-CO-NH2, -NH-CO-NHR); ethers (-O-R); halogens; carbamates (-NH-CO-OR); aldehyde-function (-CHO); then also inverse amides; sulfonamides and esters (-NH-CO-R, -NH-SO2-R, -OOC-R); with halogens; hydroxyl; ethers (-OR); amides (-CONH2, -CONHR, -CONRR1); sulfonamides (-
SO2NH2, -SO2NHR, -SO2NRR1); amines (-NHR, NR'R); and ureas (-NH-CO-NH2, -
NH-CO-NHR); being especially preferred, [00334] or a pharmaceutically acceptable salt thereof, as such or especially for use in the diagnostic or therapeutic treatment of a warm-blooded animal, especially a human.
[00335] Especially preferred is a compound of the formula (I), wherein [00336] A is H; a halo (such as Br); or aryl (such as phenyl or benzyl) or heterocyclyl (such as pyridinyl, indolyl or benzothiophenyl), [00337] wherein the aryl or heterocyclyl may be substituted or unsubstituted with up to 4, preferably up to 2 substituents, wherein the substituents are the same or different and are independently selected from halo (such as Cl or Br); hydroxy; amino; amino lower alkyl (such as dimethylamino); amino lower alkoxy (such as ethoxyamine); lower alkyl (such as methyl); lower alkoxy (such as methoxy); substituted or unsubstituted sulfonamide (such as benzo sulfonamide, chlorobenzene sulfonamide or dichloro benzene sulfonamide); carbamates; R4R5, wherein R4 and R5 can be the same or different and are independently H; lower alkyl (e.g. methyl, ethyl or propyl); or Rj. and R5 together with the N atom form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms (e.g. piperazinyl or lower alkyl piperazinyl) where when R4 and R5 together with the N form an heterocyclic ring, said ring may be substituted with 1, 2 or more of any of the substituents described herein, preferably piperazinyl, pyrrolidinyl, alkyl such as methyl, or hydroxy alkyl such as ethanyl. Examples of the heteroring formed by R4 and R5 together with the N include morpholinyl, which can be unsubstituted or substituted with methyl or dimethyl; piperazinyl which can be unsubstituted or substituted with 1, 2 or 3 substituents prefereably methyl, oxy or ethanol; or piperadinyl which can be unsubstituted or substituted with 1, 2 or 3 substituents prefereably pyrrolidinyl, amine, alkyl amine, methyl amine, dialkyl amine, dimethylamine or diethylamine;
[00338] R2 is H, C1-C3 lower alkyl (such as methyl) or aryl (such as phenyl or benzyl) or heterocyclyl (such as pyridyl, indolyl, thiophenyl. thiazolyl or benzothiophenyl), wherein the aryl or heterocyclyl may be substituted or unsubstituted with up to 4, preferably up to 2 substituents, wherein the substituents are the same or different and are independently selected from halo (such as Cl, F or Br); hydroxy; amino; amino lower alkyl; C1-C3 lower alkyl; alkoxy (such as methoxy and benzyloxy where the benzyl ring may be substituted or unsubstituted, such as 3, 4 — dichlorobenzyloxy); sulfoamino; substituted or unsubstituted benzosulfonamide (such as 2, 3-dichlorobenzene sulfonamide); substituted or unsubstituted sulfonate (such as chloro-phenyl sulfonate); substituted or unsubstituted ureas (such as 3-trifluoro- methyl-phenyl urea or 4-morpholin-4-yl-3-trifluroπnethyl-phenyl-urea) or carbamates (such as ethyl-N-phenyl carbamate);
[00339] R3 is H; Ci-C3 alkyl; phenyl; pyridinyl or oxaz-5-yl; [00340] or a pharmaceutically acceptable salt thereof, as such or especially for use in the diagnostic or therapeutic treatment of a warm-blooded animal, especially a human.
[00341] Especially preferred is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a pharmaceutical preparation for the treatment of an Eph receptor-related (e.g., neurological) injury and disorder. Also preferred is a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as shown above for use in the treatment of an Eph receptor- related (e.g., neurological) injury and disorder.
[00342] Pharmaceutical Compositions
[00343] The invention relates also to the use of pharmaceutical compositions comprising a compound of formula (I) in the therapeutic (in a broader aspect of the invention also prophylactic) treatment of an Eph receptor-related (e.g., neurological) injury and disorde.
[00344] The pharmacologically acceptable compounds of the present invention may be used, for example, for the preparation of pharmaceutical compositions that comprise an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as active ingredient together or in admixture with a significant amount of one or more inorganic or organic, solid or liquid, pharmaceutically acceptable carriers.
[00345] The invention relates also to a pharmaceutical composition that is suitable for administration to a warm-blooded animal, especially a human (or to cells or cell lines derived from a warm-blooded animal, especially a human, e.g. lymphocytes), for the treatment or, in a broader aspect of the invention, prevention of (= prophylaxis against) a disease that responds to inhibition of kinase activity, comprising an amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which is effective for said inhibition, especially the in, together with at least one pharmaceutically acceptable carrier. [00346] The pharmaceutical compositions according to the invention are those for enteral, such as nasal, rectal or oral, or parenteral, such as intramuscular or intravenous, administration to warm-blooded animals (especially a human), that comprise an effective dose of the pharmacologically active ingredient, alone or together with a significant amount of a pharmaceutically acceptable carrier. The dose of the active ingredient depends on the species of warm-blooded animal, the body weight, the age and the individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
[00347] The invention relates also to a method of treatment for a disease that responds to inhibition of a kinase; which comprises administering an (against the mentioned disease) prophylactically or especially therapeutically effective amount of a compound of formula (I)according to the invention, especially to a warm-blooded animal, for example a human, that, on account of one of the mentioned diseases, requires such treatment.
[00348] The dose of a compound of the formula (I) or a pharmaceutically acceptable salt thereof to be administered to warm-blooded animals, for example humans of approximately 70 kg body weight, is preferably from approximately 3 mg to approximately 1O g, more preferably from approximately 10 mg to approximately 1.5 g, most preferably from about 100 mg to about 1000 mg /person/day, divided preferably into 1-3 single doses which may, for example, be of the same size. Usually, children receive half of the adult dose.
[00349] The pharmaceutical compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient. Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragees, tablets or capsules.
[00350] The pharmaceutical compositions of the present invention are prepared in a manner known per se, for example by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes.
[00351] Solutions of the active ingredient, and also suspensions, and especially isotonic aqueous solutions or suspensions, are preferably used, it being possible, for example in the case of lyophilized compositions that comprise the active ingredient alone or together with a carrier, for example mannitol, for such solutions or suspensions to be produced prior to use. The pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting and/or emulsifying agents, solubilizers, salts for regulating the osmotic pressure and/or buffers, and are prepared in a manner known per se, for example by means of conventional dissolving or lyophilizing processes. The said solutions or suspensions may comprise viscosity-increasing substances, such as sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone or gelatin.
[00352] Suspensions in oil comprise as the oil component the vegetable, synthetic or semi-synthetic oils customary for injection purposes. There may be mentioned as such especially liquid fatty acid esters that contain as the acid component a long- chained fatty acid having from 8-22, especially from 12-22, carbon atoms, for example lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brasidic acid or linoleic acid, if desired with the addition of antioxidants, for example vitamin E, β-carotene or 3,5-di- tert-butyl-4-hydroxytoluene. The alcohol component of those fatty acid esters has a maximum of 6 carbon atoms and is a mono- or poly-hydroxy, for example a mono-, di- or tri-hydroxy, alcohol, for example methanol, ethanol, propanol, butanol or pentanol or the isomers thereof, but especially glycol and glycerol. The following examples of fatty acid esters are therefore to be mentioned: ethyl oleate, isopropyl myristate, isopropyl palmitate, "Labrafil M 2375" (polyoxyethylene glycerol trioleate, Gattefosse, Paris), "Miglyol 812" (triglyceride of saturated fatty acids with a chain length of C8 to C 12, Hϋls AG, Germany), but especially vegetable oils, such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.
[00353] The injection compositions are prepared in customary manner under sterile conditions; the same applies also to introducing the compositions into ampoules or vials and sealing the containers.
[00354] Pharmaceutical compositions for oral administration can be obtained by combining the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture, if desired or necessary, after the addition of appropriate excipients, into tablets, dragee cores or capsules. It is also possible for them to be incorporated into plasties carriers that allow the active ingredients to diffuse or be released in measured amounts.
[00355] Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and binders, such as starch pastes using for example corn, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above- mentioned starches, and/or carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate. Excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable, optionally enteric, coatings, there being used, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as ethylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Capsules are dry-filled capsules made of gelatin and soft sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The dry-filled capsules may comprise the active ingredient in the form of granules, for example with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and if desired with stabilizers. In soft capsules the active ingredient is preferably dissolved or suspended in suitable oily excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilizers and/or antibacterial agents to be added. Dyes or pigments may be added to the tablets or dragee coatings or the capsule casings, for example for identification purposes or to indicate different doses of active ingredient.
[00356] Combinations
[00357] The compounds of the invention may also be used to advantage in combination with other agents known to overcome process outgrowth inhibition such as Rho kinase inhibitors; inhibitors of classical PKC isoforms; blocking antibodies against NogoA or the Nogo receptor; Chondroitinase ABC or other reagents that cleave the GAG sidechains off proteoglycans; and agents that increase intrinsic growth capacity of neurons (e.g., cAMP and bcl-2).
[00358] By way of a non-exclusive example, the compounds of the invention may be used in combinatorial therapy with an agent capable of blocking myelin inhibitors
Nogo, myelin-associated glycoprotein (MAG), or oligodendrocyte-myelin glycoprotein OMgp.
[00359] The structure of the active agents identified by code nos., generic or trade names may be taken from the actual edition of the standard compendium "The Merck
Index" or from databases, e.g. Patents International (e.g. IMS World Publications).
[00360] The above-mentioned compounds, which can be used in combination with a compound of the formula (I), can be prepared and administered as described in the art such as in the documents cited above.
[00361] The following examples are merely illustrative and not meant to limit the scope of the present claims in any manner.
EXAMPLES
[00362] Example 1: EphA4 Mode and Mechanism of Action
[00363] In order to distinguish between the the forward and bi-directional signaling that ephrins are capable of in the context of axon regeneration, lenti viral expression vectors for wild type and kinase dead EphA4 are generated and overexpressed in purified astrocytes. Cortical neurons are plated on the two astrocytic populations and neurite outgrowth assayed and compared. Biological peptides that have been demonstrated to block the interaction of EphA4 with relevant ligands, consequently inhibiting receptor activation (Murai, K.K., et al., (2003) MoI Cell Neurosci 24(4): p. 1000), are tested for their EphA4 inhibitory activity in the astrocyte / cortical neuron culture system. Identification of the neuronal ligand / ephrin mediating EphA4 inhibition is achieved by systematically blocking candidate ephrin expression in neurons using RNA interference to knock down ephrins or by using dominant negative ephrin constructs and subsequently plating them on wild type astrocytes. These experiments collectively clarify the mode of EphA4 activation. [00364] To illustrate intracellular events triggered by EphA4 activation, cytokine induced activation of astrocytes are used to explore the precise signaling pathways activated. Cultured astrocytes are treated with inflammatory cytokines (which have been shown to be involved in activating astrocytes) LIF or IFN in the presence or absence of EphA4 blocking peptides, and the cells are lysed and analyzed by Western Blots for the activation of major signaling pathways (MAPK, PI3K, JNK, STAT, RhoA) using appropriate phospho-antibodies. The signaling involved in neurite outgrowth inhibition by EphA4 is assessed by culturing cortical neurons on astrocytes or on CNS myelin or spinal cord extracts in the presence or absence of commercially available pharmacological inhibitors of the major signaling pathways and also the EρhA4 inhibitory peptides.
[00365] Example 2: Autophosphorylation and Ligand-Dependent Phosphorylation Assays
[00366] Primary astrocyte cultures are established from neonatal mouse cortex and purified so as to get about 95-98 pure astrocyte cultures. For detecting autophosphorylation the cells are incubated in the presence or absence of pharmacological inhibitors and then directly lysed and subjected to immunoprecipitation and Western analysis (as seen in Figure IA). For ligand dependent phosphorylation (as seen in Figure IB), the cultures are then serum starved for 36 hours to reduce basal receptor phosphorylation and then stimulated for varying lengths of time with a soluble form of the cognate ligand in the presence or absence of candidate kinase inhibitors or blocking peptides, which are added at various concentrations. Cells are lysed, and the lysates subjected to EphA4 immunoprecipitation and subsequently analysed on Westerns for level of receptor phosphorylation using a phospho-tyrosine antibody.
[00367] Example 3: In vitro Assay for Neurite Outgrowth / Axon Regeneration [00368] This assay is used to assess neurite outgrowth inhibition" of embryonic cortical neurons by Eph receptors expressed on astrocytes or neurite outgrowth inhibition of post-natal cortical neurons by ephrin ligand present in myelin. El 6 (embryonic day 16) cortical neurons are plated onto confluent astrocyte monolayers plated in 4-well chamber slides. Pharmacological inhibitors, are added to the medium and the length of longest neurite from each neuron is measured under each condition (Figure 2 A depicts an example of neurons plated in the presence of Compound 1 and visualized with the neuronal marker, Tuj-1) and compared to average neurite length on astrocytes in the absence of any pharmacological agents. Figure 2B depicts the quantitation of neurite outgrowth effects observed with Compound 6 and Compound 7 (all tested at 10OnM concentration) in cortical cultures plated on astrocytes. [00369] Example 4: In vitro Assay for Astrogliosis - Astrocyte Scratch Wound [00370] Assay Astrocytes are prepared from the cerebral cortex of neonatal C57BL/6 mice(Pl-P2). Cells are maintained in Dulbecco's modified Eagle's medium with 10% FBS.4-7 weeks old astrocytes are plated to confluence in 2 well chamber slides coated with poly-D-lysine for the scratch wound assay and serum starved. 48 hrs after serum starvation, the monolayer of astrocytes is scratched with sterile 200 μl tips and washed twice with PBS to get rid of cell debris. Conditioned medium (+/- cytokines) is added to the wounded astrocytes. The microscopic images of the scratch is captured at a magnification of 10 X right after scratch and considered as time point 0. 24hrs, 48hrs or 72hrs after scratch, the same region of scratch is imaged and fixed with methanol containing lμg/ml of DAPI to monitor migration and proliferation of astrocytes.
[00371] Example 5: Proof of mechanism
[00372] The experiment demonstrates that the compounds of the invention cross the blood brain barrier and effectively block phosphorylation of EphA4 receptor in vivo. Male NMRI mice were injected with relevant compounds at a dose of 10 mg/kg body weight and were sacrificed either 25 minutes or 1 hour following the dosing (0.25h or Ih shown in Figure 4). The brains were removed and one half of each brain was weighed and homogenized in appropriate volume of lysis buffer for 30 seconds (10 seconds pulse and 10 seconds off— 3 times). The homogenate was spun at 12,000 g for 30 minutes. Protein amounts were estimated for supernatants (using BCA) and equal amounts of protein for each condition were subjected to EphA4 immunoprecipitation followed by a phospho-tyrosine western blot. Four control animals were used and three experimental animals per time point were used for each of the compounds tested (Compounds 1, 2, 6, and 7) [00373] Example 6: High Throughput screening (HTS)
[00374] High throughput screens can be developed to look for selective and specific pharmacological inhibitors of EphA4 activity. Such compounds, as with the compounds of the invention, include kinase inhibitors or binding antagonists that block EphA4 interaction with its ligand and/or specifically block EphA4 kinase activation. Such compounds, as with the compounds of the invention, can serve as inhibitors that efficiently block EphA4 activity in the context of gliosis and axon regeneration [00375] Example 7: In vivo Target Validation in a Mouse SCI Model [00376] Existing EphA4 inhibitory peptides / hits from the HTS described herein, e.g., the compounds of the invention such as Compounds 1, 6, and 7 can be used for in vivo spinal cord injury (SCI) experiments to determine their efficacy in promoting axon regeneration. Mice are divided into three groups: unlesioned; lesioned with vehicle infusion; and lesioned with drug / peptide infusion. Animals of the lesioned groups undergo spinal hemisection surgery. Drug or vehicle (e.g., containing one of the compounds of the invention) is administered intrathecally via an osmotic pump, and an anterograde tracer is used to track anatomical regeneration of lesioned axons. Appropriate behavioral and electrophysiological assays can be performed to assess functional recovery of sensory and motor functions.
[00377] In addition to the SCI model experiments described above, EphA4 inhibitory agents, e.g., the compounds of the invention, can also be tested while Nogo signaling is compromised, to see if this results in a synergistic effect leading to improved functional recovery.
[00378] Examples 8-122: Syntheses
[00379] The following examples employ the abbreviations listed herein, and unless otherwise listed, the following conditions: where no temperatures are given, the reaction takes place at ambient (room) temperature; and ratios of solvents, e.g., in eluents or solvent mixtures, are given in volume by volume (v/v). [00380] Flash chromatography is performed by using silica gel (Merck; 40-63 μm). For thin layer chromatograhy, pre-coated silica gel (Merck 60 F254) plates are used. Detection of the components is made by UV light (254 nm). HPLC is performed on an Agilent HP 1100 using a Nucleosil 100-3 Ci8 HD 125 x 4.0 mm column [1 mL/min.; 20-100% NeCN / 0.1% TFA in 7 minutes) (Method A); SpectraSystem SP8800/UV2000 using a Nucleosil 100-5 C18 AB 250 x 4.6 mm column (2 mL/min.; 2-100% MeCN / 0.1% TFA in 10 minutes) (Method B); using a Chromalith Speed ROD RP18 50-4.6 mm column (Merck) (2 mL/min.; 2-100% MeCN / 0.1% TFA in 2 minutes) (Method C); or a C82.1-50 mm 3 μm column (Waters) (2 mL/min.; 5-95% MeCN / 0.1% TFA in 2 minutes) (Method D). 1H-NMR measurements are performed on a Varian Gemini 400 or a Bruker DRX 500 spectrometer using tetraethylsilane as internal standard. Chemical shifts are expressed in ppm downfield from tetraethylsilane and coupling constants (J) are expressed in Hertz (Hz). Electrospray mass spectra are obtained with a Fisons Instruments VG Platform II. Melting points are measured with a Bϋchi 510 melting point apparatus. Commercially-available solvents and chemicals are used for syntheses.
[00381] Example 8: 3-{7-Amino-3-[4-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[ 1 ,5-a]pyrimidin-6-yl} -phenol
[00382] 6-(3-Beπ2yloxy-phenyl)-3-[4-(4-methyl-piperazin- 1 -yl)-phenyl]- pyτazolo[l,5-«]pyrimidin-7-ylamine (Stage 1.1) (25 mg, 0.051 mmol) dissolved in
THF (6 mL) is hydrogenated in the presence of Pd/C (10% Engelhard 4505, 6 mg) for
13 hours. After filtration and evaporating the solvent under reduced pressure, the residue is flash chromatographed (silica gel, CH2Cl2 / MeOH / NH3 = 95:5:0.1) to give compound of Example 1 as white solid (14 mg, 0.035 mmol; 70%): ES-MS:
M+H = 401.1, Rf (CH2Cl2 / MeOH /NH3 = 90:10:0.1) = 0.33, HPLC: \et = 2.77 minutes.
[00383] 1H-NMR (400 MHz, DMSO-de): 9.59 (s, IH, OH), 8.58/8.18 (s/s, 1H/1H, pyrazolopyrimidinyl), 8.01 (d, 9.0 Hz, 2H, phenyl), 7.48 (s, 2H, NH2), 7.32 (t, 8.5 Hz,
IH, phenyl-OH), 6.99 (d, 9.0 Hz, 2H, phenyl), 6.96 (d, 8.5 Hz, IH, phenyl-OH), 6.93
(s, IH, phenyl-OH), 6.80 (d, 8.5 Hz, IH, phenyl-OH), 3.17/2.48 (m/m, 4H/4H, piperazinyl), 2.24 (s, 3H, CH3).
[00384] Staee 1.1 6-(3-Benzyloxy-phenyl)-3-[4-(4-methyl-piperazin-l-yl)- phenyl]-pyrazolo[l,5-α]pyrimidin-7-ylamine
[00385] 4-(4-(4-methyl-piperazin-l-yl)-phenyl)-2/-r-pyrazol-3-ylamine (Stage 1.2)
(100 mg, 0.388 mmol), 2-(3-benzyloxy-phenyl)-3-oxo-propionitrile (Stage 13) (98 mg, 0.388 mmol), HCl (2.5 mM in EtOH; 1,55 mmol, 0.9 mL) dissolved in EtOH (1 mL) are stirred for 17 hours at RT. After adding H2O (4 mL) and K2CO3 (250 mg), the reaction mixture is extracted with CH2Cl2 (20 mL, 2 x). The combined organic phases are washed with H2O (10 mL), dried (Na2SO-O, concentrated under reduced pressure and flash chromatographed (silica gel, 2.5 x 15 cm, CH2Cl2 / MeOH = 9:1) to give compound of Stage 1.1 as white solid (60 mg, 0.122 mmol; 32%); ES-MS: M+H
= 491.0, Rf (CH2Cl2 / MeOH /NH3 = 90:10:0.1) = 0.42; HPLC: %,, = 4.69 minutes.
[00386] 1H-NMR (400 MHz, DMSO-dβ): 8.79/8.21 (s/s, 1H/1H, pyrazolopyrimidinyl), 8.03 (d, 9.0 Hz, 2H, phenyl), 7.53 (s, 2H, NH2), 7.44 (m, 5H, benzyl), 7.32 (t, 8.5 Hz, IH, phenyl-OH), 7.29 (s, IH, phenyl-OH), 7.13 (d, 8.5 Hz,
IH, phenyl-OH), 7.06 (d, 8.5 Hz, IH, phenyl-OH), 6.97 (d, 9.0 Hz, 2H, phenyl), 5.19
(s, 2H, benzyl), 3.17/2.48 (m/m, 4H/4H, piperazinyl), 2.24 (s, 3H, CH3).
[00387] Staee 1.2 4-(4-(4-Methyl-piperazin- 1 -yl)-phenyl)-2/f-pyrazol-3-ylamine [00388] 2-[4-(4-Methyl-piperazin-l-yl)-phenyl]-3-oxo-propionitrile (Stage 1.4) (370 mg, 1.52 mmol), hydrazine monohydrate (0.185 mL, 3.8 mmol) dissolved in AcOH are stirred at 98°C for 3 hours. After cooling down to RT, H2O (8 mL) and concentrated HCl (0.8 mL) are added and the reaction mixture is stirred under reflux for 20 minutes. After cooling down to RT, the reaction mixture is adjusted to alkaline pH by slowly adding NH3 (25%). Precipitating material is filtered-off and kept for further purification. The reaction solution is extracted with CH2Cb (50 mL, 3 x), dried (Na2SO4) and concentrated under reduced pressure. Precipitated and extracted material is combined and flash chromatographed (silica gel, 3.0 x 18 cm, CH2CI2 / MeOH / NH3 = 9:1 :01) to give compound of Stage 1.2 as white solid (277 mg,
1.08 mmol; 71%); ES-MS: M+H = 258.1, Rf (CH2Cl2 / MeOH /NH3 = 90:10:0.1) = 0.28; HPLC: \e, = 4.33 minutes.
[00389] 1H-NMR (400 MHz, DMSO-Cl6): 11.55 (s/broad, IH, NH), 7.55 (s, IH, pyrolyl), 7.35 (d, 9.0 Hz, 2H, phenyl), 6.91 (d, 9.0 Hz, 2H, phenyl), 4.55 (s/broad, 2H, NH2), 3.10/2.46 (m/m, 4H/4H, piperazinyl), 2.23 (s, 3H, CH3). [00390] Stage 1.3 2-(3-Ben2yloxy-phenyl)-3-oxo-propionitrile [00391] Na (260 mg, 11.3 mmol) is dissolved in absolute EtOH (11 mL) under Ar during 20 minutes. After adding (3-benzylox-phenyl)-acetonitrile (1.9 g, 8.68 mmol) and ethyl formate (1.05 mL, 13.0 mmol), the reaction mixture is stirred under reflux for 2 hours. After evaporating the solvent under reduced pressure, adding H2O (20 mL), and adjusting to pH = 4.0 by adding AcOH, the reaction suspension is extracted with CH2CI2 (30 mL, 2 x). The combined organic phases are washed with H2O (10 mL), dried (Na2SO4), concentrated under reduced pressure and flash chromatographed (silica gel, 4.5 x 25 cm, CH2Cl2 / MeOH = 98:2) to give compound of Stage 1.3 as white solid (780 mg, 3.11 mmol; 36%); ES-MS: M-H = 250.0, Rf (CH2Cl2 / MeOH = 95:5) = 0.49; HPLC: %,, = 6.07 minutes. [00392] 1H-NMR (400 MHz, DMSO-d6): 7.45-7.25/6.98-6.88 (m/m, 8 H, aryl),
5.09 (s, 2H, CH2), 3.98 (s, 2H, CH2).
[00393] Stage 1.4 2-[4-(4-Methyl-piperazin-l-yl)-phenyl]-3-oxo-propionitrile [00394] Na 160 mg (7.0 mmol) is dissolved in absolute EtOH (6 mL) under Ar during 10 minutes. After adding [4-(4-methyl-piperazin-l-yl)-phenyl]-acetonitrile (Stage 1.5) (1 g, 4.64 mmol) and ethyl formate (0.56 mL, 7.0 mmol), the reaction mixture is stirred under reflux for 1 hour. After washing the reaction pulp with ether (50 mL, 3 x), the solid residue is dissolved in H2O (60 mL) and adjusted to pH = 3.9 by adding AcOH. The aqueous solution is extracted with CH2CI2 (50 mL, 3 x). The combined organic phases are washed with H2O (50 mL). Both aqueous phases are combined and lyophilized. The resulting residue is crystallized from MeOH / CH2CI2 to give compound of Stage 1.4 as white crystals (721 mg, 3.0 mmol; 64%); ES-MS:
M+H = 244.1; HPLC: \Re, = 2.43 minutes.
[00395] 1H-NMR (400 MHz, DMSO-d6): the compound forms a tautomeric equilibrium in solution: 7.87/7.77 (s/s, IH, CH=ZCH-OH), 7.53/7.17 (d/d, 9.0 Hz, 2H, phenyl), 7.84/7.82 (d/d, 9.0 Hz, 2H5 phenyl), 3.10 (m, 4H, piperazinyl), 2.57/2.51
(m/m, 4H, piperazinyl), 2.29/2.26 (s, 3H, CH3).
[00396] Stage 1.5 [4-(4-Methyl-piperazin-l-yl)-phenyl]-acetonitrile
[00397] (4-Bromo-phenyl)-acetonitrile (5 g, 25.5 mmol), 1-methyl-piperazine (3.4 mL, 30.6 mmol), K2CO3 (7.68 g, 35.7 mmol), Pd(AcO)2 (280 mg, 1.275 mmol), 2-(di- ter/-butylphosphino)-biphenyl (1.14 g, 3.825 mmol) dissolved in 1 ,2-dimethoxyethane
(70 mL) are stirred under Ar at 85°C for 20 hours. After adding H2O (100 mL), the reaction mixture is extracted with CH2Cl2 (100 mL, 3 x). The combined organic phases are washed with H2O (100 mL), dried (Na2SO4), concentrated under reduced pressure and flash chromatographed (silica gel, 4.5 x 34 cm, CH2Cl2 / MeOH = 95:5) to give compound of Stage 1.5 as white solid (2.8 g, 13 mmol; 51%); ES-MS: M+H =
216.1; Rf (CH2Cl2 / MeOH = 9:1) = 0.47; HPLC: ^= 2.24 minutes.
[00398] 1H-NMR (400 MHz, DMSO-d6): 7.14/6.91 (d/d, 9.5 Hz, 2H/2H, phenyl),
7.53 (s, 2H, NH2), 7.44 (m, 5H, benzyl), 7.32 (t, 8.5 Hz, IH, phenyl-OH), 7.29 (s, IH, phenyl-OH), 3.84 (s, 2H, benzyl), 3.09/2.42 (t/t, 5.0 Hz, 4H/4H, piperazinyl), 2.18 (s,
3H, CH3).
[00399] Example 9: 6-(3-Methoxy-phenyl)-3-[4-(4-methyl-piperazin-l-yl)- phenyl]-pyrazolo[ 1 ,5-α]pyrimidin-7-ylamine
[00400] 6-(3-Methoxy-ρhenyl)-3-[4-(4-methyl-ρiperazin- 1 -yl)-phenyl]- pyrazolo[l,5-α]pyrimidin-7-ylamine is synthesized by condensation of compound of
Stage 1.2 and 2-(3-methoxy-phenyl)-3-oxo-propionitrile (Stage 2.1) analogously to the preparation of compound of Example 1. Yield: 48%, solid powder; ES-MS: M+H
= 415.1; HPLC: %* = 3.45 minutes.
[00401] 1H-NMR (400 MHz, DMSO-d6): 8.59/8.23 (s/s, 1H/1H, pyrazolopyrimidinyl), 8.06 (d, 9.0 Hz, 2H, phenyl), 7.55 (s, 2H, NH2), 7.43 (t, 8.5 Hz, m,phenyl-OM&), 7.10 (d, 8.5 Hz, YΑ, phenyl-OM&\ 7.08 (s, IH, phenyl-OMe), 6.80 (d, 8.5 Hz, IK, phenyl-OUe), 6.98 (d, 9.0 Hz, 2H, phenyl), 3.83 (s, 3H5 CH3-O),
3.16/2.47 (m/m, 4H/4H, piperazinyl), 2.25 (s, 3H, CH3).
[00402] Stage 2.1 2-(3-Methoxy-phenyl)-3-oxo-propionitrile
[00403] 2-(3-Methoxy-phenyl)-3-oxo-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3: Yield: 76%; white powder; ES-MS: M-H
= 174.0; HPLC: \Ret = 4.75 minutes.
[00404] 1H-NMR (400 MHz, DMSO-C-6): the compound forms a tautomeric equilibrium in solution: 8.09/7.67 (s/s, IH, CH=/C#-OH), 7.38-7.23 (m, 2H, phenyl),
7.01-6.97 (m, IH, phenyl), 6.88-6.79 (m, IH, phenyl), 3.74 (s/broad, 3H, CH3-O).
[00405] Example 10: 6-(3,5-Dimethoxy-phenyl)-3-[4-(4-methyl-piperazin-l-yl)- phenyl]-pyrazolo[l,5-«]pyrimidin-7-ylamine
[00406] 6-(3,5-Dimethoxy-phenyl)-3-[4-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l,5-α]pyrimidin-7-ylamine is synthesized by condensation of compound of
Stage 1.2 and 2-(3,5-dimethoxy-phenyl)-3-oxo-propionitrile (Stage 3.1) analogously to the preparation of compound of Example 1. Yield: 44%, solid powder; ES-MS:
M+H = 445.0; HPLC: \Ret = 3.77 minutes.
[004071 1H-NMR (400 MHz, DMSO-d6): 8.59/8.23 (s/s, 1H/1H, pyrazolopyrimidinyl), 8.06 (d, 9.0 Hz, 2H, phenyl), 7.55 (s, 2H, NH2), 7.43 (t, 8.5 Hz, lH,phenyI-OMc), 7.10 (d, 8.4 Hz, m, phenyl-OM6), 7.57 (s, 2H, NH2), 7.01 (d, 9.0
Hz, 2H, phenyl), 6.89 (s, 2H,_p/je«yl-OMe), 6.54 (s, YΑ, pheny\-OM€), 3.83 (s, 6H,
CH3-O), 3.16/2.47 (m/m, 4H/4H, piperazinyl), 2.24 (s, 3H, N-CH3).
[00408] Staee 3.1 2-(3,5-Dimethoxy-phenyl)-3-oxo-propionitrile
[00409] 2-(3,5-Dimethoxy-phenyl)-3-oxo-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3. Yield: 48%; white powder; ES-MS:
M+H
Figure imgf000064_0001
4.79 minutes.
[00410] 1H-NMR (400 MHz, DMSO-d6): the compound forms a tautomeric equilibrium in solution: 8.11/7.68 (s/s, IH, CU=ZCH-OH), 6.85/6.54 (s/s, 2H, phenyl), 6.44/6.38 (s/s, IH, phenyl), 3.74 (s/broad, 6H, CH3-O).
[00411] Example 11 : Stage 1.1 : 6-(3-Benzyloxy-phenyl)-3-[4-(4-methyl-piperazin-
1 -yl)-phenyl3~pyrazolo[l ,5-α]pyrimidin-7-ylamine
[00412] Prepared by the step disclosed in Stage 1.1
[00413] Examples 12-76
[00414] The following Examples enlisted on Table 1 are synthesized analogously to the preparation of Example 8. As far as not being commercially-available, the syntheses of intermediates for the preparation of compounds of Examples 12-76 are described below Table II. In cases where the title compounds carry a free amino group (Examples 59-61), the final products are generated from their corresponding nitro-function carrying precursors by hydrogenation in the presence of Pd/C (10 %) in THF/MeOH during several hours. [00415] Table II.
Figure imgf000065_0001
Figure imgf000065_0002
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
[00417] Staze 5.1: 2-(4-Chloro-phenyl)-3-oxo-propϊonitrile
[00418] 2-(4-Chloro-phenyl)-3-oxo-propionitrile is prepared analogously to the preparation of compound of Stage 1.3: 89%; ES-MS [M-I]" = Ml.91119.9; HPLC
^Rei — 5.67 minutes.
[00419] Staee 6.1: 2-(3-Chloro-phenyl)-3-oxo-propionitrile
[00420] 2-(3-Chloro-phenyl)-3-oxo-propionitrile is prepared analogously to the preparation of compound of Stage 1.3: 89%; ES-MS [M-I]" - 177.9/179.9; HPLC
^Ret = 5.60 minutes.
[00421] Staee 8.1 3-Oxo-2-phenyl-butyronitrile
[00422] 3-Oxo-2-phenyl-butyronitrile is prepared analogously to the preparation of compound of Stage 1.3: 62%, white crystals, m.p. >215°C; ES-ES-MS M-H = 157.9,
Rf (hexane / AcOEt = 1:1) = 0.57.
[00423] 1H-NMR (400 MHz, DMSOd6): 7.84 (d, 9.0 Hz52H)9 7.04 (t, 9.0 Hz, 2H),
6.68 (t, 9.0 Hz, IH), 3.21 (s/broad, IH, CH), 2.03 (s, 3H, CH3).
[00424] Stase 9.1 2-Methyl-3-oxo-3-phenyl-propionitrile
[00425] 2-Methyl-3-oxo-3-phenyl-propionitrile is prepared analogously to the procedure of Yoo et al., Tetrahedron Lett., Vol. 43, No.27, pp. 4813-4815 (2002). 2-
Bromo-propionitrile (0.965 mL, 11.05 mmol) and In-powder (975 mg, 8.5 mmol) are stirred under Ar in THF (15 mL) for 1 hour. After adding benzoylnitrile (735 mg, 5.6 mmol) during 2 minutes, the reaction mixture is stirred at 60σC in a microwave ofen (Emrys optimizer, personal chemistry, Sweden) for 30 minutes. After filtration over Hyflo and washing with THF (5 mL), the reaction solution is concentrated under reduced pressure and partitioned between ether (150 mL) and phosphate buffer (pH = 7, 150 mL). After separation of the organic phase, the aqueous phase is extracted with ether (150 mL). The combined organic phases are washed with brine (30 mL), dried (Na2SO4), concentrated under reduced pressure and flash chromatography (silica gel, 2 x 18 cm, hexane / AcOEt = 3:1) to compound of Stage 9.1 as slightly yellowish oil (300 mg, 1.9 mmol; 34%); ES-MS: M-H = 157.9; Rf (hexane / AcOEt = 1:1) = 0.60.
[00426] 1H-NMR (400 MHz, DMSO-de): 8.06 (d, 8.5 Hz, 2H), 7.74 (t, 8.5 Hz, IH), 7.62 (t, 8.5 Hz, 2H), 5.17 (q, 8.5 Hz, IH, CH), 1.52 (s, 3H, CH3). [00427] The compound of Example 24 is synthesized analogously to the preparation of compound of Stage 1.1 by condensing 2,3-dichloro-N-[4-(cyano-formyl-methyl)- phenyl]-benzenesulfonamide (Stage 10.1) and 4-(4-dimethylamino-phenyl)-2H- pyrazol-3-ylamine (Stage 10.3).
[00428] Staee 10.1 2,3-Dichloro-JV-[4-(cyano-formyl-methyl)-phenyl]- benzenesulfonamide
[00429] Under an atmosphere of N2 is added portion- wise freshly-cut pieces of sodium (2.3 g total, 100 irunol) to EtOH abs. (230 mL) within 15 minutes which is a slightly exothermic (up to 43°C). After all sodium is dissolved (ca. 1 hour) 2,3- dichloro-JV-(4-cyanomethyl-phenyl)-benzene-sulfonamide (Stage 10.2) (26.27 g, 77 mmol) and formic acid ethyl ester (11.2 mL, 139 mmol) is added to the colorless solution at RT. The mixture is heated to reflux for 2 hours. After cooling to RT, the solvent is removed under reduced pressure and the residue dissolved in H2O (20 mL), followed by addition of AcOH (200 mL; pH 4). The aqueous layer is extracted with CH2Cl2 (2 x, 500 mL), the combined organics are washed with H2O and dried over Na2SO4. Purification is done by repeated chromatography (silica gel, EtOAc and CH2Cl2 / MeOH = 98:2) to obtain 2,3-dichloro-N-[4-(cyano-formyl-methyl)-ρhenyl]- benzenesulfonamide (233 mg, 1% yield) as beige crystals: m.p. 88-1020C; (CH2Cl2 / MeOH = 95:5): 0.22; ES-MS [M+l]+ = 368; HPLC %,, = 5.61 minutes. [00430] Stase 102 2,3-Dichloro-JV-(4-cyanomethyl-phenyl)-benzenesulfonamide [00431] To the solution of 4-aminobenzylcyanide (12 g, 90.8 mmol) in pyridine (11 mL) at RT, a solution of 2,3-dichlorobenzene-sulphonylchloride (22.29 g, 90.8 mmol) in THF (80 mL) is added within 20 minutes. The reaction is stirred at reflux for 2 hours. After cooling, the solvent is removed under reduced pressure and the remaining solid suspended in 10% HCl (200 mL). The crude crystalline product is fϊltered-off, washed with H2O and dried at 6O0C. Final purification is done by suspending the crude compound in MeOH (250 mL), heating to reflux, filtration and drying. 2,3-Dichloro-iV-(4-cyanomethyl-phenyl)-benzenesulfonamide (26.54 g, 86%) is obtained as orange crystals: m.p: 202-2060C; (CH2Cl2 / MeOH 98:2): 0.54; ES-MS
[M-I]" = 338.8; HPLC %,, = 5.85 minutes.
[00432] Stage 10.3 4-(4-Dimethylamino-phenyl)-2if-pyrazol-3-ylamine
[00433J 4-(4-Dimethylamino-phenyl)-2H-pyrazol-3-ylamine is prepared from
2-(4-dimethylamino-phenyl)-3-oxo-propionitrile (Stage 10.4) and hydrazine hydrate as described in U.S. Patent No. 2,989,539 (20.6.61; Anderson and Reiff; Example 18).
4-(4-Dimethylamino-phenyl)-2H-pyrazol-3-ylamine : m.p. 173-176°C; (CH2Cl2 /
MeOH / NH3 = 90: 10:1): 0.37; ES-MS [M+l]+ = 203; HPLC BtΛe, = 1.40 minutes.
[00434] Stage 10.4 2-(4-Dimethylamino-phenyl)-3-oxo-propionitrile
[00435] 2-(4-Dimethylamino-phenyl)-3-oxo-propionitrile is prepared from (4- dimethylamino-phenyl)-acetonitrile, ethyl formate and sodium as described in U.S.
Patent No. 2,989,539 (Example 25).
[00436] 2-(4-Dimethylamino-phenyl)-3-oxo-propionitrile: m.p. 175- 178°C; ES-MS
[M+l]+ = 189; HPLC BtΛe,= 2.00 minutes.
[00437] The compound of Example 18 is prepared analogously to the synthesis of the compound of Example 17 using 4-(4-dimethylamino-phenyl)-2//-pyrazol-3- ylamine (Stage 10.3) and 4-chloro-benzenesulfbnic acid 4-(cyano-formyl-methyl)- phenyl ester (Stage 11.1).
[00438] Stage 11 1 4-Chloro-benzenesulfonic acid 4-(cyano-formyl-methyl)- phenyl ester
[00439] 4-Chloro-benzenesulfonic acid 4-(cyano-formyl-methyl)-phenyl ester is prepared as described in Example 17 (Stage 10.1), using commercially-available 4-
(cyanomethyl)phenyl-4-chlorobenzene-l -sulfonate instead.
[00440] 4-Chloro-benzenesulfonic acid 4-(cyano-formyl-methyl)-phenyl ester (162 mg); yellowish solid; (CH2Cl2 / MeOH = 95:2): 0.32; ES-MS [M+l]+ = 335; HPLC
Bt/ter = 6.23 minutes. [00441] Stase 12.1 2-(4-Methoxy-phenyl)-3-oxo-butyronitrile
[00442] 2-(4-Methoxy-phenyl)-3-oxo-butyronitrile is prepared as described by
Smith, Breen, Hajek and Awang, J. Org. Chem., Vol. 35, No. 7, pp.2215-2221
(1970).
[00443] Stage 14.1 2-(4-Bromo-phenyl)-3-oxo-butyronitrile
[00444] 2-(4-Bromo-phenyl)-3-oxo-butyronitrile is synthesized according to the procedure of Rau, Ger. Offen., DE 3001266 (1980).
[00445] Stase 16.1 l,2-(2,6-Dichloro-phenyl)-3-oxo-propionitrile
[00446] l,2-(2,6-Dichloro-phenyl)-3-oxo-propionitrile is prepared as described by
Menzer, Lankau and Unverferth, Ger. Offen., DE 19521822 (1996).
[00447] Stase 17.1 4-(3-Methoxy-phenyl)-2H-pyrazol-3-ylamine
[00448] 4-(3-Methoxy-phenyl)-2/-r-pyrazol-3-ylamine and Stage 22.2 are prepared as described by Bruni et al., Heterocyclic. Chem., Vol. 32, No. 1, pp. 291-298 (1995).
[00449] Stase 19.1 2-Benzo[δ]thiophen-3-yl-3-oxo-propionitrile
[00450] 2-Benzo[6]thiophen-3-yl-3-oxo-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3: Yield: 56%; white powder; ES-MS: M-H
= 123.9; HPLC: \Ret = 2.20 minutes.
[00451] 1H-NMR (300 MHz, DMSOd6): 12.0 (s/broad, IH), 8.00-7.70 (m, 3H),
7.45-7.35 (m, 2H).
[00452] Stase 21.1 3-Oxo-2-thiophen-3-yl-propionitrile
[00453] 3-Oxo-2-thiophen-3-yl-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3: Yield: 51%; white powder, ES-MS: M-H =
112.9; HPLC: %* = 2.03 minutes.
[00454] The compound forms a tautomeric equilibrium in solution: 1H-NMR (300
MHz, DMSOd6): 7.95/7.55 (s/s, IH, CH=/Ci/-OH), 7.55-7.50 (m, 2H)S 7.30-7.20
(m, IH).
[00455] Stase 22.1 4-Benzo[ό]thiophen-3-yl-l//-pyrazol-3-ylamine
[00456] 4-Benzo [£]thiophen-3 -y 1- 1 H-pyrazol-3 -ylamine is synthesized analogously to the preparation of compound of Stage 1.2: Yield: 80%; white powder; ES-MS:
M+H = 216.0.
[00457] 1H-NMR (300 MHz, DMSO-d6): 12.0 (s/broad, IH), 8.00-7.80 (m, 2H),
7.75 (s/broad, IH), 7.60 (s/broad, IH), 7.40-7.30 (m, 2H).
[00458] Stase 22.2 (2-(3-Methoxy-ρhenyl)-3-oxo-propionitrile) [00459] (2-(3-Methoxy-phenyl)-3-oxo-propionitrile) is prepared as described by
Bruni et al., Heterocyclic. Chem., Vol. 32, No. I9 pp. 291-298 (1995).
[00460] Staεe 23.1 2-Formyl-3-pheπyl-propionitrile
[00461] 2-Formyl-3-phenyl-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3: Yield: 77%; oil; ES-MS: M-H = 158.0.
[00462] The compound forms a tautomeric equilibrium in solution: 1H-NMR (300
MHz5 DMSO-d6): 7.40-7.15 (m, 5H), 2.85-2.75 (m, 2H).
[00463] Staεe 24.1 4 [3-(4-Methyl-piperazin-l-yl)-phenyl]-acetonitrile
[00464] 4 [3-(4-Methyl-piperazin-l-yl)-phenyl]-acetonitrile is synthesized analogously to the preparation of compound of Stage 1.5: Yield: 55 %; brown solid;
ES-MS: M+H = 216.7; HPLC: ctΛe, = 1.65 minutes.
[00465] 1H-NMR (300 MHz5 CDCl3): 7.30-7.25 (m, IH)56.90-6.82 (m, 2H), 6.80-
6.75 (m, IH), 3.70 (s, 2H), 3.25-3.15 (m, 4H), 2.60-2.50 (m, 4H)5 2.35 (s, 3H).
[00466] Staεe 24.2 2-[3-(4-Methyl-piperazin-l-yl)-phenyl]-3-oxo-propionitrile
[00467] 2-[3-(4-Methyl-piperazin-l-yl)-phenyl]-3-oxo-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3: Yield: 100%; brown solid;
ES-MS: M+H - 244.1; HPLC: %et = 1.67 minutes.
[00468] Staεe 24.3 4-[3-(4-Methyl-piperazin-l-yl)-phenyl]-lH-pyrazol-3-ylamine
[00469] 4-[3-(4-Methyl-piperazin-l-yl)-phenyl]-li/-pyrazol-3-ylamine is synthesized analogously to the preparation of compound of Stage 1.2: Yield: 36%; yellow foam; ES-MS: M+Η = 258.2; ΗPLC: CW = 1.46 minutes.
[00470] 1H-NMR (300 MHz5 CDCl3): 7.45 (s, IH), 7.30-7.25 (m, IH)5 7.05-7.00
(m, IH)5 6.95-6.90 (m, IH)5 6.85-6.80 (m, IH)54.00 (s/broad52H)5 3.30-3.20 (m, 4H)5
2.65-2.58 (m, 4H), 2.35 (s, 3H).
[00471] Staεe 25.1 2-(l -Methyl- lH-ϊndol-3-yl)-3-oxo-propionitrile
[00472] 2-(l-Methyl-lH'-indol-3-yl)-3-oxo-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3: Yield: 59%; oil; ES-MS: M+Η = 199.1.
[00473] The compound forms a tautomeric equilibrium in solution: 1H-NMR (300
MHz5 CDCl3): 8.00/7.95 (s/s, IH)5 7.60-7.20 (m, 5H), 3.75 (s, 3H).
[00474] Staεe 26.1 2-(4-Methoxy-phenyl)-3-oxo-propionitrile
[00475] 2-(4-Methoxy-phenyl)-3-oxo-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3: Yield: 80%; white solid; ES-MS: M-H
=174.3. [00476] The compound forms a tautomeric equilibrium in solution: 1H-NMR (300
MHz3 DMSOd6): 7.80/7.58(s/s, IH), 7.55-7.50 (m, IH)5 7.30-7.20 (m, IH), 6.90-
6.80 (m, 2H), 3.73/3.70 (s/s, 3H).
[00477] Stase 27.1 2-(2-Methoxy-phenyl)-3-oxo-propionitrile
[00478] 2-(2-Methoxy-phenyl)-3-oxo-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3: Yield: 40%; brown oil; ES-MS: M-H =
174.3; HPLC ctΛe, = 2.01 minutes.
[00479] Staee 28.1 3-Oxo-2-ρyridin-3-yl-ρropionitrile
[00480] 3-Oxo-2-pyridin-3-yl-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3: Yield: 71%; brown solid; ES-MS: M+H =
147.2; HPLC ctRet = 1.31 minutes.
[00481] Stas e 28.2 4-Pyridm-3-yl-l#-pyrazol-3-ylamine
[00482] 4-Pyridin-3-yl-lH-pyrazol-3-ylarnine is synthesized analogously to the preparation of compound of Stage 1.2: Yield: 68%; brown solid; ES-MS: M+Η =
161.2; ΗPLC CW= 0.50 minutes.
[00483] Stage 30.1 [2-Methoxy-5-(4-methyl-piperazin-l-yl)-phenyl]-acetonitrile
[00484] [2-Methoxy-5-(4-methyl-piperazin-l-yl)-phenyl]-acetonitrile is synthesized analogously to the preparation of compound of Stage 1.5: Yield: 51%; brown solid;
ES-MS: M+Η = 246.6; ΗPLC: %,, = 1.72 minutes.
[00485] 1H-NMR (300 MHz, CDCl3): 7.00-6.95 (m, IH), 6.85-6.75 (m, 2H), 3.80
(s, 3H), 3.65 (s, 2H), 3.15-3.05 (m, 4H), 2.60-2.55 (m, 4H), 2.35 (s, 3H).
[00486] Stage 30.2 2-[2-Methoxy-5-(4-methyl-piperazin-l-yl)-phenyl]-3-oxo- propionitrile
[00487] 2-[2-Methoxy-5-(4-methyl-piperazin- 1 -yl)-phenyl]-3-oxo-propionitrile is synthesized analogously to the preparation of compound of Stage 1.4: Yield: 100%; brown solid; ES-MS: M+H = 274.1 ; HPLC: ctRet = 1.62 minutes.
[00488] St age 30.3 4-[2-Methoxy-5-(4-methyl-piperazin-l-yl)-phenyl]-2H- pyrazol-3 -ylamine
[00489] 4-[2-Methoxy-5-(4-methyl-piperazin-l-yl)-phenyl]-2H-pyrazol-3-ylamine is synthesized analogously to the preparation of compound of Stage 1.2: Yield: 32%; brown solid; ES-MS: M+Η = 288.2; ΗPLC: cXRel = 1.46 minutes.
[00490] 1H-NMR (300 MHz, CDCl3): 7.50 (s, IH), 7.00-6.95 (m, IH), 6.90-6.80
(m, 2H), 3.80 (s, 3H), 3.20-3.10 (m, 4H), 2.65-2.55 (m, 4H)52.35 (s, 3H).
[00491] Stage 32.1 2-(2-Benzyloxy-phenyl)-3-oxo-propionitrile [00492] 2-(2-Benzyloxy-phenyl)-3-oxo-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3: Yield: 85%; white solid; ES-MS:. M+H =
252.6; HPLC: ctRe, = 2.35 minutes.
[00493] The compound forms a tautomeric equilibrium in solution: 1H-NMR (300
MHz, DMSOd6): 11.6/7-78 (s, IH), 7.55-7.45 (m, 2H), 7.40-7.20 (m, 5H), 7.15-7.05
(m, IH), 7.00-6.90 (m, IH), 5.15 (s, 2H).
[00494] Stage 34.] 2-(4-Benzyloxy-phenyl)-3-oxo-propionitrile
[00495] 2-(4-Benzyloxy-phenyl)-3-oxo-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3: Yield: 95%; white solid; ES-MS: M-H =
250.3; HPLC: ctRet = 2.41 minutes.
[00496] The compound forms a tautomeric equilibrium in solution: 1H-NMR (300
MHz, DMSO-dβ): 12.0/11.7 (s, IH), 7.90-7.80 and 7.60-7.50 (m, IH). 7.40-7.25 (m,
6H), 7.05-6.95 (m, 2H), 5.10 (S5 2H).
[00497] Staee 44.1 4-(l-Methyl-lH-indol-3-yl)-2H-pyrazol-3-ylamine
[00498] 4-(l-Methyl-lH>indol-3-yl)-2H-pyrazol-3-ylamine is synthesized analogously to the preparation of compound of Stage 1.2: Yield: 10%; brown foam;
ES-MS: M+Η = 213.2; ΗPLC: ctΛe, = 1.66 minutes.
[00499] 1H-NMR (300 MHz, DMSOd6): 7.70 (d, IH), 7.60 (s, IH), 7.35 (d, IH),
7.30-7.25. (m, IH), 7.20-7.10 (m, 2H), 3.80 (s, 3H).
[00500] . Stase 47.1 2-(2-Methoxy-phenyl)-3-oxo-propionitrile
[00501] 2-(2-Methoxy-phenyl)-3-oxo-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3: Yield: 59%; white solid; ES-MS: M+H =
175.3; HPLC: ctΛe, = 2.01 minutes.
[00502] Staze 47.2 4-(2-Methoxy-phenyl)-2/f-pyrazol-3-ylamine
[00503] 4-(2-Methoxy-phenyl)-2H-pyrazol-3-ylamine is synthesized analogously to the preparation of compound of Stage 1.2: Yield: 35%; white solid; ES-MS: M+Η =
190.1; ΗPLC: ctΛef = 1.40 minutes.
[00504] 1H-NMR (300 MHz, DMSOd6): 11.5 (bs, IH), 7.50 (bs, IH), 7.30 (bs,
IH), 7.20-7.05 (m, IH), 7.00-6.85 (m, 2H), 4.30 (bs, 2H), 3.75 (s, 3H).
[00505] Stase 51.1 3-Oxo-2-pyridin-4-yl-propionitrile
[00506] 3-Oxo-2-pyridin-4-yl-propionitrile is synthesized analogously to the preparation of compound of Stage 1.3: Yield: 59%; orange solid; ES-MS: M+H =
147.2; HPLC: %,, = 1.00 minute. [00507] The compound forms a tautomeric equilibrium in solution: 1H-NMR (300
MHz5 DMSO-dβ): 13.1/9.60 (bs, IH), 9.10 (bs, IH), 8.20-8.00 (m, 2H), 7.95-7.80 (m,
IH).
[00508] Staee 52.1 (2)-3-Dimethylamino-2-(3-nitro-ρhenyl)-acrylonitrile
[00509] (3-Nitro-phenyl)-acetonitrile (1.51 g, 9.31 mmol), dimethoxymethyl- dimethyl-amine (6.2 mL, 46.5 mmol) in xylene (30 mL) are stirred at reflux for 1 hour. After adding hexane (20 mL), the reaction mixture is cooled at 00C.
Precipitating material is filtered-off to give compound of Stage 52.1 as brown solid
(1.76 g, 8.19 mmol; 88%); ES-MS: M+H = 218.1; HPLC: ctRet = 2.24 minutes.
[00510] 1H-NMR (300 MHz, DMSOd6): 8.10-8.05 (m, IH), 7.90-7.85 (m, IH),
7.75-7.72 (m, IH)5 7.70 (s, IH), 7.65-7.60 (m, IH), 3.30 (s, 6H).
[00511] Staee 52.2 3-[3-(4-Methyl-piperazin-l-yl)-ρhenyl]-6-(3-nitro-phenyl)- pyrazolo[l ,5-α]pyrimidin-7-ylamine
[00512] 4-[3-(4-Methyl-piperazin-l-yl)-phenyI]-lH-pyrazol-3-ylamine (Stage 24.3)
(305 mg, 1.18 mmol), (Z)-3-dimethylamino-2-(3-nitro-phenyl)-acrylonitrile (Stage
52.1) (335 mg, 1.54 mmol) dissolved in AcOH (10 mL) and BuOH (10 mL) are stirred at reflux for 16 hours. After adding saturated NaHCθ3 aqueous solution, the reaction mixture is extracted with EtOAc (50 mL, 2 x). The combined organic phases are washed with H2O (10 mL), dried (NaiSO-j), concentrated under reduced pressure and flash chromatographed (silica gel, 2.5 x 15 cm, CH2Cb / MeOH = 9:1) to give compound of Stage 52.2 as orange solid (224 mg, 0.52 mmol; 44%); ES-MS: M+H =
430.1; HPLC: %>, = 1.91 minutes.
[00513] 1H-NMR (300 MHz, DMSO-de): 8.70 (s, IH), 8.35-8.30 (m, IH), 8.25 (s,
IH), 8.22-8.18 (m, IH), 7.98-7.95 (m, IH), 7.90 (bs, 2H), 7.80-7.70 (m, 2H), 7.65-
7.60 (m, IH), 7.25-7.18 (m, IH), 6.80-6.75 (m, IH), 3.20-3.10 (m, 4H), 2.50-2.40 (m,
4H), 2.20 (s, 3H).
[00514} Staee 53.1 3-[4-(4-Methyl-piperazin-l-yl)-phenyl]-6-(3-nitro-phenyl)- pyrazolo[l,5-α]pyrimidin-7-ylamine
[00515] 3-[4-(4-Methyl-piperazin-l -yl)-phenyl]-6-(3-nitro-phenyl)-pyrazolo[l ,5- α]pyrimidin-7-ylamine is synthesized analogously to the preparation of compound of
Stage 52.2: Yield: 30%; red solid; ES-MS: M+H = 430.0.
[00516] 1H-NMR (300 MHz5 DMSO-dβ): 8.60 (s, IH), 8.35-8.30 (m, IH), 8.22 (s,
IH), 8.20-8.10 (m, IH), 8.00 (d, 2H, J=7.9Hz), 7.95-7.90 (m, IH), 7.85 (bs, 2H)9 7.80-7.75 (m, IH), 6.95 (d, IH, J=7.9Hz), 3.20-3.10 (m, 4H), 2.50-2.40 (m, 4H), 2.20
(S5 3H).
[00517] Stage 54.1 (Z)-3-Dimethylamino-2-(2-nitro-phenyl)-acrylonitrile
[00518] (Z)-3-Dimethylamino-2-(2-nitro-phenyl)-acrylonitrile is synthesized analogously to the preparation of compound of Stage 52.1: Yield: 97%; brown solid.
[00519] 1H-NMR (300 MHz, DMSOd6): 7.82-7.78 (m, IH), 7.62-7.55 (m, IH),
7.45-7.35 (m, 2H), 7.20 (s, IH), 3.15 (s, 6H).
[00520] Stage 54.2 3-[4-(4-Methyl-piperazin-l-yl)-phenyl]-6-(2-nitro-phenyl)- pyrazolofl ,5-α]pyrimidin-7-ylamine
[00521] 3-[4-(4-Methyl-piperazin- 1 -yl)-phenyl]-6-(2-nitro-phenyl)-pyrazolo[l ,5- α]pyrimidin-7-ylarnine is synthesized analogously to the preparation of compound of
Stage 55.2: brown solidl; ES-MS: M+H = 430.0; HPLC: %e, = 1.61 minutes.
[00522] 1H-NMR (300 MHz, DMSO-de): 8.55 (s, IH), 8.20-8.15 (m, IH), 8.05-
7.95 (m, 3H), 7.82-7.60 (m, 5H), 7.00-6.95 (m, 2H), 3.15-3.05 (m, 4H), 2.45-2.40 (m,
4H), 2.20 (s, 3H).
[00523] Stage 55.1 (JE)-3-Dimethylamino-2-(4-methyl-thiazol-2-yl)-acrylonitrile
[00524] (E)-3-Dimethylamino-2-(4-methyl-thiazol-2-yl)-acrylonitrile is synthesized analogously to the preparation of compound of Stage 52.1 : Yield: 74%; black solid;
ES-MS: M+H = 194.2; HPLC: ctΛe, = 1.57 minutes.
[00525] 1H-NMR (300 MHz, DMSO-dβ): 7.76 (s, IH), 6.60 (s, IH), 3.25 (bs, 6H),
2.35 (s, 3H).
[00526] Example 68
3 - { 7- Amino-2-methyl-3 - [4-(4-methyl-piperazin- 1 -yl)phenyl]-pyrazolo[ 1 , 5- ar]pyrimidin-6-yl} -phenol
[00527] 3-{7-Amino-2-methyl-3-[4-(4-methyl-piperazin-l-yl)phenyl]-pyrazolo[l,5- α]pyrimidin-6-yl} -phenol is synthesized analogously to the preparation of Example 1 by using methyl hydrazine instead of hydrazine when the pyrazole ring is formed: ES-
MS: M+H = 415.2; HPLC: %el = 1.45 minutes.
[00528] 1H-NMR (300 MHz, DMSO-dβ): 9.53 (s, IH, OH), 2.56 (s, 3H CH3), 2.24
(s, 3H CH3).
[00529] Example 69 (4-{7-Amino-3-[4-(4-methyl-piperazin-l-yl)-phenyl]-pyrazolo[l,5-α]pyrimidin-6-yl}- phenyl)-carbamic acid ethyl ester
[00530] 4-(4-(4-Methyl-ρiρerazin-l-yl)-phenyl)-2H-pyrazol-3-ylamine (Stage L2) (200 mg, 0.81 mmol) and [4-(2-cyano-l-formyl-ethyl)-phenyl]-carbamic acid ethyl ester (Stage 62.1) (275 mg, 0.04 mmol) dissolved in EtOH (4 mL) and ethanolic HCl (1.6 mL, 2.5 N) are stirred under reflux for 17 hours under Ar. After adding H2O (4 mL) and K2CO3 (250 mg), the reaction mixture is extracted with CH2CI2 (20 mL, 2 x). The combined organic phases are washed with H2O (10 mL), dried (NaZSO4), concentrated under reduced pressure and flash chromatographed (silica gel, 2.5 x 15 cm, CH2CI2 / MeOH / NH3 = 95:5:0.5) to give compound of Example 62 as white solid (58 mg, 0.123 mmol; 15%); ES-MS: M+H = 472.0; Rf (CH2Cl2 / MeOH / NH3 = 90:10:0.1) = 0.42; HPLC: %* = 4.26 minutes. [00531] 1H-NMR (400 MHz, DMSO-dδ): 8.75/8.58 (s/s, 1H/1H, pyrazolopyrimidinyl), 8.03 (d, 9.0 Hz, 2H, phenyl), 7.61 (d, 9 Hz, 2H, phenyl), 7.53 (s, 2H, NH2), 7.46 (d, 9 Hz, 2H, phenyl), 7.00 (d, 9 Hz, 2H, phenyl), 4.17 (q, 7.5 Hz, 2H, CH2-EtTIyI), 3.17/2.48 (m/m, 4H/4H, piperazinyl), 2.24 (t, 7.5 Hz, 3H, CH3). [00532] Stage 62a.1 f4-(Cvano-l -formvl-methvD-phenvlVcarbamic acid ethyl ester [00533] [4-(Cyano-methyl)-phenyl]-carbamic acid benzyl ester (Stage 62a.2) (I g, 3.76 mmol) is formylated in analogy to the preparation of Stage 1.3 giving the corresponding carbamic acid ethyl ester (thereby also transforming the benzyl ester function into the ethyl ester function): colorless crystals (654 mg, 2.66 mmol, 70%). ES-MS: M+H = 233.0.
[00534] 1H-NMR (400 MHz, DMSO-d6): 4.12 (q/broad, 7.5 Hz, 2H, CH2-Ethyl), • 1.23 (t/broad, 7.5 Hz, 3H, CH3-Ethyl).
[00535] Stage 62.2 [4-(Cyano-methyl)-phenyl]-carbamic acid benzyl ester [00536] (4-Amino-phenyl)-acetonitrile (2 g, 15.1 mmol) and dibenzyl dicarbonate (4.33 g, 15.1 mmol) dissolved in dioxane (16 mL) are stirred for 1 hour at RT. After evaporating the solvent, the product is isolated by flash chromatography (silica gel, 4.5 x 25 cm, CH2Cl2 / MeOH = 99:1): white solid (3.82 g, 14.4 mmol; 95%); ES-MS: M-H = 265.0; Rf(CH2Cl2 / MeOH = 95:5) = 0.49; HPLC: %* = 6.32 minutes. [00537] 1H-NMR (400 MHz, DMSO-d6): 9.82 (s, IH, NH), 7.51 - 7.35 (m, 7H, aryl), 7.26 (d, 8.5 Hz, 2H, aryl), 5.15 (s, 2H. CH2), 3.95 (s, 2H, CH2). [00538] (Z-)3-Dimethylamino-2-thiazol-4-yl-acrylonitrile [00539] (Z-)3-Dimethylamino-2-thiazol-4-yl-acrylonitrile is synthesized analogously to the preparation ofcompound of Stage 52.1 : ES-MS [M+l]+ = 180.1;
HPLC : %?,,, = 1.91 minutes
[00540] Compounds 68, 69, 71, 74, and 75 carrying sulfonamide and acetylamide functions (compounds 50, 72 and 76) are prepared by reacting the amino precursor with the corresponding sulfonic acid chloride or acetic acid anhydride in the presence of pyridine.
[00541] Examples 77 and 78
[00542] The compounds in Table 2 and Table 3 are prepared according to Example
8.
Table 2 - Example 77
Figure imgf000086_0001
Figure imgf000086_0002
Figure imgf000087_0001
Figure imgf000088_0001
Nb. R> R2 R3
Z9 4-(4-Methyl-piperazin- 1 -yl) H
ZlO 4-(4-Methyl-piperazin- 1 -yl) H
zll 3-(4-Methyl-piperazin- 1 -yl) H
zl2 3-(4-Methyl-piperazin- 1 -yl) H
zl3 5 -(4-Methy 1-piperazin- 1 -yl)/2- H methoxy
zl4 5-(4-Methyl-piperazin-l-yl) 12- H methoxy
zl5 4-(4-Methyl-piperazϊn- 1 -yl)/2- H methoxy
zl6 4-(4-Methyl-piperazin-l-yl) 12- H methoxy
Figure imgf000089_0001
zl7 4-(4-Methyl-piperazin- 1 -yl) Br H zl8 3-(4-Methyl-piperazin- 1 -yl) H
Figure imgf000089_0002
Z19 4-(4-Methyl-piperazin-l-yl)/2- 3-Benzyloxyphenyl H Methoxy
Figure imgf000090_0003
Figure imgf000090_0001
Table 3 - Example 78
Figure imgf000090_0002
[00543] Example 79: 6-(3-Chloro-phenyl)-5-methyl-3-[3-(4-methyl-piperazin-l- yl)-phenyl]-pyrazo- lo[l ,5-a]pyrimidin-7-ylamine
[00544] 4-[3-(4-Methyl-piperazin-l-yl)-phenyl]-lH-pyτazol-3-ylamine (Stage 72.2) (1.29 g, 5 mmol), is dissolved in EtOH (25 mL), followed by the addition of 2-(3- Chloro-phenyl)-3-oxo-butyronitiile (Stage 72.3) (0.97 g, 5 mmol) and HCl (1.25 M in EtOH; 20 mmol, 16 mL) at RT. The yellowish solution is refluxed under stirring for 20 h. After cooling to RT, H2O (80 mL) is added as well as K2CO3 (2.5 g) to render the mixture basic. The aequeous layer is extracted with CH2CI2 (200 mL, 2.times.). The combined organic phases are washed with H2O (50 mL, 2. times.), dried (Na2SO4), concentrated under reduced pressure and chromatographed (silica gel, 120 g RediSep, ISCO Sg-IOO CH2Cl2/MeOH/NH3=95:5:0,l) to obtain the title compound 72 as white crystals (1.03 g, 2.38 mmol; 48%); mp. 110-115°C; MS(ESI+):m/z=433 (M+H)+; HPLC: ΛRET =3.72 minutes (Systeml). [00545] Stage 72.1 : 2-(3-Chloro-phenyl)-3-oxo-butyronitrile [00546] 355 ml of ethanol is heated to 55°C. under N2. To this solution is added sodium (3.91 g; 0.17 mol) within 30 min. and stirred for 1.5 h until all metal is dissolved. 3-Chlorobenzyl cyanide (15.31 g; 0.1 mol) and ethyl acetate (28.53 mL; 0.29 mol) are added to the colorless solution, followed by stirring under reflux for 5 h. After completion of the reaction, the yellow mixture is cooled to rt. and evaporated under reduced pressure. The crude material is taken up into water (200 mL) and neutralized by addition of 25 g of citric acid. The aqueous layer is extracted with CH2Cl2 (2.times.250 mL). The combined organic phases are washed with H2O (2.times.150 mL,), dried (Na2SO^, concentrated under reduced pressure and chromatographed (silica gel, 1 kg, Merck 60 (0.040-0.063), eluting with EtOAc/Hexanes 1:1) to obtain the title compound 72.1 as yellowish crystals (9.7 g, 0.05 mol; 50%); mp. 92-97°C; MS(ESI+):m/z=302.9 (M+H)+; HPLC: AtRET =5.67 minutes (Systeml).
[00547] Stage 72.2: 4-[3-(4-Methyl-piperazin-l-yl)-phenyl]-lH-pyrazol-3-ylamine [00548] The title compound is prepared as described in example 31 ; Stage 24.1 - 24.3
[00549] Example 80: 6-(3-Chloro-phenyl)-5-methyl-3-[4-(4-methyl-piperazin-l- yl)-phenyl]-pyrazo- lo[l ,5-a]pyrimidin-7-ylamine [00550] The title compound is prepared as described in example 86; using 4-[4-(4-
Methyl-piperazin-l-yl)-phenyl]-2H-pyrazol-3-ylamine (Example 8; Stage 1.2) and 2-
(3-Chloro-phenyl)-3-oxo-butyronitrile (Example 80, Stage 73.1) instead. Beige crystals; mp. 113-115°C; MS(ESH-):m/z=433 (M+H)+; HPLC: VET =3.56 minutes
(Systeml).
[00551] Example 81: 6-(3-Chloro-phenyl)-3-[2-methoxy-5-(4-methyl-piperazin-l- yl)-phenyl]-5-met- hyl-pyrazolo[l ,5-a]pyrimidin-7-ylamine
[00552] The title compound is prepared as described in example 86; using 4-[2-
Methoxy-5-(4-methyl-piperazin- 1 -yl)-phenyl]-2H-pyrazol-3-ylamine and 2-(3-
Chloro-phenyl)-3-oxo-butyronitrile (Example 79, Stage 72.1) instead. Beige crystals; mp. 116-121 0C; MS(ESI+):m/z=463 (M+H)+; HPLC: VET =3.68 minutes
(Systeml).
[00553] Stage 74.1 : 4-[2-Methoxy-5-(4-methyl-piρerazin- 1 -yl)-phenyl]-2H- pyrazol-3~ ylamine
[00554] The title compound is prepared as described in example 8, (Stage 1.2; Stage
1.4 and 1.5); using 5-Bromo-2-methoxy-phenylacetonitrile and N-methylpiperazine instead. Yellowish foam; MS(ESI+):m/z=288.2 (M+H)+; HPLC: VET =3.53 minutes
(System2).
[00555] Example 82: 6-(3-Chloro-phenyl)-3-[2-methoxy-4-(4-methyl-piperazin-l- yl)-phenyl]-5-met- hyl-pyrazolo[l ,5-a]pyrimidin-7-ylamine
[00556] The title compound is prepared as described in example 86; using 4-[2-
Methoxy-4-(4-methyl-piperazin-l-yl)-phenyl]-2H-pyrazol-3-ylamine and 2-(3-
Chloro-phenyl)-3-oxo-butyronitrile (Example 79, Stage 72.1) instead. Beige crystals; mp.215-217 0C; MS(ESH-):m/z=463 (M+H)+; HPLC: VET =3.63 minutes
(Systeml).
[00557] Stage 75.1 : 4-[2-Methoxy-5-(4-methyl-piperazin-l-yl)-phenyl]-2H-pyr- azol-3 -ylamine. The title compound is prepared as described in example 8,
(Stage.1.2; Stage 1.4 and 1.5); using 4-Bromo-2-methoxy-phenylacetonitril- e and N- methylpiperazine instead. Green-brown crystals; mp. 173.7-178.1 0C;
Figure imgf000092_0001
minutes (System 2).
[00558] Example 83: 3-{7-Amino-3-[2-methoxy-4-(4-methyl-piperazin-l-yl)- phenyl]-ρyrazolo[l,5-a- ]pyrimidin-6-yl} -phenol [00559] The title compound is prepared by dissolving 6-(3-Benzyloxy-phenyl)-3-
[2-methoxy-4-(4-methyl-piperazin-l-yl)-phenyl]-p- yrazolo[l,5-a]pyrimidin-7- ylamine in methanol and subjecting it to catalytic hydrogenation in the presence of
Pd/C as described in example 1.: Beige crystals; mp. 217-220 0C;
MS(ESI+):m/z=431.0 (M+H)+; HPLC: \EΓ =2.65 minutes (Systeml).
[00560] Stage 76.1 : 6-(3-Ben2yloxy-phenyl)-3-[2-methoxy-4-(4-methyl-piperaz- in-
1 -yl)-phenyl]-pyrazolo[l ,5-a]pyrimidin-7-ylamine
[00561] The title compound is prepared as described in example 8, (Stage 1.2; Stage
1.4 and 1.5); using 4-Bromo-2-methoxy-phenylacetonitrile and N-methylpiperazine instead. Yellowish solid; MS(ESI+):m/z=521 (M+H)+; HPLC: VET =4.38 minutes
(System 1).
[00562] Example 84: 6-(2-Chloro-phenyl)-3-[4-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l,5-a]- pyrimidin-7-ylamine
[00563] The title compound is prepared as described in example 86; using 4-[4-(4-
Methyl-piperazin-1 -yl)-phenyl]-2H-pyrazol-3 -ylamine and (Z)-2-(2-Chloro-phenyl)-
3-dimethylamino-acrylonitrile instead. Yellow solid; mp. 197-200° C;
MS(ESI+):m/z=419 (M+H)+; HPLC: VET =3.33 minutes (Systeml).
[00564] Stage 77.1 : (Z)-2-(2-Chloro-phenyl)-3-dimethylamino-acrylonitrile.
[00565] N,N-Dimethylformamide-dimethylacetal (9.06 mL; 64.3 mMol) and 2- chlorobenzylcyanide (1.95 g; 12.86 mMol) is heated under stirring to 1000C. under an atmosphere of Argon. After cooling to rt, the mixture is concentrated under reduced pressure and purified by and chromatography (silica gel, 12O g RediSep,
ISCO Sg-IOO, eluting with EtOAc/hexanes 1 :1) to obtain the title compound as yellow thick oil (2.44 g, 11.8 mmol; 92%); MS(ESI+):m/z=207 (M+H)+; TLC
(EtOAc/hexanes 1:1) Rf=0.38.
[00566] Example 85: 6-(2-Chloro-phenyl)-3-[3-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l,5-a]- pyrimidin-7-ylamine
[00567] The title compound is prepared as described in example 86; using (Z)-2-(2-
Chloro-phenyl)-3-dimethylamino-acrylonitrile (Example 84, Stage 77.1) instead.
Yellowish crystals; mp. 200-203 °C; MS(ESI+):m/z=419.0 (M+H)+; HPLC: ^RET
=3.65 minutes (Systeml).
[00568] Example 86: 6-(4-Fluoro-phenyl)-5-methyl-3 -[4-(4-methyl-piperazin- 1 - yl)-phenyl]-pyrazo- lo[l ,5-a]pyrimidin-7-ylamine [00569] The title compound is prepared as described in example 86; using 4-[4-(4-
Methyl-piperazin- 1 -yl)-phenyl] -2H-pyrazol-3 -ylamine and 2-(4-Fluoro-phenyl)-3- oxo-butyronitrile instead. White crystals; mp. 289-291° C; MS(ESr):m/z=417.1
(M+H)+; HPLC: VET =3.21 minutes (Systeml).
[00570] Stage 79.1 : 2-(4-Fluoro-phenyl)-3-oxo-butyronitrile
[00571] The title compound is prepared as described for example 79, Stage 72.1 using (4-Fluoro-phenyl)-acetonitrile instead. Beige crystals; mp. 77-83 °C;
MS(ESr):m/z=176.9 (M+H)+; HPLC: VET =S-IS minutes (Systeml).
[00572] Example 87: 6-(4-Fluoro-phenyl)-5-methyl-3-[3-(4-methyl-piperazin-l- yl)-phenyl]-pyrazo- lo[l ,5-a]pyrimidin-7-ylamine
[00573] The title compound is prepared as described in example 86; using 2-(4-
Fluoro-phenyl)-3-oxo-butyronitrile (Example 86, Stage 79.1) instead. White crystals; mp. 204-206 0C; MS(ESI+):m/z=417.1 (M+H)+; HPLC: AtREτ =3.34 minutes
(Systeml).
[00574] Example 88: 6-(3-Chloro-phenyl)-5-methyl-3-{3-[4-(l-methyl-piperidin-
4-yl)-pϊperazin- 1 - -yl]-phenyl}-pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine
[00575] The title compound is prepared as described in example 86; using 4-{3-[4-
(l-Methyl-piperidin-4-yl)-piperazin-l-yl]-phenyl)-2H-pyrazol-3-yl- amine instead.
Beige crystals; mp. 180-185 0C; MS(ESI+):m/z=516.0 (M+H)+; HPLC: VET =4.96 minutes (Systeml).
[00576] Stage 81.1: 4-{3-[4-(l-Methyl-piperidin-4-yl)-piperazin-l-yl]-phenyl}-2H- p- yrazol-3-ylamine.
[00577] The title compound is prepared as described in example 8, (Stage 1.2 and
1.4 and 1.5); using (3-Bromo-phenyl)-acetonitrile and l-(l-Methyl-piperidin-4-yl)- piperazine instead. Yellowish crystals; mp. 213-220 °C; MS(ESI+): m/z=341.18
(M+H)+; HPLC: VET =3.57 minutes (Systeml).
[00578] Example 89: 6-(3-Chloro-4-fluoro-phenyl)-5-methyl-3-[3-(4-methyl- piperazin- 1 -yl)-pheny- l]pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine
[00579] The title compound is prepared as described in example 86; using 2-(3-
Chloro-4-fluoro-phenyl)-3-oxo-butyronitrile instead. White crystals; mp. 224-226 0C;
MS(ESI+):m/z=451 (M+H)+; HPLC: VET =3.86 minutes (Systeml).
[00580] Stage 82.1 : 2-(3-Chloro-4-fluoro-phenyl)-3-oxo-butyromtrile [00581] The title compound is prepared as described for example 79, Stage 72.1 using (3-Chloro-4-fluoro-phenyl)-acetonitrile instead. White crystals; mp. 133-134
0C; MS(ESr):m/z=209.9 (M-H)"; HPLC: AtRET=5.79 minutes (Systeml).
[00582] Example 90: 6-(3-Chloro-4-fluoro-phenyl)-5-methyl-3-[4-(4-methyl- piperazin-l-yl)-pheny- l]-pyrazolo[l,5-a]pyrimidin-7-ylamine
[00583] The title compound is prepared as described for example 79, using 4-[4-(4-
Methyl-piperazin-l-yl)-phenyl]-2H-pyrazol-3-ylamine and 2-(3-Chloro-4-fluoro- phenyl)-3-oxo-butyronitrile (Example 89; stage 82.1) instead. White crystals; mp.
264-265 0C; MS(ESI+):m/z=451 (M+H)+; HPLC: VET =3.72 minutes (Systeml).
[00584] Example 91: 6-(3-Bromo-phenyl)-5-methyl-3-[3-(4-methyl-piperazin-l- yl)-phenyl]-pyrazol- o[l ,5-a]pyrimidin-7-ylamine
[00585] The title compound is prepared as described for example 79, Stage 72.1 using 2-(3-Bromo-phenyl)-3-oxo-butyronitrile instead. White crystals; mp. 107-113
0C; MS(ESI+):m/z=477 (M+H)+; HPLC: ^RET =4.90 minutes (Systeml).
[00586] Stage 84.1 : 2-(3-Bromo-phenyl)-3-oxo-butyronitrile
[00587] The title compound is prepared as described for example 79, Stage 72.1 using (3-Bromo-phenyl)-acetonitrile instead. White crystals; mp. 96-100 0C; MS(ESr
):m/z=235.9 (M-H)"; HPLC: \EΓ =5-76 minutes (Systeml).
[00588] Example 92: 6-(3-Bromo-ben2yl)-3-[3-(4-methyl-piρerazin-l-yl)- phenyl]pyrazolo[l ,5-a]py- rimidin-7-ylamine
[00589] The title compound is prepared as described in example 86; using 3-(3-
Bromo-phenyl)-2-formyl-propionitrile instead. White crystals; mp. 170-1710C;
MS(ESI+):m/z=477.0 (M+H)+; HPLC: ^RET =3.84 minutes (Systeml).
[00590] Stage 85.1 : 3-(3-Bromo-phenyl)-2-formyl-propionitrile
[00591] 3-(3-Bromophenyl)propionitrile (0.703 mL; 4.66 mMol) and ethyl formate
(1.499 mL; 18.64 mMol) are dissolved in THF anhydrous (12.5 mL) followed by the addition of NaH (60% in mineral oil; 670 mg) at rt. After 17 h at rt, additional NaH
(448 mg) and ethyl formate (0.765 mL) is added. Since this results in a strong exothermic reaction, additional solvent is added (15 mL of THF). After completion (3 days), the reaction mixture is cooled to 0 0C, treated with a few little ice cubes, followed by addition of 6N HCl (3 mL) to acidify the mixture. After addition of water
(50 mL), the mixture is extracted with EtOAc (3.times.100 mL). The combined organic phases are washed with H2O (50 mL, 2.times.), brine, dried (Na2SO-J), concentrated under reduced pressure and chromatographed (silica gel, 40 g RediSep,
ISCO Sg-100, eluting with EtOAc/hexanes 1 :1) to obtain the title compound as a brownish oil (220 mg; 20%); MS(ESI-):m/z=235.9 (M-H)-; TLC EtOAc/hexanes 1:1)
Rf=0.28.
[00592] Example 93: 6-(3-Bromo-phenyl)-3-[3-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l,5-a]p- yrimidin-7-ylamine
[00593] The title compound is prepared as described in example 86; using (Z)-2-(3-
Bromo-phenyl)-3-dimethylamϊno-acrylonitrile instead. White crystals; mp. 195.3-
197.2 0C; MS(ESI+)ImZz=^OS-O (M+H)+; HPLC: VET =4.05 minutes (Systeml).
[00594] Stage 86.1: (Z)-2-(3-Bromo-phenyl)-3-dimethylamino-acrylonitrile is prepared as described in example 77, Stage 77.1.: Gold brown crystals; mp. 102-105
0C; MS(ESr+):m/z=251.0 (M+H)+; HPLC: VET =6.45 minutes (Systeml).
[00595] Example 94: 6-(3-Chloro-phenyl)-5-methyl-3-(3-morpholin-4-yl-phenyl)- pyrazolo[l,5-a]py- rimidin-7-ylamine
[00596] The title compound is prepared as described in example 86; using 4-(3-
Morpholin-4-yl-phenyl)-2H-pyrazol-3-ylamine instead. Off-white crystals; mp. 165-
167 0C; MS(ESI+):m/z=420 (M+H)+; HPLC: VET =4.49 minutes (Systeml).
[00597] Stage 87.1 : 4-(3-Mθφholin-4-yl-phenyl)-2H-pyrazol-3-ylamine
[00598] The title compound is prepared as described in example 8, (Stage 1.2; Stage
1.4 and 1.5); using (3-Bromo-phenyl)-acetonitrile and morpholine instead. Off-white crystals; mp. 166-168 0C; MS(ESI+):m/z=245.1 (M+H)+; HPLC: VET =1.79 minutes
(Systeml).
[00599] Example 95: 6-(3-Chloro-phenyl)-3-(4-methoxy-phenyl)-5-methyl- pyrazolo[l,5-a]pyrimidin- -7-ylamine [00600] The title compound is prepared as described in example 86; using 4-(4-
Methoxy-phenyl)-2H-pyrazol-3-ylamine instead. White crystals; mp. 171-172°C;
MS(ESr):m/z=365 (M+H)+; HPLC: VET =4.96 minutes (Systeml).
[00601] Stage 88.1: 4-(4-Methoxy-phenyl)-2H-ρyrazol-3-ylamine
[00602] The title compound is prepared as described in example 8, (Stage 1.4 and
1.2); using (4-methoxy-phenyl)-acetonitrile instead. White crystals; mp. 198-201 0C;
MS(ESI+^nVz=I 90 (M+H)+; HPLC: VET =2.85 minutes (Systeml).
[00603] Example 96: 6-(3-Chloro-ρhenyl)-3-[3-((2R,6S)-2,6-dimethyl-morpholin-
4-yl)-phenyl]-5-m- ethyl-pyrazolo[l ,5-a]pyrimidin-7-ylamine
[00604] The title compound is prepared as described in example 86; using 4-[3-
((2R,6S)-2,6-Dimethyl-morpholin-4-yl)-phenyl]-2H-pyrazol-3-ylamine instead. White crystals; mp. 165-167 0C; MS(ESf):m/z=448 (M-HH)+; HPLC: VET =5.14 minutes
(SYSTEMl).
[00605] Stage 89.1 : 4-[3-((2R,6S)-2,6-Dimethyl-moφholin-4-yl)-phenyl]-2H- pyrazol— 3-ylamine
[00606] The title compound is prepared as described in example 8, (Stage 1.2 and
1.4 and 1.5); using (3-Bromo-phenyl)-acetonitrile and (2R,6S)-2,6-Dimethyl- morpholine instead. White crystals; mp. 158-160 0C; MS(ESI+) :m/z=273.1 (M+H)+;
HPLC: VET =3.02 minutes (Systeml).
[00607] Example 97: 2-(4-{3-[7-Amino-6-(3-chloro-phenyl)-5-methyl- pyrazolo[l,5-a]pyrimidin-3-y- l]-phenyl}-piperazin-l-yl)-ethanol
[00608] The title compound is prepared as described in example 86; using 2-{4-[3-
(5-Amino-l H-pyrazol-4-yl)-phenyI]-piperazin-l-yl}-ethanol instead. Off-white crystals; mp. 108-116 0C; MS(ESr):m/z=463 (M+H)+; HPLC: VET =3.62 minutes
(Systeml).
[00609] Stage 90.1: 2-{4-[3-(5-Amino-lH-pyrazol-4-yl)-phenyl]-piperazin-l-yl)- etha- nol
[00610] The title compound is prepared as described in example 9, (Stage 1.2 and
1.4 and 1.5); using (3-Bromo-phenyl)-acetonitrile and 2-Piperazin-l-yl-ethanol instead. Yellowish foam; mp. 40-48 0C; MS(ESI+):m/z=288.1 (M+H)+; HPLC: VET
=3.45 minutes (Systeml).
[00611] Example 98: 6-Benzyl-3-[3-(4-methyl-piperazin-l-yl)-phenyl]- pyrazolo[l,5-a]pyrimidin-7- -ylamine [00612] The title compound is prepared as described in example 86; using 2- Foπnyl-3-phenyl-propionitrile (Example 23; Stage 23.1) instead. Yellowish crystals; mp. 72-75 0C; MS(ESI+):m/z=399.1 (M+H)+; HPLC: ^RET =3.30 minutes (Systeml). [00613] Example 99: 6-(3-Chloro-phenyl)-3-(3,4-dimethoxy-ρhenyl)-5- fluoromethyl-pyrazolo[l,5-a- ]pyrimidin-7-ylamine
[00614] The title compound is prepared as described in example 86; using 4-(3,4- Dimethoxy-phenyl)-2H-pyrazol-3-ylamine (Example 93; Stage 93.1) and 2-(3- Chloro-phenyl)-4-fluoro-3-oxo-butyronitrile instead. Yellow crystals; mp. 228-230 0C; MS(ESI+):m/z=413 (M+H)+; HPLC: ^RET =6.65 minutes (Systeml). [00615] Stage 92.1 : 2-(3-Chloro-phenyl)-4-fluoro-3-oxo-butyronitrile [00616] The title compound is prepared as described for example 72, Stage 72.1 using fluoro-acetic acid ethyl ester instead. Beige crystals; mp. 90-96 0C; MS(ESI' ):m/z=209.9 (M-H)"; HPLC: ^HRET =5.66 minutes (Systeml). [00617] Example 100: 6-(3-Chloro-phenyl)-3-(3,4-dimethoxy-ρhenyl)-5-methyl- pyrazolo[l,5~a]pyrim- idin-7-ylamine
[00618] The title compound is prepared as described in example 86; using 4-(3,4- Dimethoxy-phenyl)-2H-pyrazol-3-ylamine instead. Off-white solid; mp. 223-226 0C; MS(ESrH):m/z=395.0 (MH-H)+; HPLC: ^RET =4.69 minutes (Systeml). [00619] Stage 93.1 : 4-(3,4-Dimethoxy-phenyl)-2H-pyrazol-3-ylamine [00620] The title compound is prepared as described in example 8, (Stage 1.4 and 1.2); using (3,4-Dimethoxy-phenyl)-acetonitrile instead. White crystals; mp. 143-146 0C; MS(ESI+):m/z=220.1 (M+H)+; HPLC: 'Wr =2.28 minutes (Systeml). [00621] Example 101: 6-(3-Chloro-4-fluoro-phenyl)-3-(3,4-dimethoxy-phenyl)-5- methyl-pyrazolo[l ,- 5-a]pyrimidin-7-ylamine
[00622] The title compound is prepared as described in example 86; using 4-(3,4- Dimethoxy-phenyl)-2H-pyrazol-3-ylamine (Example 93; Stage 93.1) and 2-(3- Chloro-4-fluoro-phenyl)-3-oxo-butyronitrile (Example 82; stage 82.1) instead. Off- white solid; mp. 235-238 0C; MS(ESIf):m/z=413.0 (M+H)+; HPLC: ^^=4.83 minutes (Systeml).
[00623] Example 102: 6-(3-Chloro-4-fluoro-phenyl)-3-(4-methoxy-phenyl)-5- methyl-pyrazolo[l ,5-a]- pyrimidin-7-ylamine [00624] The title compound is prepared as described in example 86; using 4-(4-
Methoxy-phenyl)-2H-pyrazol-3-ylamine (Example 88; Stage 88.1) and 2-(3-Chloro-4- fluoro-phenyl)-3-oxo-butyronitrile (Example 82; stage 82.1) instead. White crystals; mp. 224-227 0C; MS(ESI+^mZz=SSS (M+H)+; HPLC: VET =5.08 minutes
(Systeml).
[00625] Example 103: 6-(4-Fluoro-phenyl)-3-(4-methoxy-phenyl)-5-methyl- pyrazolo[l,5-a]pyrimidin- -7-ylamine
[00626] The title compound is prepared as described in example 86; using 4-(4-
Methoxy-phenyl)-2H-pyrazol-3-ylamine (Example 88, Stage 88.1) and 2-(4-Fluoro- phenyl)-3-oxo-butyronitrile (Example 79; Stage 79.1) instead. White crystals; mp.
243-244 0C; MS(ESI+):m/z=349,l (M+H)+; HPLC: ^RET =4.56 minutes (Systeml).
[00627] Example 104: 2-(4-{3-[7-Amino-6-(4-fluoro-phenyl)-5-methyl- pyrazolo[ 1 ,5-a]pyrimidin-3-y- l]-phenyl }-piperazin- 1 -yl)-ethanol
[00628] The title compound is prepared as described in example 86; using 2-{4-[3-
(5-Amino-lH-pyrazol-4-yl)-phenyl]-piperazϊn-l-yl}-ethanol (Example 90, Stage
90.1) and 2-(4-Fluoro-phenyl)-3-oxo-butyronitrile (Example 79; Stage 79.1) instead.
Off-white crystals; mp. 209-212 0C; MS(ESI+):m/z=447.1 (MH-H)+; HPLC:
Figure imgf000099_0001
=3.24 minutes (Systeml).
[00629] Example 105: 6-(3,4-Difluoro-phenyl)-5-methyl-3-[3-(4-methyI-piperazin- l-yl)-phenyl]-py- razolo[l,5-a]pyrimidin-7-ylamine
[00630] The title compound is prepared as described in example 86; using 2-(3,4- difluoro-phenyl)-3-oxo-butyronitrile instead. White solid; mp. 216-219 0C;
MS(ESI+):m/z=435 (MH-H)+; HPLC: ^RET =3.30 minutes (SYSTEMl).
[00631] Stage 98.1 : 2-(3,4-Difluoro-phenyl)-3-oxo~butyronitrile
[00632] The title compound is prepared as described in example 8, (Stage 1.4 and,
1.2); using (3,4-difluoro-phenyl)-acetonitrile instead. White crystals;, mp. 147-152
0C; MS(ESI+):m/z=195 (M+H)+; HPLC: ^RET =5.39 minutes (Systeml).
[00633] Example 106: 6-(3,4-Difluoro-phenyl)-3-(3,4-dimethoxy-phenyl)-5- methyl-pyrazolo[l ,5-a]p- yrimidin-7-ylamine
[00634] The title compound is prepared as described in example 86; using 4-(3,4-
Dimethoxy-phenyl)-2H-pyrazol-3-ylamine (Example 93; Stage 93.1) and 2-(3,4- difluoro-phenyl)-3-oxo-butyronitrile (Example 98; Stage 98.1) instead. Off-white solid; mp. 230-235 0C; MS(ESr):m/z=397.0 (M+H)+; HPLC: ^RET =4.53 minutes
(Systeml). [00635] Example 107: 2-(4-(3-[7-Amino-6-(3-chloro-4-fluoro-phenyl)-5-methyl- pyrazolofl ,5-a]pyri- raidin-3-yl]-phenyl}-piperazin- 1 -yl)-ethanol [00636] The title compound is prepared as described in example 86; using 2- {4- [3- (5-Amino-lH-pyrazol-4-yl)-phenyl]-piperazin-l-yl}-ethanol (Example 90, Stage 90.1) and 2-(3-Chloro-4-fluoro-phenyl)-3-oxo-butyronit- rile (Example 82; stage 82.1) instead. Off-white crystals; mp. 104-107 0C; MS(ESI+):m/z=481 (M+H)+; HPLC: ^RET =4.00 minutes (Systeml).
[00637] Example 108: 2-(4-{3-[7-Amino-6-(3,4-difluoro-phenyl)-5-methyl- pyrazolo[ 1 ,5-a]pyrimidin- -3 -yl]-phenyl}-piperazin- 1 -yl)-ethanol [00638] The title compound is prepared as described in example 86; using 2-{4-[3- (5-Amino-lH-pyrazol-4-yl)-phenyl]-piperazin-l-yl)-ethanol (Example 90, Stage 90.1) and 2-(3,4-difluoro-phenyl)-3-oxo-butyronitrile (Example 98; Stage 98.1) instead. Off-white crystals; mp. 172-1740C; MS(ESI+):m/z=465 (M+H)+; HPLC: Vn- =3.71 minutes (Systeml).
[00639] Example 109: 6-(3-Chloro-ρhenyl)-5-methyl-3-[3-(4-ρyrrolidin-l-yl- piperidin-1 -yl)-pheny- l]-pyrazolo[l ,5-a]pyrimidin-7-ylamine
[00640] The title compound is prepared as described in example 86; using 4-[3-(4- Pyrrolidin- 1 -yl-piperidin- 1 -yl)-phenyl]- 1 H-pyrazol-3-ylamine instead. Yellow crystals; mp. 188-193 0C; MS(ESI+):m/z=487.0 (M+H)+; HPLC: ^RET ^^I minutes (Systeml).
[00641] Stage 102.1: 4-[3-(4-Pyrrolidin-l-yl-piperidin-l-yl)-phenyl]-lH-pyrazol-3- - ylamine
[00642] The title compound is prepared as described in example 8, (Stage 1.2 and 1.4 and 1.5); using (3-Bromo-phenyl)-acetonitrile and 4-Pyrrolidin-l-yl-piperidine instead. Yellow crystals; mp. 214-216 0C; MS(ESI+):m/z=312.1 (M+H)+; HPLC: ^RET =3.71 minutes (Systeml).
[00643] Example 110: 6-(4-Fluoro-phenyl)-5-methyl-3-[3-(4-pyrrolidin-l -yl- piperidin- l-yl)-pheny- l]-pyrazolo[l,5-a]pyrimidin-7-ylamine
[00644] The title compound is prepared as described in example 86; using 4-[3-(4- Pyrrolidin-l-yl-piperidin-l-yl)-phenyl]-lH-pyrazol-3-ylamine (Example 102; Stage 102.1) and 2-(4-Fluoro-phenyl)-3-oxo-butyronitrile (Example 79; Stage 79.1) instead. White crystals; mp. 244-249 0C; MS(ESI+):m/z=471.0 (M+H)+; HPLC:
Figure imgf000100_0001
=3.82 minutes (Systeml). [00645] Example 111: 6-(3-Chloro-phenyl)-3-[3-(4-diethylamino-piperidin-l-yl)- phenyl]-5-methyl— pvrazolo[l,5-a]pyrirnidin-7-ylarnine
[00646] The title compound is prepared as described in. example 86; using { l-[3-(3-
Amino- 1 H-pyrazol-4-yl)-phenyl]-piperidin-4-yl } -diethyl-amine instead. White crystals; mp. 163-168 0C; MS(ESf ):m/z=489.0 (M+H)+; HPLC: VET =4.02 minutes
(Systeml).
[00647] Stage 104.1: {l-[3-(3-Amino-lH-pyrazol-4-yl)-phenyl]-piperidin-4-yl}- dieth- yl-amine
[00648] The title compound is prepared as described in example 8, (Stage 1.2 and
1.4 and 1.5); using (3-bromo-phenyl)-acetonitrile and diethyl-piperidin-4-yl-amine instead. Beige solid, amorphous; MS(ESr):m/z=314.2 (M+H)+; HPLC: VET =3.75 minutes (Systeml).
[00649] Example 112: 3-[3-(4-Diethylamino-piperidin-l-yl)-phenyl]-6-(4-fluoro- phenyl)-5-methyl~ pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine
[00650] The title compound is prepared as described in example 86; using (l-[3-(3-
Amino-lH-pyrazol-4-yl)-phenyl]-piperidin-4-yl}-diethyl-amine (Example 104, Stage
104.1) and 2-(4-Fluoro-phenyl)-3-oxo-butyronitrile (Example 79; Stage 79.1) instead.
White crystals; mp. 208-210 0C; MS(ESf):m/z=473.1 (M+H)+; HPLC: VET =3.63 minutes (Systeml).
[00651] Example 113: 6-(4-Fluoro-phenyI)-5-methyl-3-[3-(4-methyl-4-oxy- piperazin-1 -yl)-phenyl]~ pyrazolo[l,5-a]pyrimidin-7-ylamine
[00652] 6-(4-Fluoro-pheny l)-5-methyl-3 -[3 -(4-methyl-piperazin- 1 -yl)-phenyl] - - pyrazolo[l,5-a]pyrimidin-7-ylamine (Example 80) (50 mg; 0.12 mMol) is dissolved in
CH2Cl2 (10 mL) and at 0 0C treated with 3-chloroperbenzoic acid (31.1 mg; 0.126 mMol) for 1 h, followed by stirring at rtfor 2 h. After removald of the solvent under reduced pressure, the crude mixture is purified by chromatography (silica gel, 12 g
RediSep, ISCO Sg-IOO CH2Cl2/MeOH/NH3=80:20:l) to obtain the title compound as beige crystals (44 mg); mp.210-223 0C; MS(ESI+) :m/z=449 (M+H)+; HPLC: VET
=3.31 minutes (Systeml).
[00653] Example 114: 6-(4-Fluoro-phenyl)-5-methyl-3-[3-(4-methyl-l,4-dioxy- piperazin- 1 -yl)-phen- yl]-pyrazolo[ 1 ,5-a]pyrimidin-7-ylamine
[00654] The title compound is isolated from the same reaction described in
Example 113: beige crystals (20 mg); mp. 161-169 0C; MS(ESI+) :m/z=433 (M+H)+;
HPLC: ^RET =3.89 minutes (Systeml). [00655] Example 115: 6-(3-Chloro-phenyl)-3-[3-(4-dimethylamino-piperidin-l-yl)- phenyl]-5-methyl- -pyrazolo[l,5-a]pyrimidin-7-ylamine
[00656] The title compound is prepared as described in example 86; using { 1 -[3-(5-
Amino- 1 H-pyrazol-4-yl)-phenyl]-piperidin-4-yl } -dimethyl-amine instead.
[00657] Stage 108.1 {l-[3-(5-Amino-lH-pyrazol-4-yl)-phenyl]-piperidin-4-yl}- dimeth- yl-amine
[00658] The title compound is prepared as described in example 8, (Stage 1.2 and
1.4 and 1.5); using (3-bromo-phenyl)-acetonitrile and dimethyl-piperidin-4-yl-amine instead.
[00659] Example 116: 6-(3,4-Difluoro-phenyl)-3-[3-(4-dimethylamino-piperidin-l- yl)-phenyl]-5-me- thyl-pyrazolo[l,5-a]pyrimidin-7-ylamine
[00660] The title compound is prepared as described in example 86; using (l-[3-(5-
Amino- 1 H-pyrazol-4-yl)-phenyl]-piperidin-4-yl} -dimethyl-amine (Example 108;
Stage 108.1) and 2-(3,4-difluoro-phenyl)-3-oxo-butyronitril- e (Example 98; Stage
98.1) instead.
[00661] Example 117: 6-(3-Chloro-phenyl)-5-methyl-3-(3,4,5-trimethoxy-phenyl)- pyrazolo[l,5-a]py- rϊmidin-7-ylamine
[00662] The title compound is prepared as described in example 86; using 4-(3,4,5- trimethoxy-phenyl)-2H-pyrazol-3 -ylamine instead.
[00663] Stage 110.1: 4-(3,4,5-Trimethoxy-phenyl)-2H-pyrazol-3-ylamine
[00664] The title compound is prepared as described in example 8, (Stage 1.4 and
1.2); using (3,4,5-trimethoxy-phenyl)-acetonitrile instead.
[00665] Example 118: 6-(3,4-Dϊfluoro-phenyl)-5-methyl-3-(3,4,5-trimethoxy- phenyl)-pyrazolo[l ,5— a]pyrimidin-7-ylamine
[00666] The title compound is prepared as described in example 86; using 4-(3,4,5- trimethoxy-phenyl)-2H-pyrazol-3-ylamine (Example 110; Stage 110.1) and 2-(3,4- difluoro-phenyl)-3-oxo-butyronitrile (Example 98; Stage 98.1) instead.
[00667] Example 119: 6-(3-Chloro-phenyl)-3-(3-methoxy-phenyl)-5-methyl- pyrazolo[l,5-a]pyrimidin- -7-ylamine
[00668] The title compound is prepared as described in example 86; using 4-(3-
Methoxy-phenyl)-2H-pyrazol-3 -ylamine instead.
[00669] Stage 112.1: 4-(3-Methoxy-ρhenyI)-2H-pyrazoi-3-ylamine
[00670] The title compound is prepared as described in example 8, (Stage 1.4 and
1.2); using (3-methoxy-phenyl)-acetonitrile instead. [00671] Example 120: 6-[7-Amino-3-(3,4-dimethoxy-phenyl)-pyτazolo[l,5- a]pyrimidin-6-yl]-pyridin- -2-ol
[00672] The title compound is prepared as described in example 8; using 2-(6-
Hydroxy-pyridin-2-y l)-3 -oxo-propionitrile and 4-(3 ,4-Dimethoxy-phenyl)-2H- pyrazol-3-ylamine (Example 93; Stage 96.1) instead.
[00673] Example 121: 6-Beri2yl-3-(3,4-dimethoxy-phenyl)-pyrazolo[l,5- a]pyrimidin-7-ylamine
[00674] The title compound is prepared as described in example 93; using 4-(3,4-
Dimethoxy-phenyl)-2H-pyrazol-3-ylamine (Example 93; Stage 93.1) instead.
[00675] Example 122: 3-(3,4-Dimethoxy-phenyl)-6-(3-fluoro-benzyl)- pyrazolo[l,5-a]pyrimidin-7-yl- amine
[00676] The title compound is prepared as described in example 121; using 2-(3-
Fluoro-benzyl)-3 -oxo-propionitrile instead.
[00677] Example 123: Tablets 1 comprising compounds of the formula (I)
[00678] Tablets, comprising, as active ingredient, 50 mg of any one of the compounds of formula (I) mentioned in the preceding Examples 8-122 of the following composition are prepared using routine methods:
Figure imgf000103_0001
[00679] Manufacture: The active ingredient is combined with part of the wheat starch, the lactose and the colloidal silica and the mixture pressed through a sieve. A further part of the wheat starch is mixed with the 5-fold amount of water on a water bath to form a paste and the mixture made first is kneaded with this paste until a weakly plastic mass is formed.
[00680] The dry granules are pressed through a sieve having a mesh size of 3 mm, mixed with a pre-sieved mixture (1 mm sieve) of the remaining corn starch, magnesium stearate and talcum and compressed to form slightly biconvex tablets. [00681] Example 124: Tablets 2 comprising compounds of the formula (I) [00682] Tablets, comprising, as active ingredient, 100 mg of any one of the compounds of formula (I) of Examples 8-122 are prepared with the following composition, following standard procedures:
Figure imgf000104_0001
[00683] Manufacture: The active ingredient is mixed with the carrier materials and compressed by means of a tabletting machine (Korsch EKO, Stempeldurchmesser 10 mm).
[00684] Example 125: Capsules
[00685] Capsules, comprising, as active ingredient, 100 mg of any one of the compounds of formula (I) given in Examples 8-122, of the following composition are prepared according to standard procedures:
Figure imgf000104_0002
[00686] Manufacturing is done by mixing the components and filling them into hard gelatine capsules, size 1.

Claims

What is claimed is:
1. A method of treating an Eph receptor-related injury or disorder comprising administering a compound of formula (I) to a warm-blooded animal, especially a human, in need of such treatment:
Figure imgf000105_0001
wherein:
R2 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
R.3 can be H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring, at least one OfR2 or R3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
A is H, halogen (such as bromo), an aliphatic moiety, a functional group, substituted or unsubstituted aryl or heteroaryl; and
R1 is H, halogen or lower alkyl, or pharmaceutically acceptable salts thereof.
2. The method according to claim 1, further comprising administering any one of Compounds 1-8.
3. The method according to claim 2, further comprising administering Compound 1.
4. The method according to claim 1, wherein the disease to be treated is a neurodegenerative disease.
5. The method according to claim 1, wherein the Eph receptor-related injury or disorder is quadriplegia, hemiplegia, and paraplegia.
6. The method of claim 5, wherein the quadriplegia, hemiplegia, and paraplegia is caused by injury or trauma.
7. The method of claim 5, wherein the quadriplegia, hemiplegia, and paraplegia is caused by hereditary illness.
8. A method according to Claim 1, wherein the injury to be treated is or results from a spinal cord injury.
9. A method according to Claim 1, wherein the injury to be treated results from a cerebral infarct such as in stroke.
10. A method of stimulating neural regeneration, or reversing neuronal degeneration, or both, comprising administering a compound of formula (I) to a warm-blooded animal, especially a human:
Figure imgf000106_0001
wherein:
R.2 is H5 substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring; R.3 can be H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring, at least one of R2 or R3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
A is H, halogen (such as bromo), an aliphatic moiety, a functional group, substituted or unsubstituted aryl or heteroaryl; and
Ri is H, halogen or lower alkyl, or pharmaceutically acceptable salts thereof.
11. The method according to claim 10, further comprising administering any one of Compounds 1-8.
12. The method according to claim 11, further comprising administering Compound 1.
13. The method of claim 10, wherein the warm-blooded animal has suffered a neuronal injury.
14. The method of claim 10, wherein the warm-blooded animal suffers from a neurological disorder.
15. The method of claim 10, wherein the warm-blooded animal suffers from quadriplegia, hemiplegia, and paraplegia caused by hereditary illness.
16. The method of claim 10, wherein the warm-blooded animal suffers from a spinal cord injury.
17. The method of claim 10, wherein the warm-blooded animal has experienced a cerebral infarct such as in stroke.
18. The method of claim 1, wherein the compound of formula (I) is combined in a combination thereapy with an agent capable of blocking myelin inhibitors Nogo, myelin-associated glycoprotein (MAG), or oligodendrocyte-myelin glycoprotein OMgp.
19. A compound of formula (I):
Figure imgf000108_0001
wherein:
R2 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted aliphatic residue which is connected by one connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring;
R3 can be H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aliphatic residue, a functional group, or a substituted or unsubstituted aliphatic residue which may be connected by a connecting group or atom to the pyrazolo[l,5a]pyrimidinyl ring, at least one of R2 or R3 is substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl residue which is connected by one connecting group or atom to the ρyrazolo[l,5a]pyrimidinyl ring;
A is H, halogen (such as bromo), an aliphatic moiety, a functional group, substituted or unsubstituted aryl or heteroaryl; and
Ri is H, halogen or lower alkyl, or pharmaceutically acceptable salts thereof.
20. A compound listed in TABLE I.
PCT/US2007/005822 2006-03-08 2007-03-06 Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders WO2007103432A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002643362A CA2643362A1 (en) 2006-03-08 2007-03-06 Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders
MX2008011430A MX2008011430A (en) 2006-03-08 2007-03-06 Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders.
JP2008558374A JP2009529054A (en) 2006-03-08 2007-03-06 Use of pyrazolo [1,5A] pyrimidin-7-ylamine derivatives in the treatment of neurological disorders
BRPI0708693-8A BRPI0708693A2 (en) 2006-03-08 2007-03-06 use of pyrazol derivatives [1,5, a] pyrimidin-7-yl amine in the treatment of neurological disorders
US12/282,110 US20090069315A1 (en) 2006-03-08 2007-03-06 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders
AU2007223865A AU2007223865A1 (en) 2006-03-08 2007-03-06 Use of pyrazolo[1,5A]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders
EP07752514A EP1993552A2 (en) 2006-03-08 2007-03-06 Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78095106P 2006-03-08 2006-03-08
US60/780,951 2006-03-08

Publications (3)

Publication Number Publication Date
WO2007103432A2 true WO2007103432A2 (en) 2007-09-13
WO2007103432A3 WO2007103432A3 (en) 2007-11-22
WO2007103432A9 WO2007103432A9 (en) 2008-01-10

Family

ID=38328646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/005822 WO2007103432A2 (en) 2006-03-08 2007-03-06 Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders

Country Status (11)

Country Link
US (1) US20090069315A1 (en)
EP (1) EP1993552A2 (en)
JP (1) JP2009529054A (en)
KR (1) KR20080106226A (en)
CN (1) CN101394853A (en)
AU (1) AU2007223865A1 (en)
BR (1) BRPI0708693A2 (en)
CA (1) CA2643362A1 (en)
MX (1) MX2008011430A (en)
RU (1) RU2008139560A (en)
WO (1) WO2007103432A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008037459A1 (en) * 2006-09-28 2008-04-03 Novartis Ag Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
WO2012156351A1 (en) * 2011-05-13 2012-11-22 Vib Vzw Epha4 is a disease modifier in motor neuron disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY141978A (en) * 2002-09-04 2010-08-16 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
DE10357568A1 (en) * 2003-12-10 2005-07-07 Bayer Cropscience Ag pyrazolopyrimidine
PE20051089A1 (en) * 2004-01-22 2006-01-25 Novartis Ag PYRAZOLE [1,5-A] PYRIMIDIN-7-IL-AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
CN101107251A (en) * 2005-01-19 2008-01-16 默克公司 Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
BRPI0613941A2 (en) * 2005-07-27 2016-11-22 Basf Ag compounds, process for preparing compounds, fungicidal agent, seed, and process for combating phytopathogenic harmful fungi
CA2624882C (en) * 2005-10-06 2014-05-20 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
WO2007044441A2 (en) * 2005-10-06 2007-04-19 Schering Corporation Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008037459A1 (en) * 2006-09-28 2008-04-03 Novartis Ag Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
WO2012156351A1 (en) * 2011-05-13 2012-11-22 Vib Vzw Epha4 is a disease modifier in motor neuron disease
US9187784B2 (en) 2011-05-13 2015-11-17 Vib Vzw EphA4 is a disease modifier in motor neuron disease

Also Published As

Publication number Publication date
WO2007103432A9 (en) 2008-01-10
US20090069315A1 (en) 2009-03-12
CA2643362A1 (en) 2007-09-13
BRPI0708693A2 (en) 2011-06-14
EP1993552A2 (en) 2008-11-26
JP2009529054A (en) 2009-08-13
AU2007223865A1 (en) 2007-09-13
KR20080106226A (en) 2008-12-04
RU2008139560A (en) 2010-04-20
MX2008011430A (en) 2008-09-18
WO2007103432A3 (en) 2007-11-22
CN101394853A (en) 2009-03-25

Similar Documents

Publication Publication Date Title
US20220395501A1 (en) Treatment of gvhd
CN109906227B (en) 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones
CA2740792C (en) Pyrazolopyrimidine jak inhibitor compounds and methods
JP5400626B2 (en) Substituted imidazo and triazolopyrimidines
US20120178751A1 (en) 2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives
US20090099167A1 (en) Organic compounds
CN105793260A (en) 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H- Pyrido[2,3-B]pyrazin-8-yl)oxy]phenyl]urea derivatives
CN107531683B (en) USP7 inhibitor compounds and methods of use
CN101432284A (en) Dihydropyrazolopyrimidinone derivative
TWI707855B (en) Novel imidazopyridazine compounds and their use
US20230142913A1 (en) Tricyclic heteroarenes, pharmaceutical compositions containing the same, and methods of using the same
WO2018200855A1 (en) Novel alk2 inhibitors and methods for inhibiting bmp signaling
WO2019011228A1 (en) Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6h)-one compound and use thereof
WO2022089389A1 (en) Heterocyclic compound, preparation method therefor, pharmaceutical composition thereof and application thereof
WO2019034153A1 (en) Chemical compound, pharmaceutical composition thereof, and use and application thereof
EP1993552A2 (en) Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders
US20090306083A1 (en) Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders
CN116063324A (en) Inhibitors of BTK and/or RET having macrocyclic structure
HK1161529B (en) Pyrazolopyrimidine jak inhibitor compounds and methods

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007752514

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007223865

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2643362

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 7227/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/011430

Country of ref document: MX

Ref document number: 200780008081.8

Country of ref document: CN

Ref document number: 1020087021732

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008558374

Country of ref document: JP

Ref document number: 12282110

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007223865

Country of ref document: AU

Date of ref document: 20070306

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2008139560

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0708693

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080908